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From the Desk of the Residency Program Director
To Friends of the Department of Medicine:
Earlier this academic year, The Institute of Medicine
(IOM) issued their most recent report, “Resident Duty
Hours: Enhancing Sleep, Supervision, and Safety,” which
recommends changes to medical residents’ duty hours and
workloads to “promote conditions for safe medical care,
improve the education of doctors in training, and increase
the safety of residents and the general public.” While the
IOM simply makes recommendations, the Accreditation
Council for Graduate Medical Education (ACGME) makes
the actual rules that a residency program must follow in
order to maintain accreditation. Under the leadership of
the ACGME, one of the Residency Review Committees
(RRC) establishes these accreditation guidelines for internal
medicine residency programs. In March 2009, the ACGME
will convene a duty hour conference to review the recent
IOM report and discuss possible changes in current RRC
rules. I will be attending this conference.
The IOM report recommends that the maximum residents’
work hours per week remain at 80 hours. However, the
report diverges from the current duty hour limits by
proposing a maximum shift length without protected sleep
time of 16 hours. Specifically, the maximum shift length
can be 30 hours provided there is a “5-hour uninterrupted
continuous sleep period” between 10:00 p.m. and 8:00
a.m. The “16 hour rule” will be the main area of focus and
contention as academic medicine comes to grip with the new
challenges proposed by the IOM.

Where do I stand on the new proposal? Currently, more that
half of our teams already work 16 hour shifts, so this is not
hard to accomplish. Furthermore, the safety imperative is not
just for patients but also for our residents. First, we should
not allow fatigued residents to enter orders after 24 hours of
continuous duty— studies have shown that fatigue impairs
human performance. But just as important, we should not
allow fatigued residents to drive home after an extended shift.
The time for 16 hours is now!
I believe a resident still can learn without 30 hour shifts.
Moreover, we might find that residents read more when
traditional overnight calls are eliminated. Ongoing studies
investigating the best ways to learn in the complex healthcare
system are essential to building better training programs.
Why don’t we implement this plan unilaterally at Jefferson and
not wait for the RRC to establish new guidelines? We can not
implement these changes now without pulling residents from
elective and ambulatory rotations (this would violate RCC rules
if done routinely) or help from hospital administration.
This debate promises to be interesting. I hope to contribute
by reminding our leading educational bodies that safety is
about the patient and the resident.
Gregory C. Kane MD, FACP, FCCP
Professor of Medicine
Residency Program Director
Vice-Chairman for Education
Department of Medicine
Jefferson Medical College

From the Editors
Argentina, California, Kenya, Alaska — these are just a few
of the places visited by our internal medicine residents and
captured in breathtaking photographs that are exhibited
throughout this issue of The Jefferson Medicine Forum. It is
easy to appreciate the beauty of nature when taking in these
pictures of stunning aerial views and colorful landscapes.
Their display in this journal is fitting amongst the academic
articles that speak to the intellectual curiosity of our residents
and the diversity of pathology seen at Thomas Jefferson
University Hospital.
The research and review articles in this journal highlight
a commitment to evidence-based medicine and scientific
inquiry. The art and poetry showcase talent and curiosity
beyond the field of medicine and an appreciation for travel,
humor, and humanity. Each case report reveals a fascinating
clinical challenge. It is remarkable to consider that these
cases represent only a fraction of the experiences in patient
care and variety of pathology that our residents are exposed
to everyday.

This issue of The Forum marks the 10th anniversary of this
scholarly publication written and edited by the internal
medicine residents. Like the photographs of diverse scenes
in the United States and abroad, the case reports, review
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reflect the breadth of interests and talents of our residents
and their continual commitment to learning.
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Congestive Heart Failure and Vitamin D Deficiency
Ankitkumar K. Patel, MD, MPH, Matthew DeCaro, MD, and Paul J. Mather, MD
Introduction

Congestive heart failure (CHF) is a chronic medical condition whose
incidence is rising. The prevalence of CHF is approximately 1% to
3% in Western countries.1 Despite innovations in medical therapy,
CHF is associated with high morbidity and mortality rates.2
CHF patients commonly experience muscle weakness and fatigue
as two major symptoms. An altered intracellular handling of
ionized calcium has been suggested to play a vital role in impaired
myocardial contraction.3 In isolated myocytes from patients
with end stage heart failure, systolic ionized calcium levels
were markedly decreased, while diastolic levels were elevated as
compared to healthy controls.4 In addition, digitalis and betablocker medical therapy is frequently used in CHF patients and
is known to increase myocardial ionized calcium levels.5

Vitamin D Sources and Action

Solar ultraviolet B radiation penetrates the skin and converts
7-dehydrocholestrol to previtamin D3 which is then converted
to vitamin D3. Vitamin D3 is then metabolized in the liver to
25-OH vitamin D. This is often used to determine a patient’s
vitamin D status. 25-OH vitamin D is converted in the kidneys
to its active form 1,25-OH vitamin D, and this conversion is
regulated by parathyroid hormone levels, serum calcium and
phosphorus levels.6
People get vitamin D from sunlight exposure, diet, and dietary
supplementation. Only a few foods such as eel, herring, and
salmon are good sources of vitamin D. Fortunately, ultraviolet
B-induced synthesis of vitamin D is extremely effective.
More than 200 genes, which regulate cellular proliferation,
differentiation, apoptosis, and angiogenesis, are either directly or
indirectly controlled by 1,25-OH vitamin D.7 It is also associated
with increased insulin production,8 decreased renin synthesis
and increased myocardial contraction.
Receptors for the vitamin D hormone (VDR) exist in a variety
of cell types including osteoblasts, myocytes, cardiomyocytes,
pancreatic cells, endothelial cells, neurons, and immune cells.
In vitro studies demonstrate that vitamin D suppresses proinflammatory cytokines (e.g., IL-6, IL-2, interferon-gamma,
TNF-alpha) and upregulates levels of the anti-inflammatory
cytokine (e.g., IL-10).9

Epidemiology of Vitamin D Deficiency

The different stages of vitamin D status can be classified as
deficiency, insufficiency, hypovitaminosis, adequacy and
toxicity. Vitamin D deficiency is associated with severe clinical
symptoms such as rickets, osteomalacia, myopathy, and
calcium malabsorption. In vitamin D insufficiency biochemical
alterations such as mild hyperparathyroidism and low intestinal
calcium absorption are noted without severe clinical symptoms.
In addition, calcitriol levels remain normal at the expense of
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elevated parathyroid hormone.10 In hypovitaminosis D, the body
stores of vitamin D are already low but only minor physiological
abnormalities, such as an elevated PTH level are seen. 11 In
vitamin D adequacy there are no disturbances in dependent
bodily functions. Finally, in vitamin D toxicity there is intestinal
calcium hyperabsorption and increased bone resorption which
leads to hypercalcemia.
In the National Health and Nutrition Examination Survey
(NHANES III), low 25-OH vitamin D levels were associated
with multiple medical problems including coronary vascular
disease, cancer, congestive heart failure, hypertension and
diabetes.12 Although there is no consensus, many researchers
believe an optimal level of 25-OH vitamin D to be 30ng/mL or
more.13 With this number, it has been estimated that 1 billion
people worldwide have vitamin D deficiency or insufficiency.14
Unfortunately, 41% of men and 53% of women in the United
States (U.S.) have levels of 25-OH vitamin D below 28ng/mL.15
In the elderly population in the U.S. and Europe that are still
living in the community (not in nursing homes) 40% to 100%
are vitamin D deficient.16
Risk factors for developing vitamin D deficiency include
sunscreen usage, dark skin, breast fed infants, aging,
inflammatory bowel disease, fat malabsorption disease, obesity
and a sedentary lifestyle.17 Severe deficiency often develops in
completely immobile patients.18 Interestingly, one study found
that 93% of people presenting to an emergency department
with complaints of muscle aches and bone pain and who had
a vast array of medical diagnoses were deficient in vitamin
D.19 Circulating levels of 25-OH vitamin D depend largely on
exposure to ultraviolet B light. Serum 25-OH vitamin D levels
decease with age because of the diminishing capability of the
skin to produce previtamin D.20

Vitamin D Deficiency and CHF

In many patients CHF is the end stage of hypertensive, coronary,
and valvular cardiovascular disease. There is increasing
evidence to support the notion that low vitamin D status may
be an important factor in the development and pathogenesis
of CHF. Patients with CHF have reduced circulating levels of
25-OH vitamin D and calcitriol and increased levels of serum
phosphorus and PTH.21 In an observational study, patients
with severe CHF were found to have vitamin D deficiency as
well as hyperparathyroidism.22 Excess PTH levels increase blood
pressure and cardiac contractility and lead to hypertrophy
of cardiac myocytes and interstitial fibrosis.23 Serum 25-OH
vitamin D is a major factor in determining the plasma level of
PTH in normal and CHF patients.24
In addition, cardiac muscle cells have a vitamin D receptor and
a calcitriol-dependent ionized calcium binding protein.25 In
experimental vitamin D deficiency models, calcitriol adminis-
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tration can normalize impaired myocardial contractility.26
Calcitriol is also known to be a negative endocrine regulator
of the renin-angiotensin-aldosterone system (RAAS), which
when inappropriately stimulated results in hypertension. 27 A
case report demonstrated that intravenous calcitriol treatment
decreased the plasma activity of renin and angiotensin II,
lowered blood pressure and reversed myocardial hypertrophy.28
In one study of hypertensive patients, who were exposed to
ultraviolet B radiation three times a week for three months had
a 180% increase in 1,25-OH vitamin D and both systolic and
diastolic blood pressure reduced by 6mmHg.29
CHF patients have been shown to have significantly lower 25OH vitamin D levels during the winter months (NovemberApril) than during the summer months (May-October) which
are results similar to healthy controls.30 However, CHF patients
have low outdoor activity due to disease symptoms and thus
have limited opportunity to generate adequate previtamin D
from the skin. This limitation may potentiate or worsen their
clinical condition during the winter months.
Interestingly, Zittermann et al report data in an unpublished case
control study that suggests that lifestyle factors that influence
vitamin D differ during childhood, adolescence and adulthood
in CHF patients versus controls. This data suggests that patients
have a low vitamin D status in these ages even when they are
free from CHF.31

The Future

As the incidence of congestive heart failure increases in the U.S.
population, a greater focus will be needed to better elucidate
the role of Vitamin D in the pathogenesis of symptoms.
Further research, in the form of randomized controlled trials
is necessary to determine whether Vitamin D supplementation
can reduce the progression of heart failure. In the near future it
is important to determine whether Vitamin D can be used as a
marker of disease progression.
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Understanding Hyperparathyroidism in Renal Disease
Rosemary Nwoko, MD, and Kara Chenitz, MD

The parathyroid glands are four pea-sized glands located on
the four corners of the thyroid gland. They secrete parathyroid
hormone (PTH), which maintains calcium and phosphorus
homeostasis.8 PTH regulates calcium such that when serum
levels of calcium fall too low, it increases the serum calcium
level by stimulating more calcium release from the bones,
increasing intestinal absorption of calcium and decreasing
calcium excretion into the urine. 9 When the serum calcium
normalizes, the parathyroid gland shuts off the production of
PTH. An excess of PTH in the system throws off the calciumphosphorus homeostatic balance, resulting in various symptoms
and clinical effects.
Hyperparathyroidism can be of two types: primary and
secondary.8 The former is commonly due to an adenoma or
hyperplasia of one or more of the four glands. In rare cases,
primary hyperparathyroidism can be secondary to a malignancy
in the glands. Secondary hyperparathyroidism occurs when
elevated PTH levels are caused by pre-existing medical
conditions such as calcium malabsorption syndromes, disorders
of vitamin D and phosphate metabolism, dietary calcium
deficiency or any other pre-existing condition that causes low
serum calcium levels with a resultant compensatory increase in
PTH levels. Chronic renal failure is the most common cause
of secondary hyperparathyroidism and will be the focus of this
review. CKD patients have high phosphate and low calcium
levels causing hypocalcemia and a resultant stimulation of the
parathyroid glands.9
Patients with hyperparathyroidism develop a wide array of
symptoms and complications, although some patients may
be asymptomatic initially. This includes but is not limited
to myopathy, fatigue, pruritis, abdominal pain, renal calculi,
confusion, memory problems, osteoporosis, and increased thirst
and urination (due to the increased excretion of calcium into the
urine causing an osmotic effect).11 With continued elevation of
PTH and therefore serum calcium levels, conjunctival, corneal,
vascular and cutaneous calcification can occur with severe
consequences. 1,8 Vascular calcification is the most dreaded
complication of hyperparathyroidism because it results in plaque
accumulation that increases the risk of cardiovascular death.
Patients can develop calcium calcification in the myocardium,
coronary arteries, and cardiac valves. They are also at risk for
palpitations, hypertension, and arrhythmias such as atrial
fibrillation.1,11 Indeed, the most common cause of death in end
stage renal disease (ESRD) patients is cardiovascular disease.1 As
another example of a serious complication, cutaneous calcification
can result in ulceration and gangrene.1 Hyperparathyroid induced
bone disease, or osteitis fibrosa cystica, which is due to increased
osteoclast and osteoblast activity, also occurs commonly with
longstanding hyperparathyroidism.
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Medical management of hyperparathyroidism includes calcium
supplements, vitamin D analogs, phosphate binders and/
or calcimimetics that have various mechanisms of action to
suppress the high PTH level. Calcium stimulates the G-protein
linked calcium sensing receptor (CaSR), inhibiting the release
of PTH at secondary sites (e.g., c cells of thyroid gland, kidney
cells, osteoblasts, GI mucosa, and hematopoietic cells in the bone
marrow).10 Vitamin D acts directly on parathyroid cell vitamin D
receptors to inhibit PTH release and phosphate binders work by
binding phosphate in the intestinal lumen. Calcimimetics, such
as cinacalcet, increase the CaSR’s sensitivity to serum calcium.4
Calcimimetics are especially beneficial because they stimulate
the calcium receptors without additionally increasing calcium,
unlike vitamin D analogs. Also this class of drugs is particularly
useful in those patients with ESRD who have nodular hyperplasia
of the parathyroid gland which causes decreased expression
of extracellular CaSR and even greater reduction in vitamin D
receptor density. This leads to decreased efficacy of calcium and
vitamin D analogs. When medical therapy fails, surgical removal
by subtotal parathyroidectomy is the next available option.
At this point, there is no official standard of care regarding the
absolute indications for parathyroidectomy in hyperparathyroidism generally or with respect to patients with ESRD.2 Many
of the symptoms discussed earlier can be present in dialysis
patients who do not have markedly elevated levels of PTH,
who therefore would not benefit from parathyroidectomy. As
mentioned above, a nodular, hyperplastic parathyroid gland
provides fewer options for medical treatment, so in these cases
surgery may be indicated. In renal transplant recipients, most
hyperparathyroidism improves post transplantation but when it
does not, the persistent hyperparathyroidism may adversely affect
renal function, leading to consideration of surgical intervention.
Studies have shown that parathyroidectomy has beneficial effects
on humoral immunological markers. The effects are thought
to be due to the marked PTH reduction and partly improved
nutritional state after surgery.2 Though this may be an attractive
postoperative benefit, no studies have suggested that this is an
indication for surgery. Unfortunately, post-transplant parathyroidectomy itself has been shown to be associated with abrupt
decompensation of renal allografts,6 so if patients have persistent
hyperparathyroidism despite renal transplantation and medical
therapy, they are left with grim options; they can either continue
medical therapy and risk calciphylaxis, or get surgery and risk
graft failure. Overall, since most abnormal parathyroid function
normalizes after transplantation, there is little evidence to suggest
a prophylactic parathyroidectomy is efficacious in patients on
the renal transplant list. For now, nephrologists must rely on
clinical instinct for the management of hyperparathyroidism,
while research is underway delineating particular standards of
care in this area.
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The Use Of Statins In Liver Disease: Risk Versus Benefit
Dina Halegoua-De Marzio, MD
Introduction

The National Cholesterol Education Program periodically
produces Adult Treatment Panel (ATP) updates as warranted by
current clinical scientific research in cholesterol management.1
Each of the guideline reports, ATP I, II, and III, has a major role
in guiding physicians how to treat abnormal cholesterol levels.
Recent clinical trials demonstrate that LDL-lowering therapy
with statins (HMG-CoA inhibitors) reduces total mortality,
coronary mortality, major coronary events, coronary procedures
and strokes in patients with established coronary heart disease.1
However, the ATP III has cited active or chronic liver disease as an
absolute contraindication to the use of statins. The reason for this
contraindication goes back to the initial clinical trials of Lipitor
(atorvastatin), which demonstrated that persistent elevations (> 3
times the upper limit of normal) in serum transaminases occurred
in 0.7% of patients who received atorvastatin. The incidence of
these abnormalities was 0.2%, 0.2%, 0.6% and 2.3% for 10, 20, 40
and 80 mg atorvastatin, respectively.2 Based on this information,
the recommendation held that liver function tests should be
performed before the initiation of treatment with statins, following
each dosage increase, and periodically thereafter.
Although several reports of significant liver injury associated
with statins have appeared in the literature, in reality it occurs
rarely. Current labeling of statins is ambiguous; for example,
what exactly does active liver disease or persistent unexplained
liver function tests (LFTs) elevations mean? Also there is an
assumption that acute hepatotoxicity that develops in a patient
with impaired liver function would potentially be more fatal,
although evidence-based data to support this theory are lacking.
The fact remains that statins are the most efficacious drugs for
decreasing low-density lipoprotein cholesterol levels, and cardiovascular disease is the leading cause of mortality in the United
States. Thus, it is important to establish whether statin therapy
should be withheld from patients with liver disease.

Risk of Statin Hepatotoxicity

The following question must be addressed: are patients with
elevated liver enzymes at a higher risk for statin hepatotoxicity?
Chalasani et al and Vuppalanchi et al evaluated the affect
of starting statin therapy on the LFTs among patients with
baseline normal LFTs and those with baseline abnormal LFTs.
They determined that patients with baseline LFT elevation
had a greater incidence of a mild to moderate increase in LFTs
during treatment as compared to those without baseline LFT
abnormalities. The study also compared patients on statin
therapy with baseline elevated LFTs to patients with elevated
baseline LFTs and no history of statin use. The study showed
elevations in LFTs regardless of statin use. Therefore, the study
surmised that elevations in LFTs in patients with baseline
abnormalities while using statins may be due to underlying liver
disease and not statin use.3,4

5

One of the most common causes of undiagnosed abnormal LFTs
is nonalcoholic steatohepatitis (NASH). NASH is characterized
by steatosis, inflammation and occasionally fibrosis of the liver
that can progress to cirrhosis. Rallidis et al studied the safety
and efficacy of pravastatin treatment on histological markers
of disease activity in patients with NASH. The study suggested
a possible beneficial role of statins in the treatment of NASH
and showed that the patients with NASH were not at an
increased risk of LFT abnormities secondary to statin use.5 This
clarification is important because many patients with NASH are
at a higher risk for cardiac events due to common co-morbidities
such as metabolic syndrome, hypercholesterolemia, obesity and
diabetes.
In clinical practice, the treatment of hyperlipidemia may
necessitate an increase in statin dosage to achieve the target goals
recommended by the ATP III. This leads to increased concerns
about statin-induced hepatotoxicity in patients with chronic
liver disease who require high doses of statin. This concern stems
from older clinical trials which showed an increased risk of LFT
elevations in patients taking high dose statins.2 A recent study by
Lewis et al compared pravastatin 80 mg to a placebo in a doubleblind clinical trial. The medications were administered daily to
hypercholesterolemic subjects greater than 18 years of age with
at least a six-month history of compensated chronic liver disease
and a low-density lipoprotein cholesterol (LDL-C) level greater
than or equal to 100 mg/dL. In comparison to placebo, highdose pravastatin (80 mg/day) significantly lowered LDL, total
cholesterol, and triglycerides and was safe and well tolerated.6
Recent research also contests the need for for routine transaminase
screening in patients taking statins. In a study by Smith et al, 1002
patients on statins were tested, and 10 (1%) of the patients were
identified as having significant LFT elevations while 5 (0.5%)
patients were identified as having moderate LFT elevations.
None of the elevations appeared to be directly related to statin
use, and no adverse outcomes were related to these abnormal lab
values.7 Therefore, the risk of severe transaminase elevations with
statin use is low. In addition, routine transaminase monitoring
may be unnecessary since it has low yield and excessive cost. The
monitoring may also lead to unnecessary evaluation of slightly
abnormal laboratory findings as well as the discontinuation of a
highly effective medication.

The Liver Expert Panel and Final Conclusions

The National Lipid Association (NLA) is a nonprofit, multidisciplinary medical society focused on enhancing the practice of
lipid management in clinical medicine. The Task Force, created
in June of 2005, was a two-year independent NLA initiative
to extensively review and evaluate the safety of statins and
other lipid-modifying drugs.8 After compilation of the analysis
and commissioned research, these experts presented their
conclusions to four Expert Panels who reviewed and considered
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the evidence relative to their respective fields of expertise:
nephrology, hepatology and neurology.
The Liver Expert Panel published their findings in the American
Journal of Cardiology in 2006. The panel’s key message was that
there is no proof that statins cause life-threatening liver damage.
LFT elevations are usually reversible after stopping the statin
therapy and do not cause long-term damage. Routine liver
enzyme monitoring is not needed during statin therapy. If an
isolated asymptomatic transaminase level of one to three times
the upper limits of normal is detected, the statin does not need
to be discontinued. If the transaminase level is more than three
times the upper limits of normal during routine evaluation, the
test should be repeated; if it is still elevated, further evaluation
should be pursued. Although routine transaminase monitoring
in patients taking statins is unnecessary, clinicians should be
alert to patient reports of jaundice, malaise, fatigue and other
possible signs of hepatotoxicity. If there is an objective evidence
of significant liver injury, the statin should be discontinued. In
conclusion, statin therapy can be safely administered to patients
with chronic liver disease, compensated cirrhosis, and NASH.8
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Tjuh Adherence to IDSA Guidelines for the Treatment
of Cryptococcal Meningitis
Matthew Grant, MD
Introduction

Cryptococcal meningitis is an infectious complication of immune
compromised states that carries a high rate of mortality or
relapse. Although Infectious Disease Society of America (IDSA)
guidelines outline the recommended treatment regimen for
cryptococcal meningitis, clinicians take a heterogenous clinical
approach. This study examines the use of antifungal regimens in
treating cryptococcal meningitis at a tertiary care hospital.

Objectives

The primary endpoint was to determine the percentage of
patients who received antifungal treatment that was backed by
the highest Sobel class recommendation (i.e., “A1”) from the
most recent IDSA-endorsed guidelines. Secondary endpoints
were mortality and clinical relapse.

Methods

After review of TJUH fungal culture data from 2003 to 2007, this
study included patients who had either:
1. A positive cerebrospinal fluid culture (CSF) for C.
neoformans (12 patients)
2. A positive blood culture with signs/symptoms of
meningitis (1 patient)
After appropriate patients were identified, chart reviews
were performed to obtain pertinent demographic, laboratory
and treatment data (see Table 1). Treatment strategies were
then compared to the most recent IDSA-endorsed practice
guidelines.1
For HIV+ patients, the class A1 recommendation for the treatment
of cryptococcal meningitis involves all of the following:
1.	“Induction”– 2 weeks of amphotericin B(0.7-1 mg/
kg/d) + flucytosine (100mg/kg/d in divided doses),
followed by
2.	“Consolidation” – 10 weeks of fluconazole 400 mg/d,
followed by
3.	“Maintenance” – lifelong fluconazole at 200 to 400
mg/d
For HIV negative patients, two endorsed regimens exist. The
first is identical to that for HIV+ patients except maintenance
therapy is not needed, and the second regimen is simply
extended induction therapy for six to ten weeks without either
consolidation or maintenance.

Results

Of the eleven HIV+ patients identified with cryptococcal
meningitis, two (18%) were treated with a regimen consistent
with the IDSA-endorsed class A1 recommendations. Of the two

7

Table 1. Patient baseline characteristics at presentation.
Patient Characteristics

1st presentation
N = 13 pts total

Age, Years [Median (Min, Max)]

42 (37, 58)

Sex - Male

12

Ethnicity
Caucasian

1

African-American

12

Recent Antifungal Therapy

0

Comorbidities
Diabetes Mellitus

1

Corticosteroid Therapy

0

Concurrent Bacterial Infection

3

HIV seropositive

11

CD4+ count [Median (Min, Max)]

14 (2, 155)

Viral load [Median (Min, Max)]

146,642 (<75, >750,000)

HAART

2

1

Pneumocystis jiroveci prophylaxis

1

MAI prophylaxis

1

2

Concurrent cryptococcal
fungemia

7

CSF
WBC count [Median (Min, Max)]

32 (1, 635)

Protein [Median (Min, Max)]

101 (41,855)

Glucose [Median (Min, Max)]

40 (4, 63)

HAART: Highly Active Antiretroviral Therapy, MAI: Mycobacterium aviumintracellulare complex, CSF: Cerebrospinal Fluid, WBC: White Blood Cell

HIV negative patients with cryptococcal meningitis, one was
treated with an endorsed regimen (see Table 2).
For the HIV + subset, the most common deviations from the
guidelines were as follows (note multiple deviations were present
in some patients):
1)

Flucytosine use during induction

a. Failure to use – 4 patients
b. Insufficient duration – 4 patients
c. Insufficient dose – 1 patient
2)

Insufficient duration of amphotericin B – 2 patients

3)	Insufficient duration of fluconazole during
consolidation – 2 patients
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For the secondary endpoint analysis, all five observed instances
of death or clinical relapse were in patients who had nonendorsed induction regimens (see Table 2).
Table 2. Clinical outcomes by treatment categories.
Treatment Group

# of pts with relapse or
death /# of pts treated

HIV (+) patients
Induction therapy
Appropriate Regimen

0/3

Inappropriate Regimen

5/ 8

Consolidation therapy
Appropriate Regimen

0/2

Appropriate After
Inappropriate Induction

4/ 7

Inappropriate Regimen

1/2

HIV (-) patients

Conclusion

The vast majority of patients diagnosed at TJUH with
cryptococcal meningitis from 2003 to 2007 were not treated
with the IDSA-endorsed regimen. Despite a small sample size,
a significantly lower rate of mortality and relapse was seen in
patients who received the IDSA-endorsed regimen.
Practitioner barriers to guideline adherence need to be further
studied, and likely involve fear of antifungal side effects,
logistical complexity of the overall treatment regimen and the
belief that amphotericin B monotherapy during induction
is non-inferior. With specific regard to the lack of clinician
adherence to flucytosine recommendations, it is worthwhile to
note that no outcome-based study exists that directly compares
amphotericin B monotherapy (at currently recommended doses)
to flucytosine combination therapy; the current recommendation to use combination therapy is based on a high quality
study that demonstrated more rapid CSF sterilization.2 Perhaps
completion of such a randomized trial that demonstrates
improved clinical outcomes with flucytosine addition would
change future clinical practice.
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Embracing Quality Improvement at Resident Clinic:
a Report Card on Our Diabetes Care
Tamara Solitro, MD
Background

The age of embracing the status quo or the “if it ain’t broke,
don’t fix it” philosophy in medical practice is long gone. The
goal of quality improvement in the medical field is one we can
all appreciate: to optimize the delivery of health care and use
advanced knowledge and technology to improve patient care.
Many industries, such as automobile and engineering, already
apply the scientific method to quality improvement efforts, and
the time has come for medical practices to follow suit.
The Improvement Guide: A Practical Approach to Enhancing
Organizational Performance1 describes a model of improvement
that can be used in a variety of settings, including medical
practices. Their model is based on cycles of “trial-and-learning,”
emphasizing the importance of testing change on a small scale
and observing its effects.
The “PDSA Cycle” provides a practical and systematic framework
for making improvements in the workplace which epitomizes
this “trial-and-learning” philosophy. The acronym PDSA stands
for Plan, Do, Study, Act. The “Plan” phase involves stating the
objective of the test and outlining the details of its execution.
The plan is executed during the “Do” phase. Analyzing and
summarizing the data occurs during the “Study” phase. Finally,
the “Act” phase involves determining further changes that will
make up the next cycle.
As quality improvement becomes an increasingly significant
part of practicing medicine, there is much we can learn from its
principles and applications during residency training. Jefferson
Hospital Ambulatory Practice (JHAP), an outpatient clinic
where internal medicine residents provide ambulatory care to
a largely underserved population, presents an ideal setting for
evaluating our own competence and quality of care.

Methods

To evaluate physician performance in practice as a component
for certification, the American Board of Internal Medicine
(ABIM) developed Web-based self-assessment programs for
physicians called “practice improvement modules” (PIMs).2 The
ABIM Diabetes PIM, for example, uses information collected
from medical record audits to gauge performance rates for
evidence-based measures of diabetes care, such as hemoglobin
A1c levels. Voluntary patient surveys about diabetes care at
the clinic are also scored. The ABIM Internet-based program
then presents a summary report of the practice’s performance,
allowing the physician(s) to view areas for improvement and
develop a quality improvement plan.
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Applying the ABIM Diabetes PIM at JHAP produced a report
card of our diabetes care that highlights several opportunities for
improvement and characterizes our patient population. Thirty
medical records of diabetic patients who have been at JHAP for
at least one year and seen in the last 12 months were randomly
audited for review, and 17 patient surveys were completed.

Results and Discussion

Patient characteristics are reviewed in Table 1. The sample
of patients are 50 years old on average, mostly female gender
(73%), of black or African-American race (67%), and have had
type 2 diabetes for greater than one year (80%).
Table 1. Patient characteristics
Characteristic
Age (y)

Mean (Range)
53 (37-72)
Number of Patients

Gender
Male

8 (27%)

Female

22 (73%)

Race
White

6 (20%)

Black or African-American

20 (67%)

Asian

0 (0%)

Hispanic or Latino

0 (0%)

Other

4 (13%)

Type of Diabetes
Type 1, < 12 months

0 (0%)

Type 1, > 12 months

4 (13%)

Type 2, < 12 months

2 (7%)

Type 2, > 12 months

24 (80%)

Target medical goals and patient evaluations show room
for improvement. Table 2 illustrates the rates of diagnostic
testing and complete patient evaluation. The majority of
patients are appropriately tested for hemoglobin A1c and
cholesterol levels, but less than 50% are tested for the
presence of protein in the urine. Patient evaluations are
mostly complete, but few diabetic patients undergo foot
and eye exams. Table 3 demonstrates that less than half of
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diabetic JHAP patients reach target goals for blood pressure,
cholesterol, and hemoglobin A1c levels.

Table 4. Treatment and Preventative Care
Treatment

Eligible

Table 2. Diagnostic Testing and Patient Evaluation
Percentage
completed
Diagnostic Testing

Treatment
Prescribed

Diet and Exercise
Individualized medical
nutrition therapy

30

10 (33%)

Individualized physical activity plan

30

12 (40%)

HbA1C tested w/in 12 months

87%

LDL cholesterol tested w/in 12 months

77%

Other treatments

HDL cholesterol tested w/in 12 months

77%

ACE inhibitor or ARB

9

5 (56%)

Triglycerides tested w/in 12 months

77%

Statin or other lipid-lowering drug

23

13 (57%)

Test for urine protein tested w/in 12 months

48%

Aspirin

30

13 (43%)

Smoking cessation support

7

6 (86%)

Patient Evaluation
History

88%

Antihyperglycemic Treatment

Height

77%

12 (40%)

97%

Single oral antihyperglycemic agent

30

Weight
Systolic blood pressure

100%

Combination oral antihyperglycemic agents

30

11 (37%)

Diastolic blood pressure

100%

Insulin

30

10 (33%)

Foot exam

17%

Eye exam

27%

Influenza vaccine during most
recent flu season

30

8 (27%)

Pneumococcal vaccine

30

3 (10%)

Table 3. Clinical Outcomes
Outcomes

Number of Patients (%)

Blood pressure < 130/80

7 (23%)

LDL cholesterol < 70 in patients
with CVD

0 (0%)

LDL cholesterol < 100 mg/dL;
tested w/in 12 months

13 (43%)

HDL cholesterol > 40 mg/dL;
tested w/in 12 months

12 (40%)

Triglycerides < 150 mg/dL; tested
w/in 12 months

10 (33%)

HbA1C < 7.0%, tested w/in
12 months

8 (27%)

ABIM’s Diabetes PIM also reports data on our treatment
plans for diabetic patients (Table 4). Smoking cessation
support is highly successful. However, most patients require
an individualized nutrition and exercise plan. The lower
rates for prescribing medications such as aspirin, ACE
inhibitors or angiotensin receptor blockers (ARBs), and
statins point out potential areas for improvement. Similarly,
our rates for influenza and pneumococcal vaccines are low
and deserve attention.

Preventative Care

The patient surveys provide useful information about patient
satisfaction and opportunities for health education. Overall
diabetic patients report a positive experience at JHAP. A
majority (82%) of patients say they would recommend the
practice to others. Most patients felt the practice managed their
blood pressure, cholesterol, and blood sugars well, but many
wanted more education about nutrition, their medications, and
foot care. Also only 53% report taking aspirin regularly. These
surveys thus underscore specific areas for improving patient
education and compliance.
Knowledge of our performance rates in diabetes care may
increase awareness of these opportunities for improvement
among internal medicine residents and change patient care for
the better. An intervention is currently in progress which aims
specifically to improve our rates of pneumococcal vaccinations
amongst diabetic patients at JHAP. Later, we will analyze
whether the intervention effectively improved preventative care
for our patients.
Like many ambulatory clinics serving a mostly underserved
community, JHAP faces challenges to optimal medical care
including variable patient education and adherence. Nonetheless,
this self-assessment and future quality improvement endeavors
can hopefully motivate us to address potential weaknesses, learn
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about quality improvement in medical practice, and continue to
strive towards the highest standards of patient care.
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Case Reports

A 68 Year-old Woman With Leukemia Under Her Skin
Ben Creelan, MD, Hari Nair, MSIII, and Joanne Filicko-O’Hara, MD
Introduction

A wide spectrum of skin manifestations occurs in leukemia.
Skin lesions are often due to infection, drug reaction, or
inflammation.1 Rarely, extramedullary leukemia can invade
the skin and is called leukemia cutis. 2 Leukemia cutis is
the infiltration of neoplastic leukocytes into the dermis or
subcutaneous tissue, resulting in an identifiable skin lesion.
These lesions show a varied morphology, and confirmatory
immunohistochemical stains are needed for the diagnosis.
Leukemia cutis may occur before, after, or concomitantly
with the onset of systemic leukemia.3 Here we report a case of
leukemia cutis occurring simultaneously with newly diagnosed
acute myelogenous leukemia.

complicated by superficial bacterial infection. She had never
smoked, used alcohol or illicit substances. Allergy and family
history was noncontributory.
Figure 2. Dermal biopsy of the skin lesion demonstrates
infiltrating atypical cells (image A) expressing myeloperoxidase
and focally CD38 (image B).

Case Report

A 68 year-old Caucasian female presented with a dry cough
and malaise for two weeks. She noted fever as high as 101°F
for the past two days. The patient reported visiting her primary
care physician the previous week for routine lab work. She
was contacted by her primary doctor and told to go to the ER
because of decreased platelets and increased white blood cells.
The patient did not take any medications. Past medical history
was significant for spinal surgery in 1996 and 2001, which was

Physical exam was significant for a papule on the right cheek.
This erythematous, firm papule had well-defined borders
measuring approximately 3 x 2 cm above the nasolabial fold on
the right cheek (Figure 1). The patient attributed this to mosquito
bites during a recent weekend camping trip. Laboratory testing
revealed leukocytosis (30 x 109/l), anemia (7.3 g/dL) and

Figure 1. An erythematous firm papule is located on right facial cheek of the patient.
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thrombocytopenia (50 x 109/l). Manual differentiation revealed
31% blast cells. Bone marrow biopsy revealed acute myelogenous
leukemia with multilineage dysplasia (AML, FAB M4). A single
punch skin biopsy to a depth of 40 millimeters was performed.
The biopsy showed dermal infiltrates of atypical cells expressing
myeloperoxidase and focally CD38 (Figure 2). A c-kit stain
revealed infiltration of mast cells consistent with leukemia cutis.
The patient was treated with induction cytarabine and
idarubicin, and her leukemia cutis lesion resolved within one
week of initiation of chemotherapy. Her day #14 and day #30
bone marrow biopsies revealed no residual neoplastic disease.

Discussion

Patients with AML generally present with vague complaints
related to complications of pancytopenia including weakness and
easy fatigue.4 Skin findings in AML commonly include pallor,
petechiae, or ecchymoses. Leukemic involvement of the skin is
uncommon. When present, it is most often found in patients
with monocytic or myelomonocytic AML variants.5 The overall
incidence of leukemia cutis in AML is unclear but varies from 3%
to 13% in separate case series.6 About 23% to 44% of leukemia
cutis is diagnosed at the same time as the systemic malignancy,
as in our case. Less than 10% are discovered before systemic
disease can be identified, and the remainder of cases appears
afterwards.7 The frequency of leukemia cutis is much higher in
children with congenital leukemia; in fact as many as 25% to
30% of infants develop cutaneous involvement. In contrast to
adult disease, this does not confer a worse prognosis.8
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infiltration of leukemic cells in the dermis and subcutaneous
tissue, often squeezed between collagen bundles. Involvement
of blood vessels and skin adnexa are seen in the granulocytic,
monocytic and myelomonocytic variants of leukemia cutis.12
The development of leukemia cutis portends a poor prognosis
in adults. More than 90% of these patients will have other sites
of extramedullary involvement, and in 40% of these cases, the
meninges will be involved.13,14 The disease course is usually
aggressive, and length of survival is short. Studies have shown
that the average survival time in AML patients with leukemia
cutis is 7.5 months, and the overall survival rate is 6% at 2 years
compared to 30% in AML patients without leukemia cutis 15.
Even with this poor prognosis, long-term disease-free survival is
possible with curative therapy directed at the skin, bone marrow
and other sites of extramedullary involvement.16
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Case Reports

A 31 Year-old Man With Chest Pain, Rash, and Ekg Changes
Neerav Sheth, MD, Rahul Anand, MD, and Matthew Stopper, MD
Case Presentation

A 31 year-old Caucasian male with no significant past medical
history presents with increasing dizziness, chest pain, and
shortness of breath of one day duration. On returning from a
camping trip to Northern Pennsylvania three weeks prior to
admission, he noted high fevers, “joint pains all over,” and a pink
blotchy rash all over his chest and back. He did not recall any
insect, tick or animal bites. His primary physician, who clinically
suspected Lyme disease, ordered Lyme serologies and offered a
prescription for doxycycline which the patient declined. Two
weeks later, the patient presented to the emergency department
after the onset of chest pain that he described as sharp, radiating
to both arms, occurring with exertion and relieved by rest. The
chest pain was associated with worsening shortness of breath
and dizziness.
The patient denied taking any medications, herbal or other
supplements. He admitted to smoking half a pack of cigarettes per
day, drinking 20 alcoholic beverages per week and occasionally
smoking marijuana. He denied any intravenous drug use. He also
denied any recent travel outside the United States or exposures
to new chemicals or pets. The patient’s mother had leukemia; his

father had hypertension, diabetes, and hyperlipidemia; and his
brother died from an anaphylactic reaction to shellfish.
On physical exam, the patient had a temperature of 99.6°
Fahrenheit, heart rate of 50 beats/minute, blood pressure of
155/77 mm Hg, respiratory rate of 14 breaths/minute with
an oxygen saturation of 100% on room air. The exam also
revealed a regularly irregular rhythm with no murmurs, rubs
or gallops. His lungs were clear to auscultation bilaterally. He
had no focal neurological deficits nor was he orthostatic. Large,
well demarcated macular erythematous lesions were noted
on his back and thorax. Initial labs showed a white blood cell
count of 10,000 cells/mm3 with a normal differential, normal
serum chemistries, and a negative troponin. Peripheral smear
was negative for babesiosis. The patient’s admission chest
radiograph showed clear lungs without evidence of infiltrate or
effusion. His initial EKG (Figure 1) showed a sinus rhythm at
an atrial rate of approximately 100 beats/minute and a highgrade atrioventricular (AV) block with a variable ventricular
response of about 40 beats/minute. The patient was admitted
to telemetry, and a transcutaneous pacer was placed. Empiric
intravenouis ceftriaxone was begun to treat for a clinical
diagnosis of Lyme carditis.

Figure 1. The patient’s admission EKG showed high grade AV block with variable conduction.
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Figure 2. EKG on hospital day two showed second degree AV Block with 2:1 conduction.
Lyme IgM and IgG antibody titers were positive, but Lyme
PCR was negative. A transthoracic echocardiogram revealed
mild mitral regurgitation, normal left ventricular size and
thickness with hyperdynamic function. His ejection fraction
was approximately 85%. By day two of hospitalization, his EKG
had changed to sinus rhythm and second degree AV Block with
2:1 conduction (Figure 2). He was treated with intravenous
ceftriaxone for 28 days with follow up in the cardiologic clinic
two weeks after discharge. The repeat EKG at the follow up visit
showed a return to normal sinus rhythm (Figure 3).

Figure 3. The patient’s follow up EKG illustrates normal sinus
rhythm.
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Discussion

Lyme disease is a multi-system spirochetal infection caused by
Borrelia burgdorferi affecting up to 20,000 Americans each year.
A Diagnosis of Lyme disease requires a high index of suspicion
and a good history. The majority of patients will report travel
to an endemic region, but many will not recall a tick bite.1,2,3
Upon exposure, patients enter an asymptomatic incubation
phase (lasting from three to 32 days). This phase is identified
only by a localized skin reaction at the site of inoculation that is
secondary to spirochetal infiltration of the dermis and epidermis.3
Following this, patient presentation varies depending on the
phase of the disease. Table 1 depicts the symptoms associated
with subsequent phases of Lyme disease if left untreated.
Our patient’s symptomatology places him in the “Early
Disseminated Phase,” presenting with fluctuating AV block
ranging from first degree heart block to high grade AV dissociation
with variable conduction. Cardiovascular complications may
occur in up to 8% of patients with untreated Lyme disease.10 AV
block is the most common cardiovascular manifestation of Lyme
disease, attributed to spirochetal infiltration of the conduction
system.4 AV block secondary to Lyme disease is considered to
be transient and is expected to resolve with treatment of the
underlying disease.5
While AV block is the most common cardiovascular
manifestation of Lyme disease,6 patients may also present with

Case Reports

Table 1. Clinical Features of Lyme disease
Early Localized Phase

Early Disseminated Phase

Late Disseminated or Chronic

(months to years)

(days to weeks)

(weeks to months)

Cardiac

(none)

Atrioventricular block; myopericarditis;
pancarditis

(none)

Constitutional

Influenza-like symptoms

Malaise; fatigue

Fatigue

Lymphatic

Regional lymphadenopathy

Regional or generalized lymphadenopathy

(none)

Musculoskeletal

Myalgia

Migratory pain in joints, bone, muscle;
brief arthritis attacks

Prolonged oligoarticular arthritis
with frequent flares

Neurologic

Headache

Meningitis; Encephalitis,
Meningoencephalitis; Bell’s palsy;
cranial neuritis; radiculoneuritis

Encephalopathy; polyneuropathy;
leukoencephalitis; Dementia; Mood
Disorder

Skin

Localized skin reaction,
Erythema migrans

Secondary annular lesions

Lymphocytoma; acrodermatitis
chronica atrophicans

System

Adapted from Steere AC. Lyme disease. N Engl J Med 1989;321:589.

myopericarditis, left ventricular dysfunction, cardiomegaly,
pancarditis, aortitis, as well as ventricular tachyarrythmias.4,7,8
The exact reason for variability in presentation is unknown,
but is theorized to be secondary to the location and degree of
spirochetal infiltration as evidenced by cardiac biopsies of nonhuman primates with Lyme disease.9 Histopathologic stains
of these biopsies show infiltration of the Borrelia spirochete
from all regions of the heart, including aorta, atrium, and
myocardium.9

Conclusion

Because of the potential for life-threatening complications,
hospitalization and continuous monitoring are advisable for
symptomatic patients (e.g., those with syncope, dyspnea, or
chest pain). These interventions are also suggested for patients
with second or third degree AV block, as well as for those with
first degree heart block when the PR interval is prolonged by
more than 30 milliseconds because the degree of block may
fluctuate and worsen very rapidly in such patients.12
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A Man With Invasive Community Acquired-mrsa
Infection in the Icu Setting
Jason Korenblit, MD, MBA
Case Presentation

A 66 year-old male presented to the emergency department (ED)
with complaints of two days of shortness of breath and pruritis.
The patient claimed that he had not had regular medical care for
more than 15 years and admitted to no past medical history or
chronic medications. One week prior, he reported an itchy rash
on both his forearms. He sought treatment at a local free clinic
and received a low-potency steroid cream which he used without
relief. While at a family event, he became increasingly dyspneic
and was brought to the ED by his family. He reported no surgical
history and no drug allergies or food intolerances. The patient
reported moderate alcohol use with one to two beers per day and
denied any tobacco use, substance abuse, or intravenous drug
use. He could report no pertinent family history.
On physical examination, the patient appeared mildly dyspneic
and uncomfortable, but in no acute distress. He was afebrile,
tachycardic with a pulse of 112 beats/minute, tachypnic with
respirations of 32 breaths/minute, and normotensive. His lung
exam revealed coarse breath sounds bilaterally with decreased
respirations at the bases, but no wheeze, rhonchi, or cough.
The cardiac exam was within normal limits except for the
noted tachycardia, with no murmurs, rubs, or gallops. The
abdominal exam revealed a freely reducible left inguinal hernia.
Examination of the patient’s skin revealed an approximately
15-cm erythematous, non-blanching lesion on his posterior
neck with some fluctuance as well as smaller, pustule lesions on
his lower back, chest, and arms. The lesions were painless and
fluctuant, with no exudates. He was drowsy but oriented, and
had no focal neurologic deficits.
The patient’s white blood cell count (WBC) was high normal at
10.2 B/L, hemoglobin was low at 6.3 g/dL, hematocrit was 19.8%,
and platelet count was elevated 534 B/L. The manual differential
of the patient’s blood count revealed 61% neutrophils and 36%
bands. The patient’s metabolic panel revealed an elevated
potassium of 6.5 mmol/L, very low bicarbonate of 6 mmol/L,
a greatly elevated BUN at 198 mg/dL and a greatly elevated
creatinine at 17.8 mg/dL. The patient’s lactate was greatly
elevated at 26.1 mg/dL. The patient’s ESR was 120 mm/hr.
Prothrombin time was prolonged at 19.6 sec which corresponds
to an INR of 1.57. Blood cortisol was 117.6 μg/dL. An initial
venous blood gas revealed a pH of 7.23, a pCO2 of 14, a pO2
of 131, and a calculated bicarbonate of 7. Urinalysis revealed
a WBC count of 187 per high-powered field, a RBC count of 9
cells per high-powered field, 3+ leukocyte esterase, and many
WBC clumps. All other laboratory values including the hepatic
function panel were within standard limits. An initial portable
chest radiograph revealed questionable bibasilar infiltrates, but
was limited by poor inspiratory effort.
The patient was admitted to the medical-respiratory ICU with
acute renal failure and a suspected diagnosis of sepsis and
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community acquired pneumonia. His PORT score on admission
was calculated at 176, which corresponds to the highest risk
class of V and a greater than 2.8% in-hospital mortality. The
patient was initially treated with aggressive fluid resuscitation,
supplemental oxygenation, and the initiation of antibiotics. He
received one gram of vancomycin and a renal-adjusted dose
of pipericillin-tazobactam and gentamicin due to the severity
of his condition. The patient also received kayexalate and
several amps of sodium bicarbonate to offset his acidemia and
hyperkalemia. Surgery was consulted for possible exploration
and debridement of the lesion on the patient’s neck.
The morning following the patient’s admission to the ICU, initial
blood and urine cultures were reported as positive for grampositive cocci in clusters. A non-contrast chest CT (Figure 1)
was obtained which demonstrated multi-lobar pneumonia with
areas of cavitations as well as a large right pleural effusion and
atelectasis. The patient’s oxygenation remained stable overnight,
but his mental status began to deteriorate. The decision was
made at this time to switch the patient’s antibiotics to linezolid
given the severity of his cavitary pneumonia and the strong
suspicion of Staphylococcus aureus infection.

Figure 1. Non-contrast chest CT demonstrating multi-focal
cavitary pneumonia and extensive left pleural effusion
Over the next 18 hours the patient’s condition deteriorated
despite aggressive intervention. Pharmacologic blood pressure
support was initiated to combat this patient’s sepsis. His renal
failure improved but his creatinine was still elevated at 12.6, and
his BUN was 165. Bedside debridement of his neck lesion yielded
copious amounts of necrotic material and brown, purulent liquid.
Urine culture results returned with confirmation of methicillin-
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resistant Staphylococcus aureus (MRSA), and while sensitivity
results were not available yet, it was presumed to be community
acquired. Infectious disease consultants advised to switch the
patient back to vancomycin given the rapid development of sepsis
and hypotension. Pipercillin-tazobactam was continued, and
IV azithromycin was added for atypical pneumonia coverage.
In addition, oral rifampin was added for synergistic treatment.
Clindamycin was debated for its anti-toxigenic properties in the
treatment of community acquired MRSA (CA-MRSA), but it was
felt that the patient’s antibiotic regimen was adequate at the time.

powerful resistance mechanism, many MRSA isolates produce
beta-lactamases as well as various effluent pumps that protect
the cell from multiple antibiotics.6 Five sub-types of the SCCmec complex have been described; sub-types one, two, and
three convey additional multi-drug resistance to quinolones,
macrolides, and sulfa-based antibiotics and represent isolates
of hospital-acquired MRSA (HA-MRSA). Sub-types four and
five represent common CA-MRSA strains without multi-drug
resistance, but with added virulence factors that make these
strains especially dangerous.7

All blood cultures, urine cultures, sputum cultures, and fluid
cultures from the surgical debridement grew CA-MRSA within
twelve hours of collection despite aggressive, optimal antibiotic
treatment. A trans-thoracic echocardiogram revealed a
vegetation on the patient’s mitral valve with severe damage to
the valve and moderate mitral regurgitation. The patient was
placed on a bicarbonate drip due to worsening acidemia, and
bi-level positive airway pressure was initiated as a non-invasive
means of ventilator support.

Panton-Valentine leukocidin (PVL) is a unique compound
found in CA-MRSA that may be responsible for the added
virulence seen in these strains. It is a hemolysin that was first
described by Panton and Valentine in 1932 that gives CAMRSA the ability to cause necrotic skin lesions and predisposes
for cavitary and hemorrhagic pneumonias, as seen with the
index patient described above.7 PVL causes transcription-level
changes in cells independent of other S. aureus toxins and cell
products as purified extracts of PVL have been shown to cause
pneumonitis in murine models even without the presence of
infection. The ability of CA-MRSA to so readily infect immunecompetent hosts may also be attributed to PVL.8 One recent
study by Moran et al showed that 97% of CA-MRSA isolates
identified at 11 university-affiliated emergency departments
were found to produce PVL.9

A meeting with the patient’s family was held where it was
determined that further aggressive measures would be futile
given the patient’s continued severe acidemia, renal failure,
mental status deterioration, and need for surgical mitral valve
replacement. Based on the patient’s prior stated wishes and those
of his family, no further escalation of care was pursued. The
patient expired less than 72 hours from his initial presentation
of the ED.

Background and Genetics

MRSA was first described in Europe in the early 1960’s, several
years after the introduction of the semi-synthetic beta-lactamase
resistant penicillin, methicillin.1 It is defined as a Staphylococcus
aureus isolate with a minimal inhibitory concentration for
oxacillin of greater than 4 micrograms per ml. Approximately
50% of all S. aureus isolates in major teaching institutions
are MRSA, resulting in extensive morbidity and mortality
from their virulence and multi-drug resistance.2 A surveillance
report of over 24,000 cases of nosocomial S. aureus bacteremia
in the United States revealed that isolates with methicillinresistance increased from 22% to 57% between 1995 and 2001.3
Worldwide, HA-MRSA prevalence varies considerably, from
<1 percent in Scandinavia to up to 40% in Japan, Israel, and
Western Europe.4
By definition, all strains of MRSA are resistant to beta-lactam
antibiotics, including all cephalosporins and extended-spectrum
penicillins. The key to this resistance lies in the mec gene, which
codes for a novel penicillin-binding protein (PBP 2a) that
enables it to resist the binding of all beta-lactam antibiotics.5
PBP2a allows the bacterium to assemble its cell wall even in the
presence of antibiotics, and the mecA gene complex is freely
transmissible in a mobile gene element known as the Staphylococcal cassette chromosome (SCC-mec). In addition to this

Presentation and Epidemiology

Presentation of CA-MRSA is usually as a skin and soft
tissue infection, but it can cause invasive disease at any
site including hematogenous osteomyelitis, septic arthritis,
cavitary pneumonia, myositis and pyomyositis, and fasciitis;
hematogenous osteomyelitis is the most common invasive
infection.8 Fridkin et al found that 87% of cases of CA-MRSA
at three community hospitals presented as skin and soft tissue
infections or traumatic wound infections, 4% presented as
urinary tract infections, 4% as sinusitis, 3% as bacteremia, and
only 2% as community acquired pneumonia.2
In a 2003 study by Naimi et al, 75% of cases of MRSA skin and
soft tissue infection were due to CA-MRSA isolates, as opposed
to nosocomial HA-MRSA which most commonly presented with
bacteremia or catheter infections.8 A similar study in 2006 in Los
Angeles indicated that a median of 59% of skin and soft tissue
infections presenting to the emergency department were due
to MRSA, over 95% of those were considered community acquired
strains based on SCCmec genotyping, and 74% of MRSA isolates
were strain U300, a common, PVL-producing strain.9
Risk factors for acquiring a CA-MRSA include recent skin trauma,
high body mass index, practice of cosmetic body shaving, male
gender, participation in contact sports, prolonged hospitalization, incarceration, military service, diabetes, intravenous
drug use, and history of a prior skin infection. No study has
consistently shown risk factors that define MRSA infections
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versus other skin and soft tissue infections; therefore empiric
coverage should always be considered.10

Treatment

Treatment of CA-MRSA is oftentimes more straightforward
since these particular strains do not exhibit multi-drug resistance
that nosocomial MRSA innately display. Retrospective studies of
CA-MRSA soft tissue infections have shown 95% were susceptible
to clindamycin, 6% to erythromycin, 60% to fluoroquinolones,
100% to rifampin and trimethoprim-sulfamethoxazole (TMPSMX), and 92% to tetracycline.9 Although proper antibiotic
choice is an important part of treatment protocol to prevent
further progression to invasive disease, the most important
treatment of focal skin involvement is adequate drainage of any
abscess or infectious collection. A 2007 prospective trial found
that lack of incision and drainage was associated with significant
non-response 30 days after initial treatment. Current CDC
recommendations state that oral clindamycin or oral TMPSMX should be first-line for empiric coverage of presumed CAMRSA for all skin and soft-tissue infections identified.12
Intravenous antibiotic therapy for invasion MRSA, whether
nosocomial or community acquired, centers on vancomycin
and achieving appropriate therapeutic levels in target tissue.
Vancomycin inhibits cell wall synthesis by preventing Nacetylmuramic acid (NAM)- and N-acetylglucosamine
(NAG)-peptide subunits from being incorporated into the
peptidoglycan matrix. It remains the antibiotic of choice for
treatment of invasive MRSA infections, given its relatively
good safety profile and favorable pharmacokinetics that
facilitate convenient administration. In addition, vancomycin
is the agent for which there is the greatest cumulative clinical
experience for the treatment of a variety of invasive clinical
syndromes including pneumonia, endocarditis, meningitis, and
osteomyelitis.13 Reports of MRSA with either intermediate or full
resistance to vancomycin or high in vitro resistance have spurred
research for newer alternative agents.
Daptomycin is a novel intravenous agent used to combat MRSA
and vancomycin-resistant enterococcus (VRE). It is a cyclic
lipopeptide bactericidal antibiotic that causes depolarization
of the bacterial cell membrane and is used for bacteremia,
endocarditis, and soft-tissue infections due to invasive
nosocomial and community acquired MRSA.14 Heteroresistance
to daptomycin may develop during treatment, especially with
co-exposure to vancomycin, so susceptibility testing may be
necessary during treatment. Daptomycin is also inactivated by
surfactant and is thus ineffective in treating pneumonia caused
by MRSA.15
Linezolid is a bacteriostatic oxazolidinone antibiotic that inhibits
initiation of protein synthesis at the 50S ribosome, and does not
exhibit cross resistance with other protein synthesis inhibitors.
Its mechanism of action may lead to enhanced efficacy against
strains producing toxins such as PVL, alpha-hemolysin, and
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toxic-shock syndrome toxin-1, making it an excellent choice
for initial therapy in severe cases of CA-MRSA.16 Linezolid has
excellent tissue distribution, especially in the lung parenchyma,
and may be administered parenterally or orally due to its high
bioavailability.
Other potential treatment options include tigecycline, a novel
tetracycline derivative that is active against most gram-positive
infections. Tigecycline mono-therapy was deemed as effective as
vancomycin plus aztreonam for complicated skin and soft tissue
infections in a prospective randomized trial. 17 Quinupristindalfopristin, a streptogramin antibiotic whose use is limited
by side effect profile and high cost, has shown efficacy when
used to treat patients who have failed vancomycin. One study
by Drew et al showed 71% response in invasive infections in
patients who could not tolerate or failed vancomycin therapy.18
Several investigational agents are undergoing trials. Dalbavancin
is a semi-synthetic lipoglycopeptide that has been demonstrated
to be at least as effective as vancomycin and linezolid, but has a
half-life of six to twelve days and can be dosed once per week.19
Ceftobiprole is an extended-spectrum cephalosporin similar
to cefepime that can circumvent PBP2a that confers betalactam resistance to MRSA. A randomized trial of 828 patients
demonstrated efficacy similar to vancomycin plus ceftazadime.20
Preparations of staphylococcal antibodies have been investigated
for the treatment of S. aureus bacteremia. Tefibazumab is a
monoclonal antibody that targets clumping factor A, a protein
on the surface of S. aureus that binds to human fibrinogen. Its
current efficacy is debatable.21 Altastaph is an agent consisting
of a pooled group of antibodies to S. aureus capsular polysaccharide types five and eight and may serve as an adjuvant
therapy.22

Prevention

Prevention of CA-MRSA infection remains a community
health challenge as few therapies have proven effective. No trial
data supports the use of empiric nasal mupiracin or topical
chlorhexadine rinse to prophylax against infection.12 Hand
washing and avoidance of contact with infected individuals
is key. Empiric treatment of close contacts of an infected
individual is controversial, and no compelling data exists at
this time. Pets have also been offered as a possible source of
bacterial reservoir, and while transmission from an infected
pet is possible, eradication therapy in household pets is not
currently recommended.12
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Severe Heart Failure and Large Left Ventricular
Thrombus Following Acute Myocardial Infarction
Ankitkumar K. Patel MD, MPH, Scott Silvestry, MD, and Paul J. Mather, MD
Case Presentation

A 58 year-old man who recently underwent a left superficial
femoral artery thrombectomy presented with a three-day history
of worsening exertional dyspnea and bilateral pedal edema. His
past medical history is significant for coronary artery disease,
myocardial infarction, and insulin dependent diabetes mellitus.
The patient initially presented to an outside hospital where he
developed ventricular tachycardia that warranted cardioversion
three times. Initial electrocardiogram showed inferior lead ST
segment elevations and lateral lead ST depression. The patient
underwent a cardiac catheterization that showed triple vessel
disease with total occlusion of the RCA, 90% occlusion of the

LAD, and 50% to 60% occlusion of left circumflex. The patient
had an echocardiogram (Figures 1 and 2) that showed severe
left ventricular dysfunction with an ejection fraction of 10% and
a large mobile thrombus occupying 60% of the left ventricular
cavity and was diagnosed with a dilated cardiomyopathy. The
patient underwent left ventricular thrombectomy (Figure 3),
coronary artery bypass graft (i.e., a saphenous vein graft to LAD)
and installation of a left ventricular assist device. The patient
currently is doing well and is awaiting heart transplantation.

Discussion

An increased incidence of thromboembolism is seen in patients
with left ventricular systolic dysfunction following myocardial
infarction (MI).1 Following an acute MI, the formation of a left
ventricular (LV) thrombus is a significant complication. LV
thrombus occurs in up to one-third of patients with anterior
wall MI and is much more frequent in patients with a large
anterior MI and subsequent heart failure.2 The vast majority
of LV thrombi are of the immobile mural type; unfortunately
for our patient, he had the more rare mobile type which has a
higher risk of embolism.3 LV thrombus has been associated with

Figure 1. Transthoracic echocardiogram shows a large mobile
thrombus occupying 60% of the left ventricular cavity.

Figure 2. In another view, the echocardiogram shows a large
mobile thrombus within the left ventricular cavity.
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Figure 1. Post-operative specimen of left ventricular
thrombetomy.
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dilated cardiomyopathy which leads to increased morbidity and
mortality.4 The mechanism for the development of a mobile
thrombus is not well understood. Moran et al5 hypothesize
that an apical infarction involves the detachment of one end
of the trabecula of the left ventricle which acts as a nidus
for thrombosis. Prompt surgery is warranted once a mobile
thrombus is identified.6 Left ventricular thrombectomy and
coronary artery bypass graft surgery after an acute MI have
increased risks. In order to improve the clinical status of our
patient, he had a left assist device inserted during the surgery
to help reduce the LV workload and provide a bridge to cardiac
transplantation.
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Jaundice in a Leukemia Patient Status-Post Allogeneic
Stem Cell Transplantation
Esther Lee, MD

Case Presentation

A 61 year-old Caucasian female with a past medical history
significant for chronic lymphocytic leukemia (CLL) presented with
dark amber-colored urine, jaundice, and nausea for three days. She
reported increased fatigue and poor appetite but denied fever, chills,
shortness of breath, chest pain, vomiting, abdominal pain, diarrhea,
constipation, or bleeding. She denied any change in her medications
or recent travel history.
She was diagnosed with CLL two years ago and had undergone a
matched unrelated allogeneic stem cell transplant three months
ago. Her post transplant course was complicated by viremia with
cytomegalovirus (CMV) and Epstein-Barr virus (EBV), which were
successfully treated with foscarnet and rituximab, respectively.
Other past medical history included hypertension and basal cell
carcinoma of the face. Past surgeries included a cholecystectomy,
a hysterectomy, and bilateral knee replacements. She denied
alcohol use, smoking, or drug abuse. Medications on
admission included atenolol, a multivitamin, trimethoprim/
sulfamethaxazole, voriconazole, and valacyclovir. She was
allergic to codeine and lorazepam.
Vital signs on admission were stable. Physical exam was
significant for icteric sclera, jaundice, and mild abdominal
discomfort on palpation of the right upper quadrant. Admission
labs were notable for total bilirubin 14.9 mg/dL, direct bilirubin
7.2 mg/dL, alkaline phosphatase (AP) 421 IU/L, aspartate
transaminase (AST) 558 IU/L, and alanine amino transferase
(ALT) 738 IU/L. White blood cell count was 3 B/L with 75%
neutrophils, hemoglobin was 9.5 g/dL, and platelet count was
124 B/L. Her basic metabolic panel was within normal limits.
Her urinalysis was significant for 1+ bilirubin.
Jaundice and abnormal hepatic function tests in this patient with
the history of CLL and allogeneic stem cell transplant raised
concerns for active hepatitis, graft-versus-host disease (GVHD)
of the liver, drug toxicity, hepatic veno-occlusive disease, and
obstructive cholestasis.

Hospital Course

The patient underwent an abdominal ultrasonography with
dopplers that showed a normal liver status-post cholecystectomy
with no intrahepatic or extrahepatic ductal dilatation and
normal hepatic vasculature, ruling out obstructive cholestasis
and hepatic veno-occlusive disease. With her history of
CMV and EBV viremia, it was crucial to rule out residual or
recurrence of either infection. Her CMV viral load was less than
100 copies/ml (reference range <100 copies/ml), and EBV viral
load was less than 350 copies/ml (reference range <350 copies/
ml). Further laboratory studies for Hepatitis A, Hepatitis B,
and Hepatitis C were all negative. Adenovirus, which has been
increasingly known to cause disease in post transplant patients,1
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was also negative. A transjugular liver biopsy was done since
there was no obvious cause of elevated liver function tests
from the available laboratory studies. The liver biopsy revealed
mild portal inflammation and bile duct injury characteristic of
GVHD with moderate cholestasis.
With the diagnosis of GVHD of the liver, the patient was
immediately started on immunosuppressive therapy which
included high-dose methylprednisolone, tacrolimus, and
micophenolate mofetil. Although she continued to have
minimal clinical symptoms other than jaundice, she failed to
show significant improvement in her hepatic function tests.
By hospital day 15, the laboratory results were as follows: total
bilirubin 39.1 mg/dL, direct bilirubin 17.8 mg/dL, AP 557 IU/L,
AST 151 IU/L, and ALT 355 IU/L. While her transaminases were
trending down, total bilirubin, direct bilirubin, and AP were
worsening. Without much improvement with the conventional
immunosuppressive therapy, a monoclonal antibody called
muromonab or OKT3 was added. Muromonab, which is a
monoclonal antibody directed against the CD3 antigen closely
associated with the T-cell receptor, has been used as a second
line therapy in patients who did not respond to steroids for
GVHD.2 Even after the treatment with muromonab for 10 days,
her hepatic function tests did not improve significantly: total
bilirubin 30.3 mg/dL, direct bilirubin 12.7 mg/dL, AP 436 IU/
L, AST 78 IU/L, and ALT 104 IU/L. She was discharged with
oral corticosteroids for continued treatment of her GVHD of
the liver. At this time, it is difficult to predict whether she will
recover completely from the GVHD. Of note, the treatment of
her GVHD was complicated by a rise in her CMV viral load on
day 24 of her hospital stay to 375 copies/mL and clostridium
difficile enterocolitis.

Discussion

Hematopoetic stem-cell transplantation is an important and
common treatment in malignancies and multiple hematologic
disorders. In the early 1960s, allogeneic transplantation
became feasible after the identification and typing of HLA, the
major histocompatibility complex.3 In the 1970s, Thomas and
colleagues conducted successful allogeneic stem cell transplants
in end-stage leukemic patients and achieved first remissions
in more than half of their patients,3 thus laying a foundation
for use of this treatment in conjunction with conventional
chemotherapy and radiation.
When allogeneic stem cell transplantation takes place,
unsuppressed donor T-cells can recognize either major
histocompatibility or minor histocompatibility antigens of
a recipient, which leads to the activation of the donor T-cells
against the recipient’s organs. This phenomenon is also known
as graft-versus-host disease (GVHD).
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GVHD that occurs within 100 days after transplantation is
considered acute GVHD, as was the case for this patient. GVHD
that occurs after 100 days is considered chronic. Both types of
GVHD occur more frequently with cases involving older patients,
unrelated donors, older donors, CMV-positive donors, female
donors, and donors with previous pregnancies or transfusion
sensitization.4 Clinically significant GVHD happens in 30% to
50 % of recipients of allogeneic hematopoietic transplants.4
The primary target organs in GVHD are the skin, liver,
gastrointestinal tract, and the hematopoietic system. The liver
is the second most commonly involved organ in acute GVHD,
and manifests with abnormal liver function tests.5 The earliest
and most common finding is the rise in direct bilirubin and
alkaline phosphatase, which is explained by the fact that GVHD
causes damage to bile canaliculi and results in cholestasis.
The rise in direct bilirubin and alkaline phosphatase is
nonspecific, however, so other causes of hepatic damage require
evaluation. Hepatic infections, primarily viral hepatitis, must be
ruled out since many of these patients are immunocompromised
and are at an increased risk of infection. Another important
diagnosis to consider is hepatic veno-occlusive disease, which is
characterized by obstruction in the hepatic circulation as result
of damaged sinusoidal endothelium.3 Total-body irradiation and
chemotherapy that are used as preparative agents for stem cell
transplant are the cause of this relatively common complication.
Patients with hepatic veno-occlusive disease present with painful
hepatomegaly, jaundice, and retain fluid.3 Another diagnosis
to consider is drug toxicity from chemotherapeutic drugs,
corticosteroids, antibiotics, antifungal agents, and anti-GVHD
drugs.1 Biopsy is the definitive method to diagnose GVHD of
the liver, and transjugular liver biopsy may be preferable over
percutaneous liver biopsy due to the high bleeding risk since
many of these patients are thrombocytopenic. Transjugular
biopsy may be also helpful in assessing the hepatic venous
pressure gradient to identify hepatic veno-occlusive disease.1
The first and most effective treatment of GVHD is the use of
glucocorticoids. Research suggests that starting with low dose
steroids (2mg/kg per day) is appropriate; randomized studies

showed no difference in mean response rates or actual survival
rates between different dosages of steroids. If glucocorticoids
are not successful, other immunosuppressive drugs such
as cyclosporine, tacrolimus, antithymocyte globulin, or
mycophenolate mofetil may be considered. If these treatment
strategies fail, then a more aggressive approach such as using
extracorporeal photophoresis and monoclonal antibodies
directed against CD 25, TNF-alpha, T-cell receptor, and IL-2
receptor may be considered.2
In summary, this is a case of a 61 year-old female with a history
of CLL status-post allogeneic stem cell transplant who presented
with jaundice and a rise in bilirubin and alkaline phosphatase on
laboratory testing, which raised concerns for possible GVHD of
the liver. However, it was very important to consider all other
disease possibilities. Especially in this case, a distinction between
an active infection versus graft-versus-host disease was crucial as
immunosuppressive therapy would have worsened the patient’s
condition if the cause had been an active infection. The patient
underwent a transjugular liver biopsy that was consistent with
the GVHD of the liver, and she has been on different regimens
of immunosuppressive drugs. The immunosuppressive therapy
for the GVHD led to the complications of elevation of the CMV
viral load and clostridium difficile infection, which highlights
the fact that sometimes medicines intended for treatment can in
effect cause harm. This reinforces the lesson to always weigh the
benefits against the risks when choosing to implement a therapy.

References

1.

Levitsky, J, Sorrell, MF. Hepatic complications of hematopoietic cell transplantation. Current Gastroenterology Reports. 2007; 9:60-5.

2.

Chao, NJ, Negrin, RS, Landaw, SA. Treatment of acute graft-versus-host disease:
clinical trials. UpToDate. 2008.

3.

Copean, EA. Hematopoietic stem-cell transplantation. New England Journal of
Medicine. 2006; 354:1813-26.

4.

Antin, JH. Long-term care after hematopoietic-cell transplantation in adults.
New England Journal of Medicine. 2002; 347: 36-42.

5.

Chao, NJ, Negrin, RS, Landaw, SA. Clinical manifestations and diagnosis of acute
graft-versus-host disease. UpToDate. 13 June 2008. 10 Aug 2008. <http://www.
uptodate.com>.

6.

Goker, H, Haznedaroglu, IC, Chao, NJ. Acute graft-vs.-host disease:
pathobiology and management. Experimental Hematology. 2001; 29:259-277.

24

A 57 Year-old Man With Prolonged Shortness of Breath
and Fevers
Loren Chen, MD

Case Presentation

A 57 year-old Caucasian male was initially admitted to Methodist
Hospital from an outside hospital for dehydration, increased
heart rate, and weight loss. He has a past medical history of
coronary artery disease status post myocardial infarction and
coronary artery bypass graft, congestive heart failure, paroxysmal
atrial fibrillation on coumadin, diabetes type II on insulin, and
an orthotopic liver transplant in 1997 for end-stage liver disease
secondary to hepatitis C virus and alpha-1 antitrypsin disorder.
At the outside hospital, his one-month hospital course was
complicated by acute on chronic renal failure which warranted
hemodialysis, anemia that required transfusions, MRSA line
sepsis from his Perm-A-Cath treated with vancomycin, and
pneumonia, which was possibly secondary to aspiration. The
patient was transferred to our facility for further management.

He continued to have intermittent fevers, shortness of breath,
a non-productive cough, and hypoxia that required oxygen
therapy. Prior to this prolonged hospitalization, the patient was
able to breath on room air. Serial chest radiographs showed
increasing pulmonary infiltrates despite treatment with a
triple antibiotic regimen. At this time, physical exam was only
remarkable for bibasilar, course crackles, but no wheezes or
rhonchi. He had a trans-thoracic echocardiogram that was
negative for endocarditis, a CT of the abdomen and pelvis that
was negative for abscess, and a chest CT that showed persisting
bilateral lower lobe pulmonary opacities, left greater than right,
and scattered abnormal mediastinal lymph nodes (Figure 2).
Cultures were negative since his episode of E. coli bacteremia,
and labs were unremarkable.

Additional past medical history is significant for hyperlipidemia,
depression and C3 to C5 fracture. Additional surgeries include
AICD placement, a C3 to C4 diskectomy, cholecystectomy and
appendectomy. Social history was negative for alcohol and
substance abuse, but positive for a 30 pack year smoking history,
which he quit one year ago. Family history was significant for
diabetes, coronary artery disease and lung cancer. Current
medications included amiodarone, aspirin, carvedilol, nexium,
zetia, insulin, nebulizers, sirolimus, vancomycin, zosyn, and
gentamicin. His only allergy was to meperidine.
Initial vital signs were temperature 98.9˚ Fahrenheit, pulse 77
beats/minutes, respirations 16 breaths/minute, blood pressure
126/70 mm Hg, oxygen saturation 99 % on room air. The patient
was in no acute distress. Physical exam was significant only for
bilateral crackles at the lung bases, multiple skin tattoos, a rightsided Perm-A-Cath in the chest that was non-tender without
surrounding erythema or swelling, and a surgical scar in the
right upper quadrant.
Chest radiograph on admission showed a right lower lobe
consolidation, and he was continued on antibiotics for presumed
pneumonia. The patient appeared to be improving after
finishing his course of antibiotics for line sepsis and suspected
pneumonia, and plans were made to transfer him to a subacute
rehab with outpatient dialysis. One week after hospital transfer,
he developed fevers and chills with accompanying shortness of
breath. Blood cultures grew out pan-sensitive E. coli from his
Perm-A-Cath. The catheter was removed and a Shiley catheter
was placed. After completing a course of antibiotics, he remained
afebrile, and when his blood cultures showed no growth for 48
hours, another Perm-A-Cath was placed. However, he became
febrile again. A repeat chest radiograph showed increasing left
lingular pneumonia in addition to an unchanged right lower
lobe consolidation (Figure 1). At this point, he finished a course
of empiric moxifloxacin which was recommended by the
infectious disease service.
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Figure 1. Chest radiograph shows persistent, asymetric,
bilateral parenchymal infiltrates without change from two
weeks prior. No effusions noted.
A bronchoscopy showed normal airways and no endobronchial
lesions. Biopsies and bronchial alveolar lavage (BAL) were
taken from the superior segment of the left lingua. The BAL
revealed numerous foamy, hemosiderin-laden macrophages,
and the biopsy revealed interstitial pneumonitis consistent with
amiodarone-induced lung toxicity. Stains were negative for
malignant cells.
Amiodarone and antibiotics were stopped, and the patient was
started on prednisone 50 mg PO once daily (1mg/kg/day) with
a taper to 20 mgs per day as his infiltrates cleared. Within one
week of treatment, his fevers resolved with near resolution of
his respiratory symptoms by the time of transfer to rehab. His
vasculitis labs including ANCA, ANA, ESR, double-stranded
DNA, anti-Jo, RF, anti-GBM and IgA, were negative. Further tests
for Legionella, AFB, respiratory viruses, hepatitis B, HIV, CMV,
and EBV were negative. In regards to his atrial fibrillation, since
amiodarone was discontinued, his carvedilol was increased, and
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Figure 2. Chest CT shows persistent bilateral lower lobe
pulmonary opacities, left greater than right, extending to the
periphery.

Figure 3. Two month follow-up chest CT shows resolving
infiltrates and ground glass opacities.

the patient remained in sinus rhythm throughout the rest of his
hospitalization.

for atrial fibrillation and acute management of sustained
ventricular tachyarrythmias.2 It can have a prophylactic role
during the perioperative period of cardiac surgery and may be
an effective adjunct to implantable cardioverter-defibrillator
therapy to reduce the number of shocks. However, adverse
side effects are common and include corneal microdeposits
(>90%), optic neuropathy/neuritis (<1% to 2%), blue-gray
skin discoloration (4% to 9%), photosensitivity (25% to 75%),
hypothyroidism (6%), hyperthyroidism (0.9% to 2%), peripheral
neuropathy(0.3%), hepatotoxicity (15% to 30%), hepatitis and
cirrhosis (<3%), and pulmonary toxicity (1% to 7%).2

A follow-up chest CT two months later revealed significant
improvement of his infiltrates and ground glass opacities.

Discussion

Although amiodarone is approved by the Food and Drug
Administration only for refractory ventricular arrhythmias,
it is one of the most frequently prescribed antiarrhythmic
medications in the United States.1 According to a large evidencebased review, amiodarone has clinical value in patients with left
ventricular dysfunction and heart failure as first-line treatment
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Amiodarone was initially developed in the 1960s as an antianginal
agent due to its vasodilatory properties and serendipitously
was found to suppress arrythmias. Despite widespread use for
nearly two decades in Western Europe, there were no reported
cases of associated pulmonary toxicity until 1980, after it was
introduced as an investigational agent in this country. This
was initially thought to be due to the higher doses used for
ventricular arrythmias,3 but retrospective analysis revealed that
cases had been observed in Europe, but were missed. Currently,
amiodarone-induced pulmonary toxicity (APT) carries a
mortality between 21% to 33% of patients who are admitted to
the hospital.4
The cause of APT is not well understood. Amiodarone and
its metabolite, desethyl-amiodarone (DEAm), are amphiphilic
cations which accumulate in tissues, including the lung. It can
also infiltrate into the liver, skin, thyroid, and eye, which are
other common sites for adverse effects. In regards to pulmonary
toxicity, amiodarone can damage lung tissue directly via a
cytotoxic process and indirectly via immunological reactions,
supported by findings of CD-8-positive, cytotoxic T cells on
bronchoalveolar lavage often in combination with polymorphonuclear cells, increased production of toxic oxygen radicals, and
accumulation of phospholipids complexes which interfere with
normal cellular metabolic pathways.4, 5, 6
Risk factors for developing APT are increased age, pre-existing
lung disease, recent pulmonary insults, cardiopulmonary surgery
involving oxygen given at high concentrations, and dosages
greater than 400mg/day. It is more frequent in men and unusual
in patients younger than 40 years old, though rare case have been
described in children. Most amiodarone-induced pulmonary
manifestations are found to occur when the dosage exceeds
400mg/day administered for more than 2 months or when a
lower dosage is given for more than 2 years.2, 4, 5 However, APT
has been noted to occur in lower doses, albeit not as frequently.7
On average, pulmonary toxicity will develop in 5% to 15% of
patients who take 500mg/day or more and 0.1% to 0.5% who
take up to 200mg/day.4
The diagnosis of APT is one of exclusion including, but not
limited to heart failure, infectious pneumonia, organizing
pneumonia, pulmonary embolism, pulmonary infarct, and
malignancy. Onset of pneumonitis can develop at any time from
a few days after an initial loading dose to more than a decade
into treatment. Signs and symptoms are generally nonspecific
and include nonproductive cough, dyspnea, fever, weight loss,
and pleuritic chest pain.
Physical exam typically reveals bilateral rales. Patients with
APT may have nonspecific elevations in WBC, LDH, and
ESR. Amiodarone levels or DEAm have not been shown to be
predictive or diagnostic of APT. Pulmonary Function Testing
usually demonstrates typical changes of restrictive lung disease
and reduced diffusing capacity of the lung for carbon monoxide
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(DLCO), but most patients on amiodarone already have abnormal
PFTs.2
Chest radiograph may reveal diffuse or localized interstitial,
alveolar, or mixed opacities, and often presents with an
asymmetrical pattern. It can also be accompanied by pleural
thickening, especially if the opacities are localized in the
periphery, pleural effusion, or a mass (or masses). Acute
Respiratory Distress Syndrome (ARDS) can occur in patients
treated with amiodarone almost exclusively following thoracic
surgery. Diuresis that does not result in clearing of pulmonary
infiltrates should increase consideration of APT. 2,4 Most
progressing lung parenchymal disorders will eventually be
evaluated by a bronchoscopic evaluation.
In the setting of APT, on bronchoalveolar lavage, the presence
of foam cells with lamellar inclusions in patients chronically
exposed to amiodarone is a routine finding and dose not
indicate drug toxicity. However, the absence of foam cells makes
APT highly unlikely. A lung biopsy specimen of substantial size
maybe required to establish a more certain diagnosis and would
reveal parenchymal lung changes consistent with nonspecific
interstitial pneumonitis, organizing pneumonia, or diffuse
alveolar damage. It may also be useful in revealing another
potential cause of pulmonary injury, such as malignancy.
However, since ARDS can develop in patients on amiodarone
following thoracic surgery, open or thoracoscopic lung biopsies
are indicated when an accurate diagnosis is required early for
example, in patients in whom amiodarone cannot be held
without risks, if a diagnosis of pulmonary opacities is required
prior to heart surgery, and in patients who do not improve by
one to two months after drug cessation and initiation of steroids
to evaluate for other causes.4
In summary, one should consider the diagnosis of APT in the
presence of three or more of the following: new or worsening
symptoms or signs, new abnormalities on chest imaging, a
decline in the total lung capacity >15% or DLCO >20%, presence
of phospholipidosis in lung cells, a marked CD8+lymphocytosis
in lavage fluid, a lung biopsy that reveals diffuse alveolar damage,
organizing pneumonia, interstitial pneumonitis, or fibrosis, and
improvement in respiratory status following withdrawal of the
drug with or without steroid therapy.2
Treatment of APT consists primarily of discontinuing
amiodarone. This can, however, lead to an increased risk of
recurrence of life-threatening arrhythmias. One option is to
substitute another antiarrhythmic medicine though it may have
more negative inotropic and proarrhythmic effects. Another
option is to withhold amiodarone for several days, and then,
reduce the dosage to its lowest effective level, though pulmonary
toxicity has been noted to still occur at such doses. Other
options include radiofrequency ablation of a causative re-entry
mechanism and implantation of an automatic cardioverter
defibrillator.5 Despite the lack of controlled studies, there is
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growing evidence that corticosteroids are beneficial. The current
recommendations are to start with an adequate dose of 0.75 to
1mg/kg of prednisolone or equivalent. The initial dosage should
then be maintained until definite clinical and radiographic
response is obtained, otherwise consider increasing the dose.
Tapering should be slow since recurrences have been described
up to eight months of cessation of therapy. A reasonable estimate
of duration of treatment is six months, more often one year, and
patients should be monitored carefully after discontinuation of
corticosteroids for possible recurrence. Clinical improvement
and clearing of pulmonary opacities typically require one to
three months. Toxic effects may continue and even temporarily
progress because of its persistence in the lung and accumulation
in fatty tissues leading to a long half-life of up to 45 days.2, 4, 5
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A 61 Year-old Man With Delayed Hypersensitivity
Reaction to Joint Prosthesis
Regina C. Lee, MD
Case Presentation

61 year-old male with a past medical history of coronary artery
disease complicated by myocardial infarction in 1984, type 2
diabetes mellitus, hyperlipidemia, hypertension, and right total
knee replacement in 2006 presents to the outpatient allergist’s office
for evaluation. The patient reports that he never fully recovered
after the knee surgery and never regained function. The right knee
remained swollen and painful with limited range of motion and
weight bearing as a result. He denies any rash, redness, or itching in
the area. He also denies any history of reactions to metals in the past.
The orthopedic surgeon referred the patient to an allergist to assess
for an allergic reaction to various components of the orthopedic
hardware prior to the right knee revision surgery.
The patient has no known drug allergies. His medications include
insulin 70/30 at breakfast and dinner, diltiazem CD 360 mg daily,
simvastatin 20 mg daily, lisinopril 10 mg daily, metoprolol 12.5 mg
twice daily, nitroglycerine patch for 12 hours daily, alprazolam 5mg
three times a day for anxiety, and naproxen and percocet as needed
for pain. The patient is a lifetime non-smoker and stopped drinking
alcohol over 20 years ago. Family history is significant for coronary
artery disease and prostate cancer. There is no family history of
asthma or allergy.
At the initial visit, the patient was afebrile with stable vital signs.
The physical exam was unremarkable except for right knee
swelling, decreased range of motion, a well-healed midline scar,
and 1+ edema of the right lower extremity up to the knee. The
knee was non-tender and no warmth or erythema was noted.
To evaluate for delayed hypersensitivity reaction, a panel of
allergens using the Thin-layer Rapid Use Epicutaneous (TRUE)
patch test were placed on the patient’s skin. A vitallium metal
disk, a known component of the prosthesis, was also placed on
the patient’s skin. At 48 hours, the patch test was clearly positive
for black rubber and possibly positive for potassium dichromate
and Balsam of Peru. Since the patch did not stay entirely adherent
to the skin, the adhesive was reinforced and the patient was
instructed to return the next day for a 72-hour reading. At the
second reading, the test remained strongly positive to black
rubber. In addition, potassium dichromate showed strongly
positive reaction, and cobalt dichloride showed weakly positive
reaction. Upon re-examination, the reaction to Balsam of Peru
appeared more likely to be irritation and not a true reaction.
Given that the patient’s knee prosthesis was composed of 30%
chromium, suspicion for metal allergy to the prosthesis was high.
The finding was communicated to the orthopedic surgeon for
consideration in further management of the patient’s condition.

Discussion

Metal hypersensitivity is common in the general population and
often manifests as contact dermatitis to various everyday items
including jewelry, watches, and belt buckles. The exposure may
also occur in the form of metal ions dissolved in food and water.
29

If ingested, metal ions can cause similar dermatological reactions
or more systemic reactions such as asthma-like symptoms.1
The most common metal hypersensitivity is to nickel, followed
by cobalt and chromium.2 Nickel and cobalt show significant
cross-reactivity.
Metal allergy involves the type IV hypersensitivity response,
also known as the cell-mediated delayed-type hypersensitivity
(DTH). In DTH reaction, antigens are taken up and expressed
on antigen presenting cells (APCs) which activate sensitized Th1
lymphocytes, a subpopulation of T-cells. The T-cells then release
various cytokines, which in turn recruit and activate macrophages,
monocytes, neutrophils, and other inflammatory cells.3 Activated
macrophages can trigger the activation of more T-cells, perpetuating
the inflammatory response and leading to extensive tissue damage.3
Metals or metal ions on their own are not known to activate the
immune system. Rather, it is the metal-protein complexes, formed
by the degraded metal products binding to the native proteins, that
can function as antigens and elicit an immune response.3 Specific
APCs and T-cell receptors implicated in the DTH responses to
metal are yet unidentified, and the current management for metal
hypersensitivity is mainly based on exposure avoidance.
Metal prostheses, as with all metal exposed to biological
environment, are known to corrode over time and release wear
debris into the joint space. Nickel and cobalt ions seem to clear
rapidly from the synovial space and are eliminated in the urine, but
chromium appears to be stored in the tissue and eliminated more
slowly.5 Concern for metal hypersensitivity to joint prosthesis
was first raised in several case reports from the early 1970s, which
noted that some patients with metal-on-metal joint replacement
developed reactions that may be allergic in nature.1 Since then,
implant-related metal hypersensitivity has been documented
in numerous case reports and cohort studies. Still, as a clinical
entity, it is only loosely characterized and poorly understood.
Commonly reported findings include eczematous rash, either
generalized or on the skin overlying the orthopedic implants, along
with discomfort, pain, erythema, and swelling over the affected
joint.2 Some patients also report malaise, fatigue, and general
weakness.2 Most concerning of all, DTH to metal prostheses has
been cited as at least partially responsible for “aseptic loosening”
of the prosthetic joint, in which chronic imflammatory-mediated
osteolysis around the implant leads to loss of fixation and eventual
implant removal.4 In suspected cases of implant-associated DTH
reactions, the synovial fluid tends to be culture negative and have
only few leukocytes. Histologically, inflammation and oligoclonal
T-cell infiltrates are present in the peri-implant tissue, indicating
an immune-mediated process, and cytokines typical of DTH,
such as IL-6 and INF-γ, are expressed in high concentrations.5
The conventional method of diagnosing metal hypersensitivity is
by patch testing, in which a panel of antigens is exposed directly
onto the skin for 48 to 96 hours, and the resulting dermatological
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reactions are graded.3 It is a less-than-ideal method since the skin
is a natural barrier that protects the immune system from antigen
exposure. In the case of implant-associated metal hypersensitivity,
patch testing is even more unreliable since the synovial cavity has
a different cellular and biochemical composition than the skin.2
Furthermore, there is at least the theoretical concern that patch
testing could induce a hypersensitivity reaction in previously
insensitive patient.3 Several in vitro studies for testing DTH are
available, although their value specifically in implant-associated
metal hypersensitivity has not been studied extensively.
Lymphocyte transformation testing (LTT) measures the
proliferative response of lymphocytes to a designated challenge
antigen.3 Leukocyte migration inhibition testing (LIF or MIF)
measures the migration of lymphocytes on a culture medium
in the presence of a sensitizing antigen which tends to inhibit
migration.3 Unfortunately, both LTT and LIF are labor-intensive
and lack the sensitivity and specificity to be reliable in the clinical
setting. At this time, diagnosis of implant-associated metal
hypersensitivity is largely based on clinical presentation and
exclusion of other etiologies.
Can patients be screened for metal allergy prior to undergoing
joint replacement surgery? Some studies have suggested that
patients with documented metal allergy have more symptoms
of implant-associated DTH and that positive patch test to metal
is more common in patients with failed joint prostheses than
in those with well-functioning prostheses.1 However, studies
that looked at pre- and postoperative sensitization to metal
showed that a significant number of patients develop metal
sensitivity postoperatively.1,3,4 Furthermore, only a fraction of
those with positive patch test, both pre- and postoperatively,
developed clinical manifestations of DTH to metal implants.1,3,4
In fact, many of those with positive patch tests had no history of
reaction to metal. Studies that used in vitro tests independently
or in combination with the patch test also failed to produce any
consistent findings. At this point, there is no reliable method to
assess for implant-associated metal allergy preoperatively.

Since DTH does not involve the histamine-release pathway, the
common allergy medications are ineffective in treating metal
prosthesis allergy. Low-dose corticosteroids have been used as
a temporary solution, but their numerous adverse side effects
deem them inappropriate for long term treatment.2 As with
the cutaneous form of metal hypersensitivity, the definitive
treatment for implant-associated metal hypersensitivity is
elimination and avoidance, or, in other words, surgical removal
of the metal prosthesis. Although removal of the offending
prosthesis generally leads to complete and prompt healing, the
revision surgery is obviously a serious undertaking. Biologically
more inert materials are under investigation as alternatives to the
currently available metal prostheses. Also, research is underway
to determine genetic polymorphisms for factors involved in
DTH and to develop targeted immunosuppressive agents.4
Implant-associated metal hypersensitivity is an extremely
rare condition. However, in those few who are affected the
consequences are grave. The condition is probably underrecognized and under-reported due to the difficulty of diagnosis.
More research, including longitudinal prospective studies, are
needed to better understand this immunological, rheumatological,
and surgical enigma.
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Primary Care Follow Up Post Mitral Valve Surgery at
Ambulatory Clinic
Andrew Yin, MD

Case Presentation

A 67 year-old Cantonese speaking male was seen at primary care
clinic with complaints of dyspnea on exertion and decreased
exercise tolerance. His medical history includes rheumatic
heart disease, tricuspid regurgitation, tricuspid repair three
months ago, mitral regurgitation, mitral valve replacement with
a bioprosthetic valve three months ago, atrial fibrillation on
anticoagulation therapy, permanent pacemaker implantation,
severe pulmonary hypertension, benign prostatic hypertrophy,
gastroesophageal reflux disease, and iron deficiency anemia.
The patient reports that in the last two weeks, he has been
unable to ambulate more than two blocks limited by shortness
of breath, which represents an acute change. He also complains
of bilateral lower extremity edema. He reports that two weeks
after his mitral valve replacement, his exercise tolerance was
dramatically improved, and he was able to ambulate more than
two blocks without difficulty.
He denies associated cough, lightheadedness, dizziness, chest
discomfort, abdominal discomfort, nausea or vomiting. He
reports occasional palpitations that are not associated with his
episodes of dyspnea on exertion. Dyspnea resolves with rest in
minutes. He denies recent fevers, sweats, and chills. Medications
include metoprolol 25 mg twice a day, warfarin 4 mg daily,
furosemide 40 mg daily, enteric-coated aspirin 81 mg daily,
sustained-release potassium chloride 20 mEq daily, ferrous
sulfate 300 mg three times per day, colace 100 mg twice per day,
sennosides 8.6 mg daily and omeprazole 20 mg daily
On physical examination, the patient was alert and oriented to
person, place, and time and not in acute distress, afebrile, with
a heart rate of 76 beats/minute, blood pressure of 90/60 mm
Hg, respiratory rate 14 breaths/minute. Pupils were equal and
reactive to light, and extraocular muscles were intact. There
were no carotid bruits bilaterally, and jugular venous pressure
was estimated at 16 cm of water. His lungs were clear to
auscultation bilaterally with no wheeze, no crackles, nor rales.
Cardiac exam demonstrated a midline sternal surgical scar,
an irregularly irregular heart rhythm, no murmurs, gallops,
nor rubs. Abdominal exam demonstrated a soft, nontender,
nondistended abdomen with normoactive bowel sounds and
no organomegaly. His extremities did not demonstrate lower
extremity edema, clubbing, or cyanosis, and his pulses were 2+
radial, 2+ femoral, and 2+ dorsalis pedis bilaterally. Neurologic
exam did not reveal any focal deficits.
Electrocardiogram demonstrated atrial fibrillation with a
ventricular response rate of 90 beats per minute, normal axis,
peaked T waves, and no acute changes suggestive of ischemia.
Routine basic metabolic panel done five days prior to his office
visit was remarkable for a potassium of 5.0 mEq/L.
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The patient also had an appointment with his cardiologist
for evaluation of his symptoms. After the evaluation he was
admitted directly to hospital for further evaluation of his new
symptoms of congestive heart failure. His admission labs were
unremarkable with the exception of B-type natriuretic peptide
of 1463 pg/mL. His admission chest x-ray was suggestive of a
left pleural effusion, cardiomegaly and pulmonary edema.
Transthoracic echocardiogram revealed the bioprosthetic valve
in the mitral position had its ventricular side tilted toward the
interventricular septum. There was no evidence of rocking of the
mitral prosthesis. The peak mitral valve gradient was 13 mm of
Hg. The mean transmitral valve gradient was 4 mm of Hg. The
estimated mitral valve area was 2.6 cm2 which is described as
normal in the setting of a prosthetic valve. There was a moderate
paravalvular regurgitant leak between the prosthesis and lateral
wall of the left ventricle (LV). The effective regurgitant orifice
area of the paravalvular leak is estimated at 0.33 cm2. There was
evidence of mild aortic regurgitation, mild left atrial enlargement
and an overall severely decreased LV systolic function with
segmental wall motion abnormalities. The distal half of the LV
is akinetic. The proximal walls were severely hypokinetic. LV
ejection fraction was estimated to be 20%, and there was right
ventricular (RV) enlargement with decreased function. There
was no evidence of vegetations on the valves or pacemaker leads.
Compared with an echocardiogram done one month following
replacement, of his mitral valve, there was interval deterioration
of LV function. The paravalvular leak appeared unchanged.
Computed tomography of the thorax without contrast
demonstrated an irregular consolidation in right upper lobe
which was indeterminate, but most likely represented atelectasis
and/or pneumonitis, bilateral pleural effusions, a left lower
lobe consolidation and an enlarged left heart post mitral and
tricuspid valvular repair.
Cardiothoracic surgery was consulted. Due to the malpositioning of the prosthetic valve and evidence of worsening
ventricular function, it was decided that the patient would need
another operation to replace his prosthetic mitral valve.

Discussion

Heart valve surgery is still considered one of the most important
advances in patients with symptomatic, severe valvular heart
disease.1 Annually, there are an estimated 42,000 mitral valve
procedures in the United States.2 It is important to appreciate
that replacement of a diseased valve is not a cure for the valvular
disease process, but rather an exchange of the native disease
for a new set of complications that are associated to the new
valve prosthesis.3,4 For this reason, the frequency and intensity
of follow up and evaluation of prosthetic valves is similar to
the follow up of newly diagnosed native valve disorders. The
American College of Cardiology (ACC) and the American
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there is any change in clinical status or development of new
symptoms. An echocardiogram is indicated in any patient
whenever there is evidence of a new murmur or change in
clinical status, when there are questions about prosthetic
valve integrity and function, and when there are concerns
about ventricular function. If the patient develops valvular
regurgitation, close follow up with echocardiography every
three to six months is indicated.
Patients who do not improve after surgery or who later show
deterioration of functional capacity should be evaluated
with an echocardiogram and, if necessary, transesophageal
echocardiography and cardiac catheterization with
angiography to determine the cause.

Figure 1. The patient’s chest radiograph shows cardiomegaly,
pulmonary vascular congestion, developing consolidation in
left lower left lower lobe, a left-sided dual chamber pacemaker,
midline sternotomy wires, and evidence of a tricuspid
annuloplasty ring.
Heart Association (AHA) Task Force recommends the following
guidelines for evaluation and management of patients after
valve replacement:3
The first postoperative outpatient evaluation should be
two to four weeks after hospital discharge. By this time, the
patient’s physical capabilities and expected improvement in
functional capacity can be assessed. The focus of this initial
evaluation is to assess for infection and myocardial infarction,
an assessment of function of the prosthetic valve, electrical
conduction and other valvular disorders. Follow up should
include an interval post-op history, physical examination,
an electrocardiogram, complete blood count, electrolytes,
an INR as indicated for management of anticoagulation
therapy and a transthoracic Doppler echocardiogram.
Echocardiography can provide information about
prosthesis stenosis or regurgitation, valve area, pulmonary
hypertension, LV or RV hypertrophy, LV and RV size and
function, pericardial effusion and thickening, perivalvular
regurgitation and assess function of the other heart valves.
This initial echocardiogram is important to establish
baseline characteristics of the prosthetic valve if one was
not yet done prior to discharge.
Follow up of asymptomatic patients should be conducted
annually. No further echocardiographic testing is required
after the initial postoperative evaluation in patients who are
stable and do not have symptoms or clinical evidence of LV
dysfunction, prosthetic valve dysfunction, or dysfunction
of other heart valves. Reevaluations should be conducted if

Prosthetic heart valves are associated with a number of
complications including structural failure or deterioration, valve
obstruction from thrombosis, systemic embolization, bleeding,
endocarditis, impaired LV systolic function, hemolytic anemia,
and other infections. Perivalvular leakage, a form of structural
failure, is common. Severe perivalvular regurgitation maybe
inaudible on physical exam. Most are detected intraoperatively during the original valve surgery. Rates are reported to
be between 18 to 48%.5,6 The majority of perivalvular leaks are
trivial and are not clinically significant and do not progress.5,6
Our patient’s work up revealed that not only was his prosthetic
mitral valve malpositioned, but also his echocardiogram showed
an interval decline in his left ventricular systolic function three
months after operation.
Re-operation to replace a prosthetic heart valve is a considered
serious clinical event. The ACC/AHA Task Force recommends
re-operation for moderate to severe prosthetic dysfunction
(structural and nonstructural), dehiscence, and prosthetic
endocarditis. Other indications include patients who have
recurrent thromboembolism, severe intravascular hemolysis,
severe recurrent bleeding from anticoagulant therapy, and
thrombosed prosthetic valves. Stable patients without prosthetic
valve endocarditis under many circumstances who requires
reoperation are only slightly greater operative risk compared
to the risk of the initial surgery. In patients with catastrophic
prosthetic valvular dysfunction, surgery is clearly indicated
and urgent. Patients without endocarditis or severe prosthetic
valve dysfunction require careful hemodynamic evaluation,
and the decision about reoperation should then be based on
hemodynamic abnormalities, symptoms, ventricular function,
and the natural history of the particular prosthesis.3
In summary, patients who undergo mitral valve replacement for
treatment of their disease are not completely cured of valvular
heart disease and must be followed with the same care as
patients with native valve disease.7 A number of post-operative
complications are common and may develop early or late in
the post-operative period. The ACC/AHA Task Force on the
management of valvular heart disease recommends close annual
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evaluation and a baseline echocardiogram initially to monitor
valve structure and function. Though patients generally follow
up with subspecialists for evaluation of their prosthetic valves,
our patient sought all of this medical and post-operative care
with his primary care physician because of because of language
and cultural barriers. It is therefore critical that primary care
physicians also recognize the signs and symptoms of the serious
complications related to prosthetic valves.

Hospital Course

On day five of his hospital course, the patient was brought to the
operating room for a replacement of his prosthetic valve. It was
discovered that the patient had three major defects. The first was
a 0.5 cm defect near the mitral-aortic continuity with the surgical
pledgets having torn through the annulus with subsequent
partial dehiscence of the prosthetic mitral valve. The tissue
around the dehiscence was friable and could not be repaired.
The prosthesis was excised and replaced. The second defect was
a linear tear below the left coronary cusp of the aortic valve that
disrupted the aortic ventricular continuity. The defect could not
be repaired and thus was also replaced. Lastly, the third defect
was a tear of the pericardium which was repaired using a sheet
of bovine pericardium. Intraoperatively, the patient continued
to have significant bleeding from behind the aortic root and
was treated with various hemostatic agents including Biogel
and Surgicel. He required multiple vasoactive medications and
required multiple units of blood products but continued to be
hemodynamically unstable with a pressure of 55/30 and a heart
rate of 60 beats per minute. His cardiac rhythm on telemetry
demonstrated multiple episodes of ventricular tachycardia. His
condition and gravely poor prognosis was discussed with his

Photograph courtesy of
Esther Lee, MD

33

family, and it was decided that the medical team would halt all
attempts at cardiac resuscitation. The patient expired shortly
after with his family at his bedside.
His family consented to an autopsy which revealed evidence of
rheumatic heart disease, RV and LV dilatation and hypertrophy,
and left atrial dilatation. His lungs had signs of acute and
chronic passive congestion. Interestingly, there were histological
signs of adenocarcinoma in his prostate. His final cause of
death was determined to be due to pericardial and mediastinal
hemorrhage status post open heart surgery for mitral and aortic
valve replacement.
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A 55 Year-old Man With Mental Status Change and
Severe Anemia
Sugeet Jagpal, MD, and Anastasia Shnitser, MD
Case Presentation

A 55 year-old male with past medical history significant for mental
retardation, a stage IV sacral decubitous ulcer, iron deficiency
anemia and gastrointestinal bleeding presented from a long term
care facility for acute onset of respiratory distress and change in
mental status. On presentation the patient was found to have a
GCS of three, and he was emergently intubated in the emergency
department for airway protection. Following intubation his vital
signs were stable.
Upon review of his recent lab work, it was noted that patient had
hemoglobin (Hgb) of 6.4g/dL the day prior to admission with
a known baseline of 8g/dL. A blood transfusion was ordered.
However, the transfusion was delayed secondary to difficulties in
cross matching the patient’s blood. His admission labs returned
with a Hgb of 2.6g/dL, a stool guiac test was negative, and an
elevated LDH as well as positive direct Coombs C3 complement
and IgG were noted. The patient was transfused two units of Oblood while the blood bank worked to determine which antibodies
the patient had and find a suitable match. Eventually, the patient
was diagnosed with cold agglutinin autoimmune hemolytic anemia
based on an increase in his cold agglutin IgM antibody titer. At that
time, the options were to either delay further transfusion as it would
potentially worsen the hemolysis or to transfuse warmed blood.
Shortly after admission the patient became febrile, hypotensive
and tachycardic. Despite treatment with antibiotics and fluids,
the patient lost his pulse and required cardiopulmonary
resuscitation. Lab work during the code showed a Hgb of 2.7 g/
dL, and the patient was given additional units of warmed blood.
Unfortunately, the patient did not respond and expired within 24
hours of admission.

Discussion

Autoimmune hemolytic anemia (AIHA) is a disease in which
antibodies bind to red blood cell surface antigens and initiate
blood cell destruction. AIHA can be classified into warm and cold
reactive antibody disease. With cold agglutinin AIHA, it is thought
that the antibody binds to blood cells in the periphery (since blood
cools as it passes through the smaller peripheral vessels), activating
a complement cascade to the stage of C3b. C3b continues to adhere
to the red blood cells (RBCs) while they are in circulation. The C3bcoated RBCs encounter receptor specific macrophages, which then
engulf the RBCs and are cleared in the liver.

Cold agglutinin AIHA can range in severity from mild to life
threatening, and febrile illnesses can exacerbate chronic mild
hemolysis due to the elevation in complements as part of the acute
phase reaction. Diagnosis of this anemia is made by measuring the
cold agglutin IgM antibody titers– the antibody titers measured
at 4° C are greatly increased (up to 1:1 × 106) from a normal low
titer of <1:16 at 4° C. Also, the thermal amplitude of the antibody
is increased, and the antibody binds to the surface of RBCs at
temperatures as high as 28° to 32° C, when the normal thermal
amplitude of the antibody does not allow binding between 20 to
37 ° C.1
Rapidly developing anemia with defects in tissue perfusion, such as
in our patient, requires urgent treatment. However, treatment with
blood transfusions can be difficult due to the ongoing hemolysis.
Transfusion of warmed blood decreases the hemolysis because the
antibody binding is impaired at warmer temperatures. Steroids
are often given in conjunction with transfusions to blunt the
patient’s immune response. Inducing hypothermia is sometimes
part of the treatment in attempt to maximize tissue oxygen
delivery.2 Splenectomy, although mentioned in the literature, is
usually not helpful since the macrophages are primarily cleared in
the liver. There are also a few reports of successful treatment with
monoclonal antibodies; however, they are not used for rapidly
progressing hemolytic anemia.3
Patients with primary cold agglutinin disease usually have moderate
anemia with occasional attacks of acrocyanosis when exposed to
cold. These patients are generally elderly (70 to 80 years old) and
have underlying malignancies. When a younger patient such as
ours presents presents with acute onset of cold agglutinin disease,
an infection with either Mycoplasma pneumoniae or infectious
mononucleosis should be suspected. In these patients, additional
treatment of the underlying disorder is helpful when anemia is not
as rapidly progressive as in our patient.
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A College Student with Fulminant Hepatic Failure
Christie Crawford, MD
Case Report

A 19 year-old female college student presented to her pediatrician’s office after experiencing three weeks of fatigue, abdominal
pain, and nausea. At that time, the patient was diagnosed with
a urinary tract infection and a viral illness and was given a
prescription for Keflex. Over the next three days, the patient’s
symptoms worsened, and she developed weakness, shortness
of breath, and anorexia. She also noticed yellowing of her skin
and darkening of her urine, which prompted her to go to the
emergency department at an outside hospital. At the outside
hospital, many laboratory results were abnormal and her clinical
condition worsened. She was transferred to the intensive care
unit at Thomas Jefferson University Hospital (TJUH) for further
evaluation and treatment.
The patient had no significant past medical, surgical history, or
family history. She took a multivitamin and an oral contraceptive
daily and denied the use of any herbal supplements or overthe-counter medications. She had no known drug allergies.
She reported social alcohol and marijuana use, most recently
one month ago, and denied tobacco use. She denied recent
sexual activity or foreign travel. Review of systems was positive
for shortness of breath, nausea, vomiting, abdominal pain,
decreased urine output, dark urine, muscle cramps, headache,
dizziness, jaundice, anorexia, and a six-pound weight gain over
three weeks.
Upon admission, the patient’s vital signs were within normal
limits, and her physical exam was notable for jaundice, scleral
icterus, diffuse abdominal tenderness and distension, ascites, and
bilateral lower extremity pitting edema. Routine laboratories were
notable for a white blood cell count of 51.9 B/L, a hemoglobin
of 7.0 g/dL, and INR of 3.92, and creatinine of 2.5 mg/dL, a total
bilirubin of 52.1 mg/dL, a direct bilirubin of 21.8 mg/dL, and
alkaline phosphatase of less than 5 IU/L, a lactate dehydrogenase
of 963 IU/L, a haptoglobin of less than 6 mg/dL, and a lactate of
28.4 mg/dL.

Hospital course

With all clinical and laboratory findings pointing towards
fulminant hepatic failure, a search for the cause was initiated.
Tests for hepatitis B, hepatitis C, HIV, EBV, CMV, parvovirus,
syphilis, SLE, autoimmune hepatitis, and acetomenopheninduced liver toxicity were all negative. The suspicion for Wilson
Disease was high, but ceruloplasmin, urine and serum copper
levels were still pending. Over the first two days of the patient’s
hospitalization, her condition worsened, and it became clear that
she would require a liver transplant for survival. The patient was
listed as status one for orthotopic liver transplantation with the
presumptive diagnosis of Wilson Disease.
On the third day of hospitalization at TJUH, the patient began
to get more confused and somnolent. The patient also became
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anuric with severe and progressive renal failure, requiring
hemodialysis. The patient developed respiratory distress and was
intubated. Additionally, she became hypotensive, and pressors
were initiated. The patient was now severely acidemic, had a
lactate of 197.7 mg/dL, an INR of 6.77 with diffuse bleeding,
and one of her pupils was fixed and dilated. The patient was
taken to the operating room for hepatectomy, despite the fact
that the donor liver transplant had not yet arrived at TJUH. Two
hours later, the donor liver arrived and the patient underwent
transplantation.
After the transplant was completed, the patient improved
clinically, and her laboratory values also began to return towards
normal. Her neurologic and cognitive function returned to
baseline. She required one return trip to the operating room for
bile duct reconstruction and was discharged from the hospital
on post-operative day 19. The final diagnosis of Wilson Disease
was made post-operatively when the patient’s serum copper
came back at 270mcg/dL (normal range: 80-155), and her urine
copper came back at 2371.4mcg/dL (normal range: 0.2-8).
Ceruloplasmin was within normal limits.

Discussion

Wilson Disease, also known as hepatolenitcular degeneration,
is an autosomal recessive disorder caused by mutations in the
ATP7B gene, which codes for a membrane-bound coppertransporting ATPase. When functioning properly, this ATPase
transports copper into the bile so that it can be excreted from the
body via the gastrointestinal tract. In patients with Wilson disease,
copper cannot be excreted into the bile and thus accumulates in
the liver bound to a protein called metallothionein. Mutations
in the ATP7B gene also impair the incorporation of copper
into ceruloplasmin. Excess copper in the liver causes increased
generation of free radicals, which lead to liver damage. This
progressive liver damage eventually leads to cirrhosis. A cirrhotic
liver is unable to maintain the huge amount of accumulated
copper, so the copper begins to leak into the bloodstream where
it accumulates in and damages other tissues.1
Wilson Disease affects one in 30,000 live births. Symptoms rarely
occur before age six and are almost always present by age thirty,
with a mean age of onset of sixteen. Two times more females
with Wilson Disease progress to fulminant hepatic failure than
do their male counterparts.1, 2
Neurologic symptoms, such as Parkinsonism, dystonia, cerebellar
dysfunction, or pyramidal signs are the presenting features of
Wilson Disease in 69% of patients. These neurologic manifestations result from accumulation of copper in the basal ganglia.
Neurologic symptoms are often associated with psychiatric
symptoms such as anxiety, depression, and pyschosis, but
psychiatric symptoms are rarely seen in the absence of neurologic
symptoms. Approximately 15% of patients with Wilson Disease
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present with signs and symptoms of cirrhosis, while another
5% have asymptomatic liver function test abnormalities. It
is much less common for patients to present with isolated
musculoskeletal complaints such as premature osteoporosis or
osteoarthritis. It is also uncommon for patients to present with
fulminant hepatic failure, as the patient in this case did.2
Kayser-Fleischer rings are brownish-gray rings seen around the
iris that consist of copper deposits in Descemet’s membrane
that are commonly seen in Wilson Disease. They can only be
appreciated on a slit lamp exam and are present in greater than
90% of Wilson Disease patients with neurologic and psychiatric
symptoms. In patients with Wilson Disease without neurologic
or psychiatric symptoms, Kayser-Fleischer rings will only be
present 50% to 60% of the time.3
The patient in this case presented with fulminant hepatic
failure which is unusual for Wilson Disease. Clinicians
must have a high index of suspicion in order to make this
diagnosis. Children and young adults who present with liver
failure and also have a Coombs negative hemolytic anemia, a
coagulopathy that is unresponsive to vitamin K, renal failure,
mild AST and ALT elevations, and/or alkaline phosphatase
levels of less than 40 IU/L should be considered to have
Wilson Disease until proven otherwise, as this presentation
is associated with a very high mortality rate if not treated
appropriately and in a timely fashion.4
The gold standard for diagnosing Wilson Disease is a liver
biopsy with quantitative copper assay. However, this is rarely
the first step in making the diagnosis. Patients with suspected
Wilson Disease must first have liver function tests including
coagulation studies, a complete blood count, a ceruloplasmin
level, a 24-hour urine copper assay, and a thorough physical
exam including a slit lamp exam. Patients with Kayser-Fleischer
rings, a decreased serum ceruloplasmin, or urine copper levels
greater than 40 mcg/day need a liver biopsy to confirm the
diagnosis. Copper levels of greater than 250 mcg/g on liver
biopsy are consistent with a diagnosis of Wilson Disease. The
work-up and diagnosis of Wilson Disease is a lengthy process
and in patients with fulminant hepatic failure like the one in this
case, treatment must be initiated before a diagnosis is finalized
in order to give the patient the greatest chance of survival.3, 4

chelating agent penicillamine or with zinc, to remove copper
that has already accumulated in the liver and prevent the further
accumulation. For symptomatic patients, the copper chelating
agent trientine should be used until laboratory tests confirm
that copper levels have returned to the normal range, at which
point patients may be switched to maintenance therapy with
penicillamine or zinc. Patients with Wilson Disease must remain
on copper chelation therapy for life, for if is stopped, copper will
begin to reaccumulate. For patients that present with fulminant
hepatic failure, emergent liver transplant is the only treatment
available, and it is curative.4
Wilson Disease has an excellent prognosis if diagnosed and
treated early. Neurologic and hepatic symptoms resolve with
appropriate treatment. It is unclear as to whether there is an
increased risk of hepatocellular carcinoma in patients with
Wilson Disease. 5 Prognosis for patients who present with
fulminant hepatic failure is poor and depends on the availability
of liver transplantation.
As Wilson Disease is a genetic disorder, screening of siblings
and children of patients with the disease is necessary. Possible
patients should be screened with slit-lamp examination, liver
function tests, serum ceruloplasmin and copper levels, and 24hour urine copper excretion. If any of these tests are abnormal,
a liver biopsy should be done to confirm the diagnosis.
Occasionally, genetic testing may be performed, if the specific
mutation of the ATP7B gene in the proband is known. When a
patient’s screening test for Wilson Disease is positive, treatment
should be started immediately to ensure the best possible
outcome.
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Treatment of patients with Wilson Disease depends on whether
or not the patient is symptomatic. Asymptomatic patients
diagnosed via screening tests should be treated with the copper
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A Case of Drug-induced Hepatotoxicity: Amiodarone is
Not Always to Blame
Brendan O’Hare, MD
Case Presentation

A 54 year-old male presented to the hospital with a two week
history of new onset jaundice, anorexia and fatigue. The
patient has a past medical history of hypertension, coronary
artery disease, and ischemic cardiomyopathy with an ejection
fraction of 10% to 15%. He also has a history of atrial fibrillation
and paroxysmal ventricular tachycardia with an automated
implantable cardioverter-defibrillator placed. He denied
any history of blood transfusions, alcohol use, intravenous
drug abuse, or known hepatitis. He also denied taking herbal
medications or vitamins. The patient denied fevers, night sweats,
nausea, shortness of breath, abdominal pain, blood in his stool,
or easy bruising. Four weeks prior to admission, the patient
was diagnosed with hyperthyroidism thought to be secondary to
long-term amiodarone use which the patient had been taking for
eight years for treatment of atrial fibrillation. At that time he was
started on 10 mg of methimazole daily, and his amiodarone was
stopped. All of his other medications were chronic and include
atenolol, pantoprazole, aspirin, clopidogrel, and furosemide. He
has no known drug allergies. Upon admission his methimazole
was stopped since his symptoms could be attributable to this
medication.
On presentation the patient was afebrile. His pulse was regular
at 112 beats/minute, and his blood pressure was 91/61 mm
Hg. He was orientated to person, place, and time. His exam
was noteworthy for scleral icterus and jaundice. There was no
ascites, asterixis, palmer erythema, spider angiomata or other
evidence of liver disease. His abdominal exam was benign, with
no tenderness to palpation, organomegaly, or lymphadenopathy.

Laboratory results are shown in Table 1. All other laboratory
values were within the reference range. An EKG did not show
any acute changes, and three consecutive troponins were
negative. An abdominal ultrasound was notable for the presence
of hepatosplenomegaly with the liver measuring 14.4 cm in
sagittal length and the spleen measuring 14.4 cm. Color doppler
ultrasound showed patent portal, hepatic, and splenic veins.
There was no biliary ductal dilation, cholelithiasis or sludge.
On hospital day two the patient’s clinical status had not
improved, and a liver biopsy was obtained to help differentiate
the cause of hepatic dysfunction. The liver biopsy (Figure 1)
showed severe cholestasis with mild inflammatory changes
and mallory bodies on pathology. Given the time course of
introduction to methimazole and the development of abnormal
liver tests, the presumptive diagnosis of methimazole-induced
hepatotoxicity was made. The patient experienced a relatively
stable course until day six of his stay. At that time the patient
became clinically unstable, went into cardiac arrest and died. It
was presumed that the new onset liver failure proved to be too
much of a stressor on an already weak heart.

Discussion

Methimazole and its precursor molecule carbimazole are
common treatment options for hyperthyroidism but do not
come without significant risk to the patient: methimazole is
a known hepatotoxin. An extensive review of the literature
has not identified any previous case reports of methimazoleinduced liver injury leading to death in the United States. There

Chem 7

Sodium 140
mmol/l

Potassium
4.1 mmol/l

Chloride
105 mmol/l

Carbon Dioxide
21 mmol/l

CBC

White Blood
Cell
10.2 b/l

Hemoglobin
14.7 g/dl

Hematocrit
46.0 %

Platelets 137 b/l

LFTs

Protein
5.1 g/dl

Albumin
2.8 g/dl

Total Bilirubin
26.8 mg/dl

Coags

Protime
22.8 s

Prothrombin
Time 33 s

INR 1.90

Serologies

HAV IgM (-)

HAV IgG (+)

HBV Ant (-)

TFTS

Thyroid
Stimulating
Hormone
0.02

Thyroxine
4 1.5

Triiodothyronine
3 63

Table 1. Laboratory values at presentation.
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He did have 2+ lower extremity swelling that was thought to be
chronic and secondary to his heart disease.

Urea-Nitrogen 58
mg/dl

Creatinine
2.2 mg/dl

Glucose
136 mg/dl

Direct Bilirubin
11.4 mg/dl

Aspartate
Aminotransferase
107 IU/l

Alanine
Aminotransferase
107 IU/l

Alkaline
Phosphatase
82 IU/l

HBV Core (-)

HBV Ab (-)

HCV Ab (-)
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was a case report of necrotizing hepatitis leading to death in
Germany.1 There have been case reports associating fulminant
hepatic failure and death with the antithyroid agent propylthiouracil in the United States. 2,3 However, up to this point
methimazole liver injury has not been associated with any
deaths in the United States.
There were many diagnoses in the differential that were
sequentially ruled out during this patient’s admission, including
chronic viral hepatitis, biliary and portal vein thrombosis,
infiltrative and chronic passive congestion, and ischemic liver
injury. One drug considered in addition to methimazole for
causing hepatotoxicity in this patient was amiodarone. It was
difficult to apply the established scoring systems for assessing
causality between a drug and hepatocellular injury in this case
because the patient expired before rechallenge of the potential
offending agent was possible. However, considering the
temporality of the treatment, it is likely that methimazole and
not amiodarone was the cause of liver injury. The patient had
been stable on amiodarone for eight years without any noted
hepatotoxicity. In contrast, methimazole had been started four
weeks prior to development of jaundice. The aforementioned
scoring systems for deducing the cause of drug-induced liver
injury put a much greater weight on drugs that cause injury in
a window of roughly five days to three months. The patient’s
amiodarone use did not fall into this time interval. In fact, the
median time for liver disease associated with amiodarone is 21
months after initiation.19
The liver biopsy was also not consistent with amiodarone-induced
liver injury. Changes in pathology that are usually associated with
amiodarone drug toxicity include Mallory’s hyaline, steatosis,
ballooning of hepatocytes, focal necrosis, fibrosis, and in severe
cases, cirrhosis.6 Although our patient did have Mallory bodies
on specimen, none of the other defining characteristics of
amiodarone toxicity were present. As mentioned, the biopsy
showed diffuse cholestasis with intracanalicular bile plugging
(Figure 1). As of 1999 there had only been seven case reports
published of jaundice and cholestatisis presenting as the major
clinical and pathological manifestations of amiodarone induced
hepatotoxicity.7 Conversely, the majority of methimazole liver
injury cases have reported cholestasis and associated jaundice.8-14
This case serves as an example of a serious but uncommon drug
related liver injury. Generally, patients with severe liver injury,
as defined by serum ALT being three times the upper limit of
normal or the serum bilirubin being two times the upper limit
of normal in the absence of biliary obstruction, have a mortality
of at least 10%.15 In our case the patient had a bilirubin that
was over 20 times normal levels. Additionally, our patient
had two of the three hallmarks of acute liver failure: jaundice
and impaired hepatic synthetic function. During the course
of his admission he did not develop the third characteristic
which is encephalopathy. If the full triad of manifestations is

present in cases of drug induced hepatotoxicity, patients have
roughly a 25% survival rate without liver transplant.16 However,
prognosis also depends on agent as there is a 0% mortality of
erythromycin induced liver failure versus 40% mortality with
use of halothane.19
It is of crucial importance to recognize drug induced liver toxicity
because it is now the leading cause of acute liver failure among
patients referred for liver transplantation in the United States.17
Hepatotoxicity related specifically to antithyroid agents occurs
with an approximate frequency of 0.1% to 0.2%.18 It is plausible,
however, that this number may be falsely low secondary to
difficulty in diagnosis and underreporting.
In this case, the patient’s co-morbidities allowed for close
physician follow up and an apparent drug induced liver injury
was caught just four weeks after the inciting agent was started.
However, not all patients will be followed so vigilantly after
starting potentially hepatotoxic drugs. It is important for the
responsible physician to be aware of potential liver injury that
drugs such as methimazole may cause in order to prevent their
rare but unfortunate complications.

Figure 1. Liver biopsy shows diffuse cholestasis, mallory bodies,
and intracanalicular bile plugging. There were no viral inclusion
bodies, steatosis, necrosis, or fibrosis.
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Case Reports

A Woman With Chest Pain, Syncope, and Transaminitis
Ankitkumar K. Patel, MD, MPH, and Brendan O’Hare, MD
Case Presentation

The patient is a 49 year-old female with past medical history of
anxiety and hyperlipidemia who presented to an outside hospital
with complaints of five hours of substernal chest pain followed by
three episodes of syncope witnessed by her son. At presentation
in the emergency department the patient denied any current
chest pain or shortness of breath. She received 325 mg of aspirin
en route to the hospital by EMS. Her vital signs were temperature
100° Fahrenheit, heart rate 60 beats/minute, blood pressure
101/50 mm Hg, respiratory rate 20 breaths/minute, and a pulse
oxygenation of 98% on room air. The patient’s EKG showed ST
elevations in the inferior leads. The patient’s laboratory studies
were: white blood cell (wbc) count 14 B/L, hemoglobin 13.2 g/
dL, platelets 153 B/L, CKMB 32 U/L, troponin 8.27 ug/L, and
CK 24.5 U/L. The patient was started on intravenous heparin
and integrillin drips and transferred to Jefferson for emergent
cardiac catheterization.
The patient had left and right coronary angiography which
showed no evidence of occlusive coronary disease. Left heart
catheterization demonstrated moderate to severe inferoapical
hypokinesis and a mildly depressed left ventricular ejection
fraction (40%). During the procedure, the patient was noted to
have 2:1 AV heart block with intraventricular conduction delay,
and a temporary transvenous pacemaker was placed. The patient
was then transferred to the cardiac care unit.
In the cardiac care unit, the patient reported that she had no
known drug allergies. Her only outpatient medication was a
statin that was started six weeks ago. The patient denied any
past surgical history. The patient consumed alcohol socially,
had a 15 pack year history of smoking, and no history of illicit
drug use. The patient’s father died of a myocardial infarction
at age 62, and the patient’s mother was alive with a history of
diabetes mellitus and arrhthymia. The patient noted that she
had some nasal congestion for two days prior to the chest pain
and syncope. The patient also reported working in her garden
with rose bushes and was certain that she had a neck rash due to
poison oak. Lastly, the patient reported decreased oral intake for
the past two days due to “flu-like” disease.
Overnight, the patient had multiple episodes of bradycardia
that warranted venous pacing on telemetry. Significant
laboratory studies were: wbc 4.3 B/L, AST 539 U/L, ALT 313
U/L, and troponin 14.7 ug/L. The patient underwent successful
implantation of a dual chamber VDD pacemaker. A transthoracic
echocardiogram demonstrated an ejection fraction of 60%, mild
to moderate mitral regurgitation, and an inferior vena cava
normal in size without inspiratory collapse. The patient was
transferred to the telemetry floor service.
On the third hospital day, the patient had no overnight complaints
and wanted to be discharged home. Significant laboratory studies

were a troponin of 16.5 and AST 299 U/L, and ALT 250 U/L.
The patient had a CT of her head which showed no fracture or
bleed. A CT of her chest demonstrated multifocal pneumonia
with bilateral pleural effusions and subcentimeter pulmonary
nodules. The patient was diagnosed with pneumonia and was
started on ceftriaxone, azithromycin and flagyl.
On the fourth hospital day, the patient had an overnight fever
of 100.7° Fahrenheit and an episode of oxygen desaturation to
89% on 2 liters oxygen via nasal cannula. Significant laboratory
studies were: wbc 14.9 B/L, troponin 14.1 ug/L, AST 247 U/L,
and ALT 240 U/L.
On the morning of the fifth hospital day, the patient had a fever
of 100.6° Fahrenheit and an episode of tachycardia with oxygen
desaturation to 75% on 2 liters with an increased respiratory
rate (18 to 28 breaths/minute). An arterial blood gas showed
pH 7.50, pCO2 23, PO2 138, HCO3 18, O2 sat 99%. Significant
laboratory studies were wbc 18.9 B/L, troponin 8.9 ug/L, AST
279 U/L, ALT 288 U/L, lactate 40.8 mmol/L, and BNP 2058.
The patient was treated with nebulizer treatments, intravenous
furosemide, and an anxiolytic. A transthoracic echocardiogram
demonstrated an ejection fraction of 25%, moderate-severe
mitral regurgitation, severely decreased left ventricular systolic
function with segmental wall motion abnormalities, mild
right atrial enlargement, dilated inferior vena cava, and right
ventricular enlargement with decreased function.
Later in the afternoon, the patient had complaints of shortness
of breath and increased anxiety. Vital signs at the time were
heart rate 123 bpm, blood pressure 100/60 mm Hg, respiratory
rate 36 breaths/minute, pulse oxygenation of 90% on 100% nonrebreather mask. An arterial blood gas demonstrated pH 7.49,
pCO2 27, PO2 60, HCO3 20, O2 sat 93%. The patient was once
again treated with nebulizer treatments, intravenous lasix and had
symptomatic relief. Three hours later, the patient had worsening
respiratory distress and was found to have a respiratory rate of
48-60 with a pulse oxygenation of 68% on room air and 88%
on 100% non-rebreather mask. A rapid response was called for
worsening respiratory distress.
The patient was transferred to the cardiac care unit and emergently
intubated. Subsequently, the patient became progressively
hypotensive and a central line was placed, and intravenous
norepinephrine was started. The patient was presumed to have
worsening sepsis secondary to multifocal pneumonia with
cardiomyopathy of sepsis. Antibiotic coverage was broadened to
vancomycin and zosyn. In addition, doxycycline was added to
cover possible ricketsial infections. A complete rheumatologic
and autoimmune work up was sent for laboratory studies.
The following day, the patient had a transesophageal echocardiogram which showed no vegetations. Azithromycin was
added to cover atypical organisms, and the patient was started
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on an acute respiratory distress syndrome ventilator protocol.
Significant laboratory studies were: wbc 23.1B/L with 6% bands,
AST 1209 U/L, ALT 873 U/L, and troponin 6.29 ug/L.

conducted during the surgical procedure. A collection of all lab
results is included in Table 1.

On the seventh day, the patient underwent fiberoptic
bronchoscopy which was grossly normal and bronchoalveolar
lavage of the right upper lobe was sent for cultures. Significant
laboratory studies were: wbc 19.1 U/L, creatinine 1.5 umol/L, AST
2220 U/L, and ALT 1516 U/L. The patient became progressively
more hypotensive, and the norepinephrine drip was titrated.
The patient also had decreasing urine output and worsening
transaminitis was thought to be due to ischemic hepatitis.

Often, myocarditis is an under-diagnosed medical condition. Its
pathophysiology is marked by a triad: cardiac injury by inciting
agent, immunologic response, and inflammation. Generally
speaking 1/3rd of patients recover, 1/3rd experience permanent
cardiac dysfunction, and 1/3 rd deteriorate to either death or
cardiac transplant.

On the eighth day, the patient developed a supraventricular
tachycardia which was treated with adenosine and revealed
an underlying atrial flutter rhythm. The patient was started
on digoxin for rate control. With worsening hypotension
and tachycardia, the patient was started on phenylephrine
with plans to wean down norepinephrine. Due to worsening
clinical status, Xigris therapy was also initiated. A transthoracic
echocardiogram showed an ejection fraction of 10%, moderatesevere mitral regurgitation, severe left ventricular systolic
function (with only the basal-inferolateral segment contracting
– the remainder was hypokinetic/akinetic), right ventricular
enlargement, moderate-severe tricuspid regurgitation. Late in
the evening, the patient’s clinical exam had a significant change
with cool extremities and hypothermia. Laboratory studies were
consistent with a state of disseminated intravascular coagulation
and worsening renal function. A family meeting was called
to discuss the worsening clinical status and overall prognosis.
Cardiology consultation offered right heart catheterization and
the placement of an intraortic balloon pump (IABP). The right
heart catheterization showed HR 130, aortic pressure 91/59, PA
55/39 mean 45, wedge 54, RA 50/49 mean 40, RV 55/39, SVR
750, PVR 1126, CO by Fick 3.20, CI by Fick 1.59. The patient
was diagnosed with cardiogenic shock, and the IABP was set
at 1:1 and a Shiley catheter was placed for urgent continuous
veno-venous hemodialysis. The patient was weaned off of the
phenyephrine and started on dobutamine, dopamine, and
eventually epinephrine.
On the morning of the ninth hospital day, the cardiac care unit,
heart failure, pulmonary, renal, and cardiothoracic surgery
teams discussed the patient’s case. Significant laboratory
studies were: wbc 21 U/L, hemoglobin 7.9 g/dL, platelets 59 B/
L, creatinine 2.5 umol/L, and AST 12217 U/L, and ALT 4060 U/
L. Due to the rapid and progressive decline in cardiac function
due to severe myocarditis, a decision was made to place a
right ventricular assist device (RVAD) and a left ventricular
assist device (LVAD), commonly called a BiVAD. The patient
underwent surgery with the RVAD connecting the right atrium
to the pulmonary arteries and the LVAD connecting the left
ventricle to the aorta. A cardiac myocardial biopsy was also
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Discussion

Myocarditis’ true incidence is most likely under represented. It has
been postulated that up to 8.6% of sudden cardiac deaths may be
attributable to myocarditis.1 Up to 10% to 40% of what was thought
to be idiopathic dilated cardiomyopathy in children may in fact be
occult myocarditis.2 As diagnostic techniques such as immunohistochemistry, electron microscopy, and molecular proteomics
advance inevitably the incidence of myocarditis will rise.
The diagnosis most often implies viral infection. The most
common vectors of disease have thought to be enteroviruses
such as coxsackie or adenovirus. However, any virus can cause
myocarditis: cytomegalovirus, parvovirus, influenza, human
immunodeficiency virus, hepatitis C, and Epstein-Barr virus
have all been implicated. Furthermore, tricyclic antidepressants,
clozapine, the smallpox vaccine, radiation, heat stroke, and
hypothermia can all cause inflammation of cardiac tissue.
Clinically, the onset of symptoms can be insidious or rapid.
Acutely, a viral prodrome often predominates with signs
including fatigue, arthralgias, and fever. After this, cardiac
manifestations may develop. In this particular case our patient
presented with arrhythmia and heart block, which can be seen
as the presenting symptom in 5% of cases.3 Other symptoms
such as chest pain and heart failure are often also present.
Unfortunately, some patients may present with hemodynamic
compromise and a fulminant picture.
Laboratory testing can include elevated ESR, WBC, or troponin.
EKG findings are often non-specific and may range from
subtle abnormalities to ST elevations. One study revealed that
in the setting of an acute myocardial infarction and normal
cardiac catheterization, 38% of patients were thought to have
myocarditis.4 Non-invasive techniques include transthoracic
echocardiography in which regional wall motion abnormalities
are typically more common than cardiac dilation. This is
especially true in the acute to sub-acute period before cardiac
remodeling has occurred. A less common used modality is
indium-111 anti-myosin imaging. This is a nuclear medicine
study in which anti-myosin antibodies are introduced, they
bind to injured myocardium, and the results can then be
quantified. The technique is excellent for detecting damage;
however, distinguishing between a myocardial infarction and
myocarditis may be difficult. In fact, the sensitivity is good at
85% to 100%, but the specificity is only 55%.5 Another option
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Table 1. Laboratory results
Infectious

Cardiovascular

Hepatology

Legionella Ag negative

Cholesterol 190

Hep A IgG/IgM negative

Lyme disease Ab 0.12 (negative)

HDL 33

Hep B IgG/IgM negative

Lyme PCR negative

LDL 120

Hep B core Ab negative

M.Pneumoniae IgM negative

Triglycerides 187

Hep B surface Ab negative

Ehrlichia Ab IgG/IgM negative

Hep C Ab negative

RPR negative

Rheumatology

Hep C PCR negative

HIV negative

RF 21 (wnl)

Alpha-1 antitryp quant 251 (high)

EBV IgM negative

ACE 21 (wnl)

Copper 47.7 (high)

EBV IgG positive

ANA negative

EBV nuclear Ab positive

anti dsDNA 11 (wnl)

Hematology

CMV negative

ASM negative

Serotonin release negative

Herpes negative

C-ANCA negative

PLT factor 4 negative

RSV negative

P-ANCA negative

Iron 52 (wnl)

Varicella IgG Ab reactive

TIBC 252 (low)

VZV IgM 0.16 (negative)

Endocrinology

FeSat 24% (low-normal)

Coxsackie types negative

HgbA1C 5.7%

Ferritin 1085 (high)

Ent-virus PCR negative

TSH 0.65 (wnl)

Influenza A+B negative

Cortisol 94

CMV Ab IgM negative
Toxoplasma negative

is cardiac MRI which uses contrast kinetics to identify areas of
damage and may be able to differentiate myocardial infarction
from myocarditis. Epicardial predominance, a non-contiguous
pattern, and involvement of the lateral wall are more common
in myocarditis according to one study.6
The gold standard in the diagnosis of myocarditis is biopsy. For 20
years, the Dallas criteria have defined a positive biopsy as one that
displays inflammatory cells plus necrosis. A borderline biopsy is
one that has inflammatory cells but no necrosis.7 However, this
system is imperfect. The nature of myocarditis is such that it does
not involve the entire myocardium. As such, even if one takes five
biopsy specimens, the diagnosis will be missed 33% of the time.8
Moreover, the disease often affects the lateral wall which is difficult
to biopsy using current techniques. Detection of myocarditis via
pathology can also be subject to observer differences. Furthermore,
there are risks involved with the procedure such as vascular access
issues, arrhythmias, and perforation.
Prognosis generally depends on the type of myocarditis. For
example, giant cell myocarditis usually progresses quite rapidly,

while other forms progress more subtly. As stated previously,
patients may recover completely, sub-acutely progress to
permanent cardiac dysfunction, or rapidly deteriorate to death
or transplant. Generally, there is a 20% mortality at one year and
50% at four years. Predictors of death or requiring transplantation in the future include the presenting symptom of syncope
or bundle branch block, an ejection fraction of <40%, and
persistence of viral genome in the myocardium.9 Unfortunately,
our patient had two of these three predictors.
Regrettably, the treatment options for myocarditis leave much
to be desired. The first steps are supportive therapies such as
ACE inhibitors, diuretics, and beta blockers when clinically
stable. The National Institutes of Health conducted a trial in
which they randomized standard heart failure therapy versus
steroids + azathioprine versus steroids + cyclosporine for six
months. The results showed no difference in ejection fraction
or mortality after four years.10 There was some improvement
during the acute treatment phase, but this was transient. Final
recommendations included considering steroids in giant cell
myocarditis or in hemodynamic compromise. In another trial,
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interferon was used to treat 22 patients for six months. Virus
was eliminated from myocardium in all 22 patients and 15 of 22
showed improvement in left ventricular systolic function.11 The
results were fairly promising and, consequently, have spurred
an ongoing phase III trial. IVIG has been sought as therapy due
to its effects on auto-antibodies. In 2003, IVIG was compared
to placebo. Systolic function improved from 25% at baseline
to 41% at six months, but there was no statistical difference
in the two arms of the trial.12 Currently, the most recognized
treatments are supportive. Specifically, left ventricular assist
devices have been shown to be beneficial in select patients.
Indications for LVAD include: cardiac index < 2.0L/min/m2,
central venous pressure or left atrial pressure >20, and urine
output <20mL/hour despite maximal pharmacological therapy.13
Furthermore, the disease may be so progressive that both right
and left ventricular assist devices may be needed, such as in this
case presented here. Indications for a BiVAD are renal, hepatic,
and pulmonary dysfunction, seen with our patient.14
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Vitamins: Friend or Foe

Anastasia Shnitser, MD, and Dina Halegoua-De Marzio, MD
Case Presentation

A 39 year-old male presented to the emergency department with
generalized body aches after a recent fall. The patient underwent
urgent trauma evaluation and incidentally was found to have
multiple medications in his right colon on radiography (Figures
1 and 2). The patient was immediately screened for a drug
overdose, but he admitted to taking a large amount of Ultra-Start
vitamins that he purchased on the internet. Due to suspicion
for possible drug overdose, a nasogastric tube was placed, and
polyethylene glycol was administered to help the patient pass the
pills from his bowels. Despite the large ingestion of vitamins, the
patient remained asymptomatic throughout his hospitalization.

Discussion

The ability to visualize medications in the gastrointestinal
system on imaging depends on the radiodensity of the ingested
material. Chloral hydrate, iron-containing preparations, calcium

Figure 2. Abdominal CT scan on admission similarly
demonstrates that the right colon contains many radiopaque
vitamin tablets.
carbonate, iodinated compounds, acetazolamide, busulfan,
and potassium-containing preparations are consistently
radiopaque.1,2 The Ultra-Start vitamins ingested by our patient
contained multiple radiodense compounds including iron and
calcium carbonate.
There is minimal regulation of the content of nutritional
supplements, so patients purchasing vitamins often do not know
what they are getting. Some formulations will have extremely poor
absorption. Some of the lowest grade nutrients include magnesium
oxide, calcium carbonate, vitamins B12, B6, C and D.3 The patient
in our case was taking vitamins that contained several poorly
absorbed combinations.
It is not only important for patients to take the correct vitamin
supplementation, but it is important for providers to understand
that actual vitamin and mineral amounts often deviate from
label values. Potentially toxic levels of vitamins can be achieved
easily in people who take high potency vitamins or a large
number of pills.
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Figure 1. Lumbar X-ray on admission shows the presence of
multiple radiopaque pills in the right colon, representing the
patient’s ingestion of Ultra-Start vitamins.
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A Case of Severe Anemia in an Aids Patient
Amy K. Slenker, MD, and Rahul Anand, MD
Case Presentation

A 49 year-old African-American male presented to Thomas
Jefferson University Hospital in April of 2008 complaining of
generalized weakness and lightheadedness for 4 months. The
patient had a medical history of HIV/AIDS diagnosed in 2002
with a CD4 count of 0 cells/mm3 in 2005 and a history of noncompliance with highly active retroviral therapy (HAART). In
December of 2007 the patient was diagnosed with cryptococcal
meningitis and had a concomitant anemia with a hemoglobin
of 5.3 g/dL. At that time laboratory studies for parvovirus B19
(PB19) showed an IgG of 0.79 units and an IgM of 0.63 units
( a value less than 0.89 is considered negative). PB19 DNA by
PCR or direct DNA hybridization was not checked at that time.
A bone marrow biopsy was performed in January of 2008 to
determine the etiology of this severe hypoproliferative anemia,
revealing hypercellular marrow containing maturing trilineage
hematopoiesis with occasional non-caseating granulomas
with fungal elements. It was felt at this time that the anemia
was secondary to cryptococcal invasion of the bone marrow.
The patient was treated for cryptococcal meningitis with
fluorocytosine and liposomal amphotericin B for 2 weeks,
followed by oral fluconazole indefinitely, and was discharged
from the hospital.
When the patient presented in April of 2008, he was admitted
through the emergency department (ED) for a work-up of
symptomatic anemia. The patient was complaining of lightheadedness, generalized weakness, watery diarrhea, dry cough, and
shortness of breath. The patient denied fever, night sweats,
headache, blurry vision, joint pains, or rash. The patient denied
bloody or tarry stools, bleeding gums, easy bruising, or trauma.
On exam, the patient was afebrile and appeared disheveled and
cachectic with marked pallor. The patient had multiple small
cervical lymph nodes, no evidence of jugular venous distension,
and was clear to auscultation on lung exam. He had a regular
cardiac rhythm with no murmurs, a benign abdominal exam
with no hepatosplenomegaly, and no rashes, petechiae, or
peripheral edema.
The patient’s hemoglobin in the emergency room was 2.9 g/dL,
with a previous level of 13.1 g/dL one year prior to this admission.
The patient’s WBC count was 8.2 g/dL, with a differential of
24% neutrophils, 9% bands, 23% lymphocytes, 28% monocytes,
and 3% eosinophils, 3% metamyelocytes, and 9% myelocytes.
Laboratory values were as follows: mean corpuscular volume
was 87 fL (80-99 fL), lactate dehydrogenase 285 IU/L (100-200
IU/L), haptoglobin 331 mg/dL (16-200 mg/dL), urea-nitrogen
15 mg/dL, creatinine 1.7 mg/dL, aspartate aminotransferase 16
IU/L, alanine aminotransferase 11 IU/L, alkaline phosphatase
103 IU/L, albumin 3.6 g/dL, total bilirubin 0.3 mg/dL, and
direct bilirubin 0.0 mg/dL. CMV quantitative PCR was <100
copies/mL (<100copies/ml is negative). AFB stain from feces
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and blood cultures were negative. Stool studies were negative
for Entamoeba histolytica, Giardia lamblia, Cryptosporidium
species, Clostridium difficile and Shigella, Salmonella, and
Campylobacter species. The patient’s absolute reticulocyte
count was 3 cells/mm3 (20-76 cells/mm3), HIV viral load was
483,000 copies/mL and CD4 count was 7 cells/mm3. PB19 DNA
by PCR was positive, and there was a positive antibody response
with an IgG of 1.56 index units and IgM of 4.84 index units.
The patient received four units of packed red blood cells in
the ED and was subsequently started on intravenous immune
globulin (IVIG), to which he responded with a sustained
increase in his hemoglobin and no further requirements of
packed red blood cell transfusions. The patient’s acute renal
failure was felt to be secondary to pre-renal causes and improved
to a baseline value with fluid resuscitation. The patient was also
started on HAART with Atazanavir boosted with Ritonavir,
and Tenofovir-Emtricitabine. The patient’s hemoglobin on
discharge was 9.3 g/dL with an absolute reticulocyte count of
198 cells/mm3. On follow up, he continues to be non-compliant
with his HAART medications, but his repeat complete blood
count three months later in August 2008 revealed a hemoglobin
of 9.0 g/dL. Furthermore, the patient has not required a blood
transfusion since he completed IVIG treatment.

Discussion

Anemia is a common finding in HIV-infected patients. Several
causes of anemia have been described including medications
(e.g., antiretrovirals or trimethoprim-sulfamethoxazole),
neoplasms, opportunistic infections, and the immunological
effects of HIV itself. Although uncommon, PB19-related pure
red cell aplasia (PRCA) is an important diagnosis to consider in
this setting because it is a treatable cause of anemia.2,5 Human
PB19 infection is found worldwide in persons of all ages, with
the majority of adults having been exposed to the virus by age
50. The virus can be asymptomatic or can present in a variety of
ways including as erythema infectiosum, arthropathy, a papular
rash, pure red cell aplasia, hydrops fetalis in the neonate, and
other cardiac, rheumatologic, and neurological manifestations.2,
12
PB19 usually causes a benign, self-limited illness, but the virus
can present as a severe anemia in the immunocompromised
host.1,5
Figure 1. Characteristic giant
proerythroblasts in the bone
marrow are pathognomonic for
parvovirus B19 infection. The
diagnosis may be missed if the
biopsy is done within a few days
of a blood transfusion.
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HIV-infected patients are particularly susceptible to infection
with PB19 and may be unable to produce an adequate antibody
response to the virus. This can result in a severe PRCA and a
prolonged anemia as the PB19 interrupts the production of
red blood cells in the bone marrow.5,6 These patients have been
shown to respond to a PB19 triggered PRCA with both IVIG
therapy as well as with highly active antiretroviral therapy.7,10 In
this case report, our patient presented with a profound anemia
caused by parvovirus B19 and responded well to treatment with
IVIG. The patient was also started on HAART, but was again
non-compliant with his medications.
A diagnosis of B19-PRCA should be considered in an afebrile,
HIV-infected patient with a normocytic anemia of relatively
recent onset, a virtual absence of blood reticulocytes, and a
normal renal function. Most reported cases are with a CD4 count
less than 100 cells/mm.7,12 The symptomatology is nonspecific,
and fever, skin rash, and arthropathy are characteristically
absent. Diagnosis of PB19-induced PRCA in an HIV-infected
patient is established when the following criteria are met: a bone
marrow aspirate consistent with PB19, a positive serum PB19
DNA by PCR or direct DNA hybridization, and no alternate
explanation for the red cell aplasia.7
It is important to note that the diagnosis may be missed in
immunocompromised patients because these patients may not be
able to formulate antibodies to the virus. Thereby, only checking
IgM and IgG antibodies to PB19 is not sufficient to exclude the
diagnosis, and either DNA by PCR or direct DNA hybridization
must be ordered.4 There are no clinical guidelines about the
treatment of HIV patients with PB19 infection; however, multiple
small studies have shown success with IVIG treatment with
good initial response. In patients with a CD4 count less than 80
cells/mm3, there is an unfortunately high relapse rate.8, 9 For this
reason, HAART has been described as a treatment strategy to
consider for PB19-induced PRCA, with some success reported in
small case studies.3,10 With substantive data lacking at this time,
adequate treatment for PB19 in HIV infected patients should be
determined in conjunction with an infectious diseases specialist
and should include close follow-up.
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Man With Swollen Eye, Blurred Vision, and Fevers in the
Setting of Newly Diagnosed MDS
Rory Bowers, MD

Case Presentation

An 82 year-old male with a past medical history of prostate
cancer, atrial fibrillation, gout, and recently diagnosed myelodysplastic syndrome presented with a chief complaint of left eye
pain. The patient also reported peri-orbital numbness, swelling,
and clear discharge as well as episodic blurry vision of his left
eye. Over the previous two months he had been admitted to the
hospital multiple times complaining of cough and high fevers
and was subsequently treated with several courses of antibiotics
for presumed pneumonia. During the initial admission for
pneumonia he was noted to have a relative pancytopenia. A
bone marrow biopsy was eventually undertaken revealing a
diagnosis of myelodysplastic syndrome (MDS).
Prior to the current presentation, his facial numbness, erythema,
and peri-orbital swelling had persisted over the period of
three weeks. He was seen in an outpatient clinic, diagnosed
with a periorbital cellulitis, and treated with a course of oral
clindamycin, levofloxacin, and erythromycin eye drops. During
his last outpatient follow up he was told to go directly to the
emergency room secondary to the worsening appearance of his
left eye. On current presentation he denied any fevers, chills, or
sweats. He denied traumatic injury to his eye. He also denied
headaches or other neurological complaints but occasionally
experienced blurred vision in his left eye, which usually resolved
spontaneously. He had significant pain around his left eye, which
was worse with eye movements. He denied photophobia and
noted that his symptoms had not improved over the past three
weeks. In addition, he had continuous feelings of numbness
across his left face. He denied sore throat, chest pain, recent
weight loss, myalgias, or arthralgias. His cough had persisted
since his diagnosis of pneumonia and was non-productive in
nature.
His current medications were aspirin, erythromycin eye
drops, levofloxacin, furosemide, digoxin, potassium chloride,
metoprolol, clindamycin, and percocet. He had an allergy
to penicillin, which had caused a rash in the past. He denied
alcohol, tobacco, or substance abuse. A family history was
notable for coronary artery disease and asthma.
On physical exam his vitals were noted to be the following:
temperature 97.6° Fahrenheit, respiratory rate 20 breaths/
minute, heart rate 87 beats/minute, blood pressure 160/90 mm
Hg, and pulse oximetry of 95% on room air. He was noted to
have prominent left periorbital swelling and erythema with a
moderate amount of clear discharge. He had mild periorbital
tenderness and his left sclera appeared injected. The pupils
remained reactive to light and accommodation and his extraoccular movements were intact. The visual acuity in the left
eye was moderately reduced. His cardiac exam revealed only
an irregularly irregular rhythm consistent with known atrial
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fibrillation. His lungs had mildly decreased breath sounds
at the right base but were otherwise clear. His abdomen was
benign. He was neurologically intact with the exception of left
facial numbness. He had mild lower extremity pitting edema
bilaterally.
Laboratory tests revealed a mild pancytopenia: white blood cell
count 3.6 B/L, hemoglobin 8.5 g/dL, and platelet count of 140
B/L. A comprehensive metabolic panel was grossly normal aside
from a mildly elevated BUN and creatinine (21 U/L and 1.6
mg/dL, respectively). An orbital CT scan was quickly obtained
due to the concern for a possible retro-orbital infectious
process. The MRI scan revealed findings consistent with orbital
cellulitis of the left eye with invasive sinusitis. The patient was
emergently taken to the operating room for exploration and
debridement of his maxillary, sphenoid, and ethmoid sinuses.
Subsequent biopsies and cultures revealed a species of rhizopus
fungi as the probable etiology of the patient’s symptoms. He was
diagnosed with invasive mucormycosis involving the left orbit
and sinuses.
The patient underwent multiple surgical procedures on his
sinuses and left orbit. Intraoperatively, he received irrigation
to the affected region with amphotericin B. He also received
systemic therapy with amphotericin until he was noted to have
worsening renal function. He was subsequently started on oral
posaconazole with plans for a prolonged course of treatment.
Following improvement in his symptoms he was discharged
home with appropriate follow up with ophthalmology and
infectious disease.

Discussion

Mucormycosis refers to an infectious condition caused
by a variety of spore-forming organisms belonging to the
zygomycetes class of fungi. These organisms are ubiquitous
in nature, commonly being found in organic substrates such
as soil, plant matter, and animal feces. Humans are routinely
exposed but due to the intact functioning immune systems of
the host, clinical disease is rare. However, in certain susceptible
individuals a much more severe form of disease presentation
can occur.
An important point in the discussion of mucormycosis is the
terminology used to describe zygomycete infections. The class
of zygomycetes is broken down into two subclasses: mucorales
and entomophthorales. Mucormycosis refers to infections
caused by the mucorales subclass of organisms.1 Within the
mucorales subclass are multiple genuses including mucor,
rhizopus, rhizomucor, and absidia.
Mucormycosis was originally described in 1885 and up until the
1950s was considered an exceedingly rare diagnosis. However,
with the sharp increase in certain susceptible populations (e.g.,
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diabetics) over the past 50 years the diagnosis has become
increasingly more common.2

end result of this is additional free iron available to the invading
zygomycete organisms.

Mucormycosis has been described in a variety of different
presentations with multiple organ systems being affected.
Cerebral, pulmonary, renal, gastrointestinal, cutaneous,
disseminated, and ophthalmologic forms have all been described.
Disease can often spread locally to involve surrounding tissues
such as the sinuses in our patient. Infection typically begins with
inhalation of zygomycete spores into the nasopharynx during
an environmental exposure. In the immunocompetent host,
these spores are typically caught by the cilia of the respiratory
tract, expectorated, and are of no further significance. However,
if intact immune mechanisms are lacking in a host, local
infection may begin with the germination of the spores into
fungal elements called hyphae. Localized sites of infection can
spread aggressively and become angioinvasive resulting in
tissue infarction.3 Infection may also spread to distant sites via
hematogenous routes. Other potential sites for initial infection
occur as a result of breakdown in the skin as seen in intravenous
(IV) drug abusers or those with indwelling IV catheters. Most
commonly patients possess some underlying risk factor for
infection; however, case reports with no identifiable risk factor
do exist.4

Perhaps one of the most common examples of a susceptible
host is seen in diabetics. The mechanisms of susceptibility
are two-fold in these patients. Hyperglycemia is a known risk
factor for neutrophil dysfunction and thus presents a risk for
mucormycosis.9 In addition to this, the prominent acidotic states
seen in patients suffering from diabetic ketoacidosis provide an
optimal environment for mucormycosis infection.

Susceptible hosts usually possess a defect in the function of
their mononuclear or polymorphonuclear phagocytes.5 Other
immunosuppressive conditions can also confer risk. The most
prevalent groups of patients who suffer these infections include
those with diabetes, hematologic malignancies, neutropenia,
acidotic states, solid organ or bone marrow transplants, as well
as those who abuse IV drugs and those who are currently on
deferoxamine iron chelation therapy.2,5,6
Iron chelation therapy presents an interesting susceptibility to
mucormycosis organisms. All microorganisms require iron to
survive, and zygomycete organisms are especially sensitive to
this requirement. In the past it has been observed that patients
who carried a diagnosis of iron overload and were treated with
deferoxamine chelation therapy seemed to suffer higher rates of
mucormycosis than other populations.1 In the healthy patient,
free available iron is scarce and difficult for organisms to obtain
for growth as it is bound tightly with normal host proteins.
However, in the patient with excess free iron (e.g., hemochromatosis), zygomycete organisms can exploit elevated levels of
available free iron, and this can result in increased incidence of
clinical disease. Even more susceptible is the patient being treated
with deferoxamine. While this seems paradoxical, it is thought
that zygomycete organisms can specifically use deferoxamine
as a siderophore to sequester iron for growth thus promoting
worsening disease.7 This phenomenon is not seen with other
iron chelators. A similar susceptibility is found in patients with
acidosis. This is believed to be secondary to the inability of
proteins to effectively bind iron in acidotic environments.8 The

Patient presentation is often dictated by the site of infection.
Rhinocerebral mucormycosis is the most common form,
comprising roughly 33% to 50% of all cases.10 Poorly controlled
diabetics represent the major risk factor in this group.1,2 Patients
often present with symptoms of sinusitis (e.g., headache, fever)
combined with facial numbness secondary to involvement
of the fifth cranial nerve. This can rapidly progress to involve
surrounding tissues resulting in ocular involvement (e.g., blurred
vision, proptosis, opthalmoplegia, peri-orbital cellulitis), and in
severe cases can advance into the central nervous system and
surrounding vasculature often resulting in cerebral infarction
secondary to carotid thrombosis or cavernous sinus thrombosis.
A prompt diagnosis requires a high level of suspicion and an
understanding of underlying risk factors for disease. Computed
tomography (CT) and magnetic resonance imaging (MRI)
may show non-specific evidence for soft tissue infection.
Occasionally an eschar may be found on close examination of
skin, nasal airways, or oral mucosa. Immediate consultation with
an otolaryngologist is essential. While antifungal treatment is
needed, survival and limitation of morbidity is usually dictated
by prompt surgical debridement.
Pulmonary mucormycosis typically begins with inhalation of
spores into the lungs; however, less common hematogenous and
lymphatic spread from distant sites to the lungs has also been
described. These patients most often are neutropenic, especially
in the setting of chemotherapy and bone marrow transplant.5
Early complaints are often similar to pneumonia (e.g., fever,
cough, dyspnea, and chest pain). More advanced disease can
present with hemoptysis, often massive in quantity due to the
angioinvasive nature of these infections.5 Diagnosis can be
difficult due to non-specific symptoms and unreliable cultures.
Because of these factors, tissue biopsy is usually required to
confirm the diagnosis. Unfortunately mortality rates can range
from 60% to 95% in pulmonary mucormycosis, with increasing
mortality as the disease process becomes more invasive.2
Cutaneous mucormycosis usually presents with local infection
that has resulted from the breakdown of the normal barrier
defenses in immunocompromised hosts as seen with traumatic
injury, needle injections, and severe burns.1 Prognosis is good,
and surgical therapy can be curative if pursued early; however,
the potential for more severe disease is possible in cases left
untreated.
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Disseminated mucormycosis is perhaps the most severe form
of zygomycete infection. Severe neutropenia, hematologic
malignancies, iron overload, with or without deferoxamine
therapy, and other forms of immunosuppresion carry the
greatest risk for this form of disease.1 Disseminated disease can
spawn from any primary site of infection in the body; however,
pulmonary disease is the most common source.5 The prognosis
for these patients is dismal due to near absence of treatment
options. Surgical therapy is not an option as the spread of
disease is well beyond a focal source.
Other forms of mucormycosis are rare. Gastrointestinal
manifestations involving the stomach, colon and ileum have
been described.5 Similar risk factors are thought to play a role
in these cases. Isolated CNS disease is rare in the absence of
another primary site of infection. It is commonly seen with IV
drug abusers and may present with focal neurologic deficits.2
Other isolated cases of different organ involvement have been
described but the overwhelming majority of cases involve
rhinocerebral, pulmonary, cutaneous, and disseminated forms.
The diagnosis of mucormycosis can be difficult due to the
typically vague symptoms on presentation. Prompt diagnosis
is of the utmost importance in terms of patient survival. An
awareness of at-risk patient populations is needed in order to
prevent a delay in confirming the patient’s diagnosis. Cultures
are unlikely to yield timely results and may be contaminated
due to the ubiquitous nature of the zygomycete organisms.
Ideally, a tissue biopsy is obtained from an affected region of the
patient’s body. Careful preparation of the specimen in the lab is
important as typical grinding of specimens can destroy hyphal
elements and delay diagnosis. Fine mincing of specimens is
the suggested method for preparation and informing the lab of
your suspicions will help in this matter. Laboratory diagnosis
is based solely on microscopic appearance of hyphal elements.
While thin, frequently-septated hyphal elements with regular
branching suggest an alternative type of fungal species such as
aspergillus, the identification of broad (5 to 15 micrometers),
non-septated hyphal elements with irregular branching support
a diagnosis of a zygomycete infection. Radiologic manifestations are unlikely to be diagnostic but can provide supporting
evidence for a diagnosis. In the majority of medical centers
there are no other methods of diagnosis in use such as PCR or
serologic testing.
The treatment for mucormycosis is mostly surgical. Aggressive
and complete resection of all infected tissue is vital to improving
a patient’s chance of survival. Surgical consultation should be
obtained as soon as possible and patients may often require
multiple procedures to obtain adequate margins of resection.
Serial imaging of affected tissues is done to monitor disease
progression and may help guide further surgical procedures.
With the exception of the last few years, the mainstay of medical
therapy consisted solely of amphotericin B for the treatment of
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mucormycosis. More recently some experience with the use of
posaconazole has expanded the options available to clinicians
in the treatment of mucormycosis.11,12 While amphotericin B is
known to carry multiple adverse effects including renal failure
as seen in our patient, posaconazole is an alternative in patients
who cannot tolerate amphotericin B.13 Posaconazole is available
with oral dosing allowing for prolonged outpatient treatment
which may be necessary in certain infections. Other antifungal
medications possess little or no activity against zygomycete
species and should not be used in any therapeutic regimen. The
optimization or elimination of any predisposing risk factors
(e.g., hyperglycemia, acidosis, neutropenia, etc.) should also be
addressed as soon as possible to improve patient outcomes.
There is some interest in using iron chelation therapy as an
adjunctive treatment to surgery and antifungal medications in
the treatment of mucormycosis. Deferiprone (Ferriprox) is a
potent iron chelator that has been used in thousands of patients
outside the United States to successfully treat iron overload.14,15
Deferiprone, unlike deferoxamine, cannot be exploited by fungal
species as a siderophore.16 This would potentially reduce free
iron levels in patient serum, making it more difficult for fungal
species to grow and reproduce. Ibrahim et al, in a rhizopusinfected DKA mouse model, were able to show significant
improvements in survival of mice treated with deferiprone
vs. placebo.16 The applicability in a human host is not proven
at this time, and the use of deferiprone in the treatment of
mucormycosis is available as compassionate use only.
The overall prognosis of patients diagnosed with mucormycosis
is poor. Although outcomes have improved with the use of
amphotericin B, mortaility rates can approach greater than
80% in patients with pulmonary disease. 2 Disseminated
mucormycosis can result in mortality rates approaching 90% to
100%.2 Cutaneous disease, when addressed promptly with local
surgical resection, carries the best prognosis with a greater than
90% survival rate.2 In most cases overall survival will be largely
dictated by the underlying risk factors as well as the timeliness
of surgical intervention.
In summary, mucormycosis represents a highly lethal type
of infection typically affecting specific patient populations.
Immunocompromised patients, diabetics and especially patients
with DKA, oncology patients, patients with iron overload and
those receiving treatment with deferoxamine should be viewed
as having elevated risk for mucormycosis. Prompt consultation
with a surgical team is of utmost importance and should not
be delayed for a confirmed diagnosis. Systemic therapy with
antifungal medication such as amphotericin B or posaconazole
should be instituted quickly but should be viewed only as
adjunctive to successful surgical resection. Overall prognosis
is poor in most forms of disease with the exception of mild
localized cutaneous disease.
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A Tale of Two Women: Is There a Benefit to Bilevel
Ventilation in Pregnancy?
Laura Immordino, MD, and Adam Kaufman, MD
Case Presentation 1

The patient is a 24 year-old pregnant female at 31 and 6/7 weeks
estimated gestational age, who presented to the emergency
department with complaint of intermittent right-sided abdominal
pain, nausea, vomiting and fevers over the past twenty-four
hours. The patient’s vital signs at presentation were significant
for a heart rate of 130 beats/minute and a blood pressure of 90/32
mm Hg. Her physical examination was otherwise unremarkable,
and she was initially admitted to the maternal-fetal medicine
service and started on intravenous fluids. Over the next 12 hours,
the patient remained tachycardic with blood pressures in the
80s/40s. She began to develop respiratory distress, and an ICU
evaluation was requested.
At the time of evaluation, the patient’s physical exam revealed
a well-developed, gravid woman in moderate distress. Her
temperature was 100.7º Fahrenheit, pulse was 136 beats/minute,
blood pressure was 94/41 mm Hg, respiratory rate was 38 breaths/
minute, and pulse oximetry was 99% on a 100% non-rebreather
mask. She was anicteric with moist mucous membranes and
normal skin turgor. On cardiac examination, her heart rate was
tachycardic and regular, without any murmurs. Her lungs were
clear to auscultation and abdomen was soft and gravid without
any tenderness to palpation. She had no peripheral edema. On
vaginal exam, her cervix was long and one centimeter dilated.

Figure 1. CXR following intubation on assist-control ventilation.

Laboratory results were significant for a white blood cell (WBC)
count of 19.8 B/L and CO2 of 17 mmol/L. Arterial blood gas
was 7.46/25/125/18/99% on a 100% non-rebreather mask.
Broad spectrum antibiotics were started, and a stat CT of the
chest, abdomen and pelvis was performed, which showed dense
consolidation of the left lower lobe, consistent with pneumonia.
The patient was maintained on a non-rebreather with
stable oxygen saturations for several hours, but eventually
decompensated, requiring emergent intubation. She was
initially placed on assist-control ventilation; however, her
oxygen saturations remained in the 60s to 70s. She was noted
to have decreased left-sided breath sounds, despite pulling back
the endotracheal tube. A stat chest radiograph was performed,
which showed near complete collapse of the left lung.
The patient was subsequently switched to bilevel ventilation
with eventual improvement in her oxygenation (see Figures
1 and 2). She initially required high level settings, with an
inspiratory/ expiratory pressure of 35/10 mm Hg. The patient’s
status improved over the next few days with antibiotic treatment,
and cultures all remained negative, but serologies were positive
for Mycoplasma IgM. Pressure support was discontinued on
hospital day four, and ventilatory support was titrated down
slowly over the next few days. On hospital day seven, the patient
was successfully extubated. Antibiotics were narrowed to oral
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Figure 2. CXR following change to bi-level ventilation.

azithromycin to complete a fourteen day course of antibiotics
for mycoplasma pneumonia.

Case Presentation 2

The patient is a 19 year-old pregnant woman at 29 and 6/7 weeks
estimated gestational age, transferred from an outside hospital to
the maternal-fetal medicine service with complaints of nausea,
vomiting and fever for one week. Over the past twenty-four
hours, the patient complained of increasing abdominal pain and
developed fevers to 103º Fahrenheit.

Case Reports

The patient had no significant past medical or gynecologic history.
She denied any previous surgeries or allergies to medications. On
transfer from the outside hospital, she was receiving intravenous
ampicillin, ceftriaxone, betamethasone and fluids.

titrated down over the next few days, and on hospital day 23
she was placed on pressure support of 18. She was weaned to a
40% tracheal collar on hospital day 27, and transferred out of
the ICU on hospital day 24.

Several hours after admission, the patient began to develop
respiratory distress, and an ICU evaluation was requested.
At that time, physical examination revealed a well-developed,
gravid woman in moderate to severe distress. Her temperature
was 102.3ºFahrenheit, pulse was 127 beats/minute, blood
pressure was 115/58 mm Hg, respiratory rate was 34 breaths/
minute, and pulse ox was 98% on a 100% non-rebreather. She
was noted to have moist mucous membranes, scleral icterus,
and tachycardia without murmurs. The remainer of the exam
was significant for bilateral rales and mild abdominal tenderness
to palpation diffusely, without rebound or guarding. She was
noted to have mild lower extremity pitting edema. Neurologic
exam was within normal limits.

Discussion

Laboratory studies revealed a WBC count of 9.7 B/L, hemoglobin
of 8.1 g/dL, and platelet count of 162 B/L. Her basic metabolic
panel was within normal limits; however, liver panel showed
elevated total and direct bilirubin levels of 4.8 and 2.2 mg/dL, AST
of 698 U/L, ALT of 293 U/L, and alkaline phosphatase of 193 U/L.
LDH was 1169, fibrinogen was 326, and D-dimer was elevated at
10.21. A diagnostic amniocentesis was performed, which showed
no evidence of chorioamnionitis. Chest radiograph at that time
showed bilateral infiltrates.
Hepatitis serologies, autoimmune, and vasculities studies were
negative. Blood, urine, and bronchoalveolar lavage cultures for
viral, bacterial, and fungal infections were negative. Hematologic
work-up revealed no evidence of microangiopathic anemia, and
HUS/TTP was ruled out. Echocardiogram showed no evidence of
tamponade, lower extremity ultrasounds were negative for deep
venous thromboembolism, and abdominal ultrasound showed
no obvious liver pathology. Results from the outside hospital
were only significant for a positive Mycoplasma IgM.
The patient remained febrile in the range of 102º to 103º
Fahrenheit for nearly two weeks, despite empiric treatment with
broad-spectrum antibiotics. On hospital day five, the patient’s
respiratory status deteriorated requiring intubation. She was
placed on assist control ventilation with a respiratory rate of 20,
tidal volume of 400cc, PEEP of 5, and FiO2 of 50%. On hospital
day seven, the patient’s oxygenation dropped, requiring 100%
FiO2. At this time, her ventilator settings were changed to
ARDS protocol, and the FiO2 was titrated down over the next
few days. On hospital day 16, the patient was noted to have
high peak inspiratory and plateau pressures, with PaO2 ranging
from 65 to 90. On hospital day 18, in order to facilitate weaning,
the patient was placed on bilevel ventilation with inspiratory/
expiratory pressures of 30/5. Prior to the ventilatory switch,
her PaO2 was 90 on 50% FiO2; following the mode change, her
PaO2 was 167 on 50% FiO2. The inspiratory pressures were

Bilevel ventilation is a form of partial ventilatory support, which
allows for spontaneous breathing at any point in the ventilator
cycle. It is a time-triggered, pressure-limited,and time-cycled
mode of ventilation. Inspiratory and expiratory pressures are
set as PEEP high and PEEP low, and the physician is able to set
length of time for the PEEP low. The goal of PEEP high is to
help open the consolidated portions of the lungs that are often
present in patients with acute lung injury or ARDS. PEEP low
is a pressure release phase that allows for lung recoil and CO2
removal. A built-in valve allows for spontaneous breathing
throughout the respiratory cycle.1,2 Spontaneous breathing has
been shown to preferentially recruit dependent lung regions
while simultaneously allowing for less neuromuscular blockade
and sedation.3,4
In traditional mechanical ventilation, the majority of ventilation
occurs centrally as opposed to at the distal alveoli, where the
majority of perfusion occurs. The goal of bilevel ventilation is to
increase alveolar recruitment which leads to decreased shunting,
better arterial oxygenation, and improved ventilation-perfusion
matching.7,8 By allowing for spontaneous breathing throughout
the respiratory cycle, bilevel ventilation results in increased
patient comfort and thus a decreased need for sedation and
neuromuscular blockade.6 Since excessive sedation has been
associated with a longer duration of intubation, decreased cough
reflex, and increased risk of ventilator associated pneumonia,
many studies have suggested that the use of bilevel ventilation
can lead to a shorter ICU and hospital length of stay.5,8
Contraindications to bilevel ventilation include patients with
COPD (as they are at risk of barotrauma) and patients with
neurologic disorders with increased intracranial pressure (as
permissive hypercapnea is contraindicated in these patients).1,6,8
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A Woman With Massive Splenomegaly
Erin Meschter, MSIII, Michelle Choi, MD, and Lisa Teng, MD
Case Presentation

An 82 year-old Caucasian woman was admitted to the hospital
with marked splenomegaly and pancytopenia. Her primary
care physician noted splenomegaly on physical exam during
a recent visit, and a CT scan of the abdomen was performed
as an outpatient which revealed a massively enlarged spleen.
The patient admitted to losing up to 40 pounds over the past
six months due to decreased appetite and early satiety. She
also reported dyspepsia and a feeling of fullness in her belly
for several months. The patient denied nausea, vomiting,
constipation, or diarrhea. Other symptoms included increased
fatigue, chronically swollen legs, and frequent night sweats two
to three nights per week with occasional fevers. The patient
denied shortness of breath, cough, or chest pain. She complained
of urinary urgency and frequency.
The patient had a past medical history of hypertension and
osteoarthritis in her knees and ankles. Her past surgical history
included cataract surgery and cholecystectomy. Family history
was significant for her mother’s “heart problems” and her father
dying from pneumonia. The patient had never smoked, although
she frequently experienced second hand smoke. She did not
drink, nor did she have a history of alcohol abuse. She never
used any illegal drugs or recreational substances. Medications
on admission included Clonidine 0.1 mg BID and hydrocholorothiazide 12.5 mg every day. She had no known drug allergies.
On physical exam her temperature was 97.8° Fahrenheit, pulse
was 98 beats/minute, and respiration rate was 19 breaths/
minute. Her blood pressure was 129/71 mm Hg, and her oxygen
saturation was 98% while breathing ambient air. The patient was
in no apparent distress and was alert and oriented to time, place,
and self. She was slender with a protuberant abdomen. The
spleen was palpable beyond the umbilicus into the right upper
quadrant. She had no lymphadenopathy. She was pale, but not
jaundiced, and had no apparent ascites. She had a 2/6 systolic
ejection murmur with no heave and a normal PMI. Her lungs
were clear to auscultation bilaterally. She had numbness in her
index and ring finger on both hands and some left-sided facial
numbness in the distribution of the V2 branch of cranial nerve
five. Neurologic exam revealed no other abnormalities. She had
no joint swelling or erythema, but her legs had pitting edema
bilaterally.
On admission, chest radiograph and CT of the abdomen with
contrast showed massive splenomegaly (24.5 X 15.1 X 11.7 cm,
see Figure 1). Her CBC revealed pancytopenia with a white blood
cell count of 2.4 B/L, red blood cells 3.36 B/L, platelets 94 B/L,
hemoglobin 10.6 g/dL, and hematocrit 32.8%. Reticulocyte count
was elevated at 2.1%. Of note, she had an elevated lymphocyte
count of 45.5; neutrophils were low at 36.4. Electrolytes were
within normal limits. Albumin was low at 2.9 g/dL and LDH
was normal at 199 U/L. Her blood smear showed pancytopenia

consistent with her complete blood count along with poikilocytosis and suspected villous lymphocytes. Vitamin B12 was
very low at 52 pmol/L. A Monospot test was non-reactive.
A bone marrow biopsy was performed a few days after
admission along with flow cytometry. The bone marrow biopsy
indicated patches of hypercellularity with lymphoid aggregates
consisting of monotonous, small round cells without cytoplasm
suggestive of small lymphocytes. Paratrabecular aggregates
also were appreciated. The bone marrow had maintained good
hematopoietic activity. Of note, reticulin staining of the bone
marrow was increased in the aggregates indicating that this bone
marrow was more difficult to aspirate and thus aggregate cells
may have been less represented on smear. Markers were used to
stain the bone marrow. A marker for CD3 was used to stain T
cells, which were sprinkled throughout the bone marrow with
a few in the lymphoid aggregates. A marker for CD20 was used
to stain B cells, which were scattered throughout the marrow.
Lymphoid aggregates were predominantly CD20 positive,
suggestive of a B cell lymphoproliferative disorder.

Flow cytometry was used to distinguish what type of
lymphoproliferative disorder was present in this woman’s
bone marrow. Total lymphocytes were 35%, which is
slightly elevated. Of the lymphocytes, 31% were B cells
(15% to 20% is normal). The B cells present were CD10
negative, which eliminated follicular cell lymphoma from
the differential. The B cells were CD5 negative, making
Mantle cell lymphoma and chronic lymphocytic leukemia
(CLL) less likely. There were some B cells that were CD11c
positive, a marker for Hairy cell leukemia; but a more
specific marker for Hairy cell is CD103, which was negative
in this patient’s bone marrow biopsy. Most revealing was
the kappa and lambda Ig marker staining, which is used to
evaluate for clonality. The flow cytometry showed kappa
restricted B cell clonality (see Figure 2). Through a process
of elimination via this analysis, a diagnosis of splenic
marginal zone lymphoma (SMZL) was suspected. There
are no distinguishing markers for SMZL, and this type of
lymphoma shares many markers with other lymphoproliferative diseases. It is interesting to note that there is CD15
positivity in the B cells present in this patient, and perhaps
this marker should be followed in future diagnoses of SMZL
to discover a new correlation.
Discussion

Splenic marginal zone lymphoma (SMZL) is an indolent B-cell
malignancy involving the spleen, bone marrow, and blood. It
is a rare lymphoma type, first described in 1992, and has been
estimated as less than 2% of all patients with lymphoma.2
Splenic marginal zone lymphoma is a disease of the elderly with
a median age at presentation of 65 years old.2 Almost all patients
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present with moderate to massive splenomegaly, sometimes
with abdominal discomfort. Hepatomegaly can sometimes be
observed, but lymphadenopathy is uncommon. Anemia and
thrombocytopenia are common at presentation secondary
to hypersplenism more than bone marrow infiltration.
Autoimmune phenomena, such as primary biliary cirrhosis,
rheumatoid arthritis, immune thrombocytopenia, are present
in 10% to 20% of patients.2,4 Splenic marginal zone lymphoma
is considered a low-grade lymphoma with an indolent clinical
course, and median survival is close to ten years, with five-year
survival estimated to be greater than 65%.1 Approximately 10%
of patients undergo transformation to a high-grade lymphoma.
The diagnosis is based on lymphocyte morphology, immunophenotype, bone marrow histology, cytogenetic abnormalities,
and when available, spleen histology. Approximately 75% of
patients with splenic marginal zone lymphoma will have a
peripheral blood lymphocytosis.2 One of the most characteristic
findings is the presence of villous lymphocytes on peripheral
blood smear, which are intermediate-sized lymphocytes with
condensed chromatin and short cytoplasmic projections.2
However, the amount of circulating cells may be so small, that
it cannot be detected. Infiltration of the bone marrow is evident
in virtually all patients with SMZL, but is invariably involved.
It may be demonstrable only by flow cytometry and not by
morphology alone. The immunophenotype profile for SMZL is
typically positive for CD20, CD45RA, CD45RB, CD79A, PAX5/
BSAP, IgM, and bcl2, and negative for CD43, CD23, CD10,
bc16, and cyclin D1.1
The pattern of bone marrow infiltration can vary and may be
nodular, intransinusoidal, interstitial, and paratrabecular.4
However, intrasinusoidal infiltration is considered to be
characteristic of SMZL. In SMZL, the spleen is enlarged and
splenic sections demonstrate a nodular replacement of white
pulp, usually with a central core of lymphocytes with slightly
irregular nuclei, and an outer zone of larger cells with clear
cytoplasm in the marginal zone. Both cell populations are part
of the neoplastic clone. The splenic red pulp is also involved in
most cases, usually occupying germinal centers and is evident
by immunostaining.5 Although a primary diagnosis of SMZL is
rarely, if ever, made on the basis of lymph node biopsy, splenic
hilar nodes are typically involved. Complex chromosomal
aberrations are common in SMZL; 80% of cases have an
abnormal karyotype, but there is no single abnormality present
in all cases.2 The most frequent cytogenetic aberrations are gains
of 3q and 12q and 7q deletion.2
There is no definitive standard treatment for splenic marginal
zone lymphoma to date. The level of evidence supporting
recommendations for initiating treatment is weak due to the
absence of prospective clinical trials. Currently treatment is
based on clinical evidence obtained from clinical centers with
experience in treating SMZL. Due to the indolent course of
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SMZL, about two thirds of patients are asymptomatic at diagnosis
and as many as one third will never require therapy. In general,
the development of lymphadenopathy, high lymphocyte count,
or infiltration of non-hematopoietic sites have been found to
be associated with progression and shorter overall survival. 2
Progression may also be associated with a transformation to a
high grade lymphoma.
However, therapeutic intervention should be considered in
patients with active disease. Considering the indolent course of
SMZL, the patient’s age and comorbidities, treatment should be
aimed at achieving control of the disease and symptoms rather
than eradication of the disease.2 There are several therapeutic
options effective in these patients including splenectomy,
chemotherapy, and irradiation. Symptomatic splenomegaly
or severe cytopenia are the main indications to perform
splenectomy. However, splenectomy alone cannot reduce the
extrasplenic lymphomatous infiltrations, and one group has
reported an increase of tumor burden in the bone marrow
after splenectomy.1 Splenic irradiation has been used in a
limited number of patients and has been reported to produce
a reduction in circulating villous lymphocytes, regression of
splenomegaly, and improvement of cytopenias.1 Chemotherapy
is generally used as a first line treatment in people with more
advanced disease. Alkylating agents appear to be of marginal
benefit. Purine analogs, such as fludarabine in combination
with rituximab, or rituximab alone, have demonstrated a
greater efficacy than alkylating agents in terms of response and
progression-free survival.2
Our patient’s clinical presentation and findings were consistent with
splenic marginal zone lymphoma. She received splenic irradiation
and underwent splenectomy for symptomatic splenomegaly. She is
currently undergoing chemotherapy with Rituxan.

Figure 1. On CT of the abdomen with contrast, the spleen was
found to be massively enlarged measuring at least 24.5 X 15.1 X
11.7 cm and is homogenously enhancing.
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Figure 2. All three flow cytometry graphs show kappa-restricted B cell clonality, suggestive of a B cell lymphoproliferative disease. Graph A shows
only kappa positive marker; the same cells are negative for lambda marker. CD19 is a marker for B cells, and is utilized in Graph B and C. Graph
B displays CD19 positive cells are also kappa positive, but they are lambda negative (in Graph C).
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A Case of Diabetic Muscle Infarction Despite Good
Diabetic Control
Tessey Jose, MD, and Intekhab Ahmed, MD
Case Presentation

A 52 year-old female with type 2 diabetes of 10-year duration
was admitted with worsening of shooting pain and swelling
of her lower extremities over the previous nine days. The
pain was rated 10/10 in severity, was worse in the right side as
compared to the left, radiated from her lower legs to thighs, and
limited her mobility for the previous five days. She reported
no history of trauma, fever, chills, skin changes, or medication
noncompliance. She was managing her diabetes with two
injections of premixed insulin. Her other medical problems
include a history of congestive heart failure with an ejection
fraction of 45%, coronary artery disease, stage 4 chronic kidney
disease, and hypertension. A review of systems was remarkable
for exertional dyspnea and mild ascites.
On admission, the patient was afebrile, had blood pressure
147/101 mm Hg, a regular pulse of 88 beats/minute, respiratory
rate of 18 breaths/minute, and pulse oximetry of 100% on
two liters of oxygen via nasal cannula. Cardiovascular exam
was benign except for scattered crackles at the bases on deep
inspiration. A musculosketal examination revealed tender,
edematous lower extremities up to the top third of her thighs
without any skin excoriation or ulceration. All pulses were
palpable with normal pressure and volume in both extremities.
Neurological exam was only significant for inability to walk
secondary to pain and swelling.

The laboratory work-up revealed a hemoglobin A1C level of 6.5%,
fasting blood glucose of 95 mg/dL, serum creatinine of 3.4 mg/
dL, white blood count (WBC) of 17.1 B/L, and an erythrocyte
sedimentation rate (ESR) of 95 mL/hr.
A diuretic was initiated to lessen lower extremity edema as it was
initially thought to be due to congestive heart failure. Lowerextremity ultrasound was negative for deep vein thrombosis,
and a blood culture was negative. Magnetic resonance imaging
(MRI) of lower extremities revealed diffuse swelling and edema
involving the tensor fascia lata with areas of muscle replaced by
fluids in both legs especially in the thigh area (Figures 1 and 2).
A diagnosis of diabetic myonecrosis was made on the basis of
MRI findings, raised ESR, and elevated WBC in the absence of
negative blood cultures and fever. The patient was managed
with supportive care and analgesia as needed.

Discussion

Diabetic myonecrosis is a rare complication of diabetes, first
described in 1965 and known to affect patients with poorly
controlled diabetes of long-standing duration.1 Most common
presentation of diabetic myonecrosis is acute lower extremity
pain and swelling involving calf and thigh. These patients often
have established nephropathy, retinopathy, and a long-standing
history of poor glycemic control.

Figures 1 and 2. Coronal Image - T2 weighted with fat saturation. The image shows diffuse swelling involving the entire right tensor
fascia lata with areas of muscle replacement by fluid, findings consistent with diabetic myonecrosis. There is also swelling of the left
adductor magnus, which may represent diabetic myopathy versus early diabetic myonecrosis.
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The pathophysiology of diabetic myonecrosis is not completely
understood. The possible contributing role of athermatous
emboli, thrombo-occlusive disorder, and arteriosclerosis has
been implicated in some cases.2
Table 1. D
 ifferential Diagnosis of Acute Lower
Extremity Swelling.
Deep Vein Thrombosis
Thrombophlebitis
Trauma
Infection
Fasciitis
Hematoma
Diabetic Myotrophy
Myositis Ossificans
Muscle Strain or rupture

Laboratory tests typically reveal leukocytosis, elevated C reactive
protein, and creatinine kinase in 35%, 75%, and 45% of cases,
respectively.3 Histological features of diabetic myonecrosis
consist of large areas of muscle necrosis and edema.4 Diagnosis
is primarily made through clinical suspicion and on MRI.
Recurrence is common and has been reported in up to 50%

of cases. Diabetic myonecrosis is a self-limited condition,
which resolves on its own within weeks to months. Treatment
is supportive care with analgesia, rest, and optimal glucose
control. Physical therapy is not recommended, as it may acutely
aggravate necrotic muscle.

Conclusion

After reviewing the literature, this case is one of the first reports
of diabetic myonecrosis in a well-controlled diabetic patient.
This case demonstrates that the diagnosis of myonecrosis should
be considered even in well-controlled diabetics in the setting of
acutely painful, swollen lower extremities in patients with longstanding diabetes.
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Elderly Man With Weight Loss, Weakness, and Anorexia
Austin Hwang, MD
Case Presentation

An 81 year-old male who resides in Florida presents to the
emergency department (ED) with complaints of weakness,
20 pound weight loss, and decreased appetite over the last six
months. He is currently in the Philadelphia area to visit his
son, and after his concerned son heard of these complaints, he
brought his father to the ED. The patient indicates that he has
become progressively weak over the last six months. He has
also been increasingly fatigued, finding it difficult to walk even
two blocks. A year ago, the patient walked two to three miles a
day without a problem. Past medical history is significant for
coronary artery disease, although he reports a normal stress test
three months ago, stroke in 2004 with residual dysarthria, and
melanoma on chest wall diagnosed in 2005 status-post resection.
He lives with his wife and is a retired interior architect. He has
not drunk alcohol in two years, has not smoked cigarettes in
20 years, and has never used illicit drugs. There is no history
of cancer in his family, but significant history of stroke in his
mother and sister. He saw his primary care physician for these
symptoms in Florida, and a diagnosis had not been reached,
but the patient indicates that he had a PET scan and a needle
aspiration done on his right lung in the last month. He does not
know the results of these tests.
On presentation, the patient was afebrile with a temperature of
97.0° Fahrenheit, blood pressure of 164/77 mm Hg, heart rate
of 57 beats/minute, and respiratory rate of 20 breaths/minute
with pulse oximetry of 94% on room air. Physical exam was
unremarkable, including the neurological exam. His cranial
nerves, motor, sensory and cerebellar functions were all intact.
Reflexes were 2+ bilaterally in the upper and lower extremities,
and patient had a normal gait.

This gentleman was admitted to the general floors, and given
the patient’s symptoms of weight loss, weakness, and decreased
appetite, an occult malignancy seemed to be the most likely
diagnosis. Chest radiograph on admission showed an ill-defined
density in the right infrahilar region. PPD, HIV and ANA tests
were negative, but ESR and CRP were elevated suggesting an
inflammatory etiology. CT scan of the head, chest, abdomen,
and pelvis was done on hospital day two. CT head without
contrast showed no mass effect, bleed or intracranial lesions. CT
chest, abdomen, and pelvis showed bilateral pleural effusions,
ground glass opacities in both upper lobes, nonspecific scattered
centrilobular nodules, consolidation/atelectasis in posterior
segment of right lower lobe, three 0.5 cm nodules in the right
lower lobe, and an infiltrative soft tissue mass surrounding both
proximal collection systems in the retroperitoneal region.
On hospital day seven, PET scan results were obtained from
Florida which showed right lung lower lobe and left lung lower
lobe enhancement with greater attenuation found in the right
basilar lung region. Right lung needle aspiration results from
Florida obtained on hospital day nine were consistent with
fibrotic tissue and no evidence of malignancy. The cardiothoracic surgeons were consulted to evaluate the patient for a
VATS procedure in an attempt to obtain a tissue biopsy of the
enhancement in the right lower lobe. MRI abdomen indicated
that the soft tissue mass shown on CT abdomen and pelvis was
consistent with retroperitoneal fibrosis and not malignancy.
Despite the results of the needle aspiration from Florida, a
repeat biopsy was scheduled via VATS on the right lower lobe
of the lung. A right-sided chest tube was kept in place after the
VATS, but was only necessary for one day. Pathology slides read
two days later revealed pulmonary hyalinizing granulomas.
Figure 1. (left) CT chest
demonstrates pathology in
the right lower lung region
and specifically, a 5.2mm
nodule.
Figure 2. (right)Bilateral
ground glass opacities.
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Figure 3. CT abdomen and pelvis with soft tissue infiltrates
around bilateral kidneys

Figure 4. MRI abdomen with soft infiltrates around bilateral
kidneys.

Discussion

toneal fibrosis who worked in the oil industry for many years and
had copious exposure to toxic fumes. There was some thought
that oil could be an instigator of these spontaneous growths of
the granulomas, but the histology did not support this theory as
there were not many mineral oil droplets present on the slides.
A typical histologic slide consistent with pulmonary hyalinizing
granulomas shows densely matted, stout, hypocellular collagen
fibers with fine granular stippling with sporadic calcium
deposits. The presence of amyloid fibers can co-occur with these
granulomas also.

Pulmonary hyalinizing granulomas were first described by
Engleman et al in 1977. Just less than 100 cases have been
reported since then. Symptoms include hemoptysis, pleuritic
chest pain and cough. Retroperitoneal fibroses have been known
to be associated with this condition. The disease is rare and
idiopathic, but an autoimmune response is one of the leading
theories to explain the etiology of this disease. Autoantibodies
and circulating immune complexes have been detected in a few
patients. The pulmonary lesions in these patients have been
known to enlarge or regress spontaneously, and a search for
an inciting factor for these events has so far been fruitless. In
Thorax, an article by Dent et al in 1983 discussed a patient with
a diagnosis of pulmonary hyalinizing granulomas and retroperi-

The biopsy results for our 81 year-old male were consistent with
pulmonary hyalinizing granulomas. Initially, there were plans
to biopsy the retroperitoneal fibrosis after the patient’s VATS,
but given previous case reports describing a strong correlation
between retroperitoneal fibroses and our primary diagnosis, the
biopsy never occurred. This patient was started on high dose
prednisone at 80 mg by mouth once a day. He was to be tapered
off of the prednisone slowly. After a few days of treatment, the
patient’s weakness and appetite improved. The patient received
physical therapy for a couple more days and was discharged
from the hospital. The patient is to follow up closely with his
primary care physician in Florida.
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Hemoptysis as a Presenting Symptom for Metastatic
Pancreatic Cancer
Toshimasa Okabe, MD, Leigh Van Vranken, MSIII, and Darren N. Seril, MD
Introduction

Approximately 32,000 pancreatic neoplasms are diagnosed in the
United States annually.1 Currently, carcinoma of the pancreas is
the fourth most common cause of cancer death in both men
and women in this country, after cancers of the lung, breast/
prostate, and colon. The most common presenting symptoms
of pancreatic cancers are epigastric pain, obstructive jaundice,
and weight loss.1 However, since pancreatic cancer is frequently
metastatic when diagnosed, it may uncommonly present with
findings characteristic of the site of spread.

Case Presentation

A 42 year-old Caucasian female with no significant past medical
history presented with a four-month history of daily hemoptysis
associated with a productive cough and a two-week history of
jaundice and gray stools. The initial evaluation for hemoptysis,
performed at an outside hospital approximately three months
prior to presentation included a normal chest radiograph and
negative PPD. Two weeks prior to admission, the patient presented
to an outside hospital complaining of epigastric pain for one
week, as well as new onset jaundice and persistent hemoptysis.
Per the patient, an abdominal ultrasound performed at that time

revealed a pancreatic mass. She presented shortly thereafter to our
hospital with worsening hemoptysis, epigastric and right upper
quadrant pain, and jaundice. She described the abdominal pain
as constant and dull, with an intermittent stabbing component.
The pain was aggravated when lying down and relieved by
oxycodone-acetaminophen. She also reported generalized fatigue
and a five-pound weight loss over three weeks.
She denied fever, chills, night sweats, chest pain, shortness-ofbreath, nausea, vomiting, or diarrhea. She has no known drug
allergies. Her only medication was oxycodone-acetaminophen
which was started for abdominal pain during the previous
hospital visit. She has no history of abdominal or other surgeries.
She consumes three to four drinks of alcohol per week during
the past two years and has smoked approximately one pack of
cigarettes per day for the past 25 years. She used cocaine on
occasion more than 10 years ago. She denied intravenous drug
use. Her mother, a smoker, died from small cell lung cancer, and
her father died from prostate cancer. She denied recent travel,
as well as known exposure to individuals with tuberculosis,
asbestos, or other inhaled chemicals.

Figure 1. PA and lateral chest radiographs shows showed no evidence of infiltrates, effusions, or masses.
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Hospital Course

Initial examination revealed a jaundiced but well-appearing
middle-aged woman in no acute distress. Vital signs revealed a
temperature of 98.7° Fahrenheit, blood pressure 92/62 mm Hg,
heart rate 70 beats/minute, respiratory rate of 18 breaths/minute,
and oxygen saturation of 96% while the patient was breathing
ambient air. The sclerae were icteric. The lungs were clear to
auscultation bilaterally without wheezes, rales, or rhonchi.
Abdominal exam revealed tenderness on palpation of the right
upper quadrant and epigastrium without rebound tenderness
or guarding. No Murphy`s sign was detected. The skin was
jaundiced without rashes, spider angiomata, or palmar erythema.
The remainder of the physical examination was unremarkable.
The results of the laboratory tests were significant for total
bilirubin 10.8 mg/dL, direct bilirubin 4.9 mg/dL, AST 148 IU/L,
ALT 196 IU/L, and alkaline phosphatase 225 IU/L. CEA was 1.1
ng/mL (normal range: 0.0-5.0 ng/mL) and CA 19-9 was 12 ng/
mL (normal range: 0.0-36.0 U/mL). Her complete blood count,
basic metabolic panel including creatinine, protein, albumin,
amylase, lipase, PT, and PTT were within normal limits.

Figure 2. CT thorax with contrast illustrates a cavitary lesion in
the anterior segment of the left upper lobe (arrow).

A chest radiograph obtained on admission showed no evidence
of infiltrates, effusions, or masses (Figure 1). A chest CT with
contrast performed at an outside hospital two weeks prior to
presentation revealed a cavitary lesion in the anterior segment
of the left upper lobe. The lesion was confirmed by repeat CT
scan (Figure 2) and measured 2.6 X 2.5 cm, with no marked
changes in size or appearance from the prior study. Several
small lung nodules were noted as well. In addition, enlarged
mediastinal lymph nodes measuring 10 mm in diameter were
noted in the hila bilaterally. Multi-detector abdominal CT with
contrast (Figure 3) revealed a pancreatic head mass measuring
3.5 X 3.3 cm, with abdominal lymphadenopathy, and intra- and
extra-hepatic biliary ductal dilatation.
Based on these findings, the initial differential diagnosis included
a metastatic neoplasm of either pulmonary or pancreatic origin.
Disseminated tuberculosis or other bacterial or fungal infection,
as well as a vasculitic process, were also considered. Antineutrophil Cytoplasmic Antibody (ANCA) serologies were
obtained and were negative. ESR was 22 mm/hr (normal range:
0-15 mm/hr) and CRP was 0.7 mg/l (normal range: <12 mg/L).

Figure 3. Multi-detector CT abdomen and pelvis with contrast
detects a hypodense mass in the head of the pancreas (arrow).

For diagnostic and therapeutic purposes, endoscopic retrograde
cholangio-pancreatography (ERCP) was performed. A common
bile duct (CBD) stricture was noted, and brush cytology of the
CBD was obtained. Subsequently, an expandable metal stent
was placed in the CBD after sphincterotomy. In order to further
evaluate the pancreatic mass, endoscopic ultrasound (EUS) was
performed, and fine needle aspiration (FNA) biopsy of the mass
was performed. Bronchoscopy was performed to further evaluate
the cavitary lung lesion noted on CT scan. Bronchoalveolar
lavage (BAL) and bronchial brushings were sent for cytology,
Gram stain, and culture. Endobronchial ultrasonography-
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lesions within the left upper lobe of the lung, left adrenal gland,
and L1 vertebral body. The patient later initiated chemotherapy
as an outpatient for palliation of widely metastatic pancreatic
cancer. She was given a final diagnosis of primary pancreatic
adenocarcinoma metastatic to the lung, adrenal gland, and
spine.

Discussion

Pancreatic cancer is notoriously aggressive. Indeed, surgically
resectable cases on presentation represent the minority:
approximately 10% to 15%. Pancreatic neoplasms metastasize by
hematogenous and lymphatic routes. Locally, the celiac plexus,
superior mesenteric artery, portal vein, and ligament of Treitz
are common sites of spread. The liver appears to be the most
frequent target of distant metastasis, as well as the peritoneum.
The lung is also a common target. Lung metastases were present
in greater than 50% of patients with metastatic pancreatic cancer
in one study.2

Figure 4. CT-guided biopsy of anterior lung mass.
guided biopsy was attempted; however, the biopsy was unable to
be obtained due to excessive coughing during the procedure.
Cytologic analysis of the CBD brushings was negative for
malignant cells. However, the FNA of the pancreatic head
mass revealed features consistent with pancreatic ductal
adenocarcinoma. The microbiology and pathology from the
bronchoscopy samples were unrevealing: BAL fluid cultures
were negative for bacteria and fungus, and the bronchial brush
cytology revealed benign epithelial cells. Thus, a definitive
diagnosis of the cavitary lung lesion was lacking.
The patient’s jaundice and abdominal pain improved following
the placement of the CBD stent. She was discharged home
with a presumptive diagnosis of metastatic pancreatic cancer,
and arrangements to follow-up with medical oncology. Four
days later, the patient was re-admitted for complaints of fever
and headache. Brain MRI and bone scan showed no evidence
of metastasis to those sites. The patient’s hospital course was
complicated by E. coli bacteremia, likely secondary due to ERCP
and CBD stent placement. Having been treated with intravenous
antibiotics, and with subsequent negative blood cultures, she was
discharged to home with plans to undergo CT-guided biopsy of
the lung lesion as an outpatient. Ten days after discharge, biopsy
of the lung mass was successfully performed with CT guidance
(Figure 4). Pathology revealed malignant cells morphologically
similar to those obtained by FNA of the pancreatic mass. In order
to fully elucidate the extent of metastasis, positron emission
tomographic scanning was performed, which confirmed the
presence of a hypermetabolic mass in the pancreas, as well as

63

It is rare for metastatic pancreatic cancer to present initially with
pulmonary symptoms. Nevertheless, there are case reports of
pancreatic cancer “masquerading” as bronchogenic carcinoma,
with initial symptoms including cough and dyspnea, as well
as those related to paraneoplastic syndromes, i.e., Horner’s
syndrome.3 It has been shown that pancreatic metastases can be
radiographically indistinguishable from primary bronchogenic
carcinomas,4 highlighting the importance of obtaining biopsy
for tissue diagnosis and to guide treatment.
The treatment of pancreatic cancer is broadly based on staging
of the disease to determine resectability. With the exception of
lymph node spread restricted to the surgical field, metastasis
renders pancreatic cancer unresectable. The median survival
after diagnosis is extremely poor in the case of unresectable
pancreatic cancer: approximately three to five months.1 Surgical
resection via partial pancreaticoduodenectomy (i.e., the Whipple
procedure), typically with adjuvant chemotherapy, is the only
treatment modality with any meaningful survival benefit. Median
survival can be extended to 12 to 18 months with surgery and
still further in conjunction with chemotherapy.5 The treatment
of unresectable pancreatic cancer, including distantly metastatic
disease, is essentially palliative and entails management of
symptoms, including pain, jaundice, and malabsorption.1
The most common findings in the setting of pancreatic cancer
include jaundice and abdominal pain. Other findings include
Courvoisier’s sign (i.e., a palpable nontender gallbladder)
and Trousseau’s syndrome (i.e., superficial and deep venous
thrombosis), as well as more vague symptoms such as fatigue
and weight loss.6 The presentation is often suggestive of the
site of the pancreatic mass. Tumors of the head of the pancreas
tend to present with jaundice. Pain is often a later finding,
associated with tumors of the pancreatic body and tail. Back
pain is an ominous sign, as it may indicate local spread to the
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celiac neuroplexus posterior to the pancreas. The present case
is unusual in that pulmonary symptomatology preceded the
more typical findings of abdominal pain and jaundice. Because
pancreatic head cancers often impinge on the CBD and cause
jaundice, these cancers can sometimes be detected at an earlier,
less advanced stage than cancers of the body or tail, which are all
frequently metastatic to distant sites before pain in the abdomen
or the back emerges.
In addition to metastatic pancreatic or lung cancer, our
differential diagnosis for the concurrent findings of a cavitary
lung lesion and pancreatic mass included atypical infections, such
as mycobacterial and fungal infections, other granulomatous
diseases, and systemic vasculitides, such as Wegener’s
granulomatosis. Tuberculosis was a consideration in the present
case, although less likely in the context a negative PPD and lack
of a suggestive exposure history. Sarcoidosis is well known to
involve multiple organs, including the respiratory system, skin,
eye, heart, and liver. There are case reports of rare involvement
of the pancreas, causing symptoms similar to pancreatic cancer.7
Wegener’s granulomatosis has been reported to manifest like
pancreatic carcinoma as well.8 Interestingly, the patient in the
present case reported intermittent sinus symptoms, but negative
ANCA serologies and a lack of renal involvement made this
hypothesis less likely. Ultimately, tissue sampling of the lung
and pancreas masses by CT guidance and EUS-FNA proved
critical in establishing a definitive diagnosis in this case.

In summary, the current case represents an uncommon presentation
of metastatic pancreatic adenocarcinoma, characterized by
jaundice and abdominal pain preceded by a prolonged period of
respiratory symptoms alone.
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Clinical Image:
Large Fungus Ball and Pulmonary Embolus
Matthew Grant, MD
Case Presentation

A 62 year-old female with severe chronic obstructive pulmonary
disease and chronic Aspergillus mycetoma developed the sudden
onset of dyspnea on post-operative day two after a posterior
cervical spine laminectomy for severe arthritis.

This single image from her contrast-enhanced thoracic CT
shows the 10 cm left upper lobe pulmonary fungal ball, a new
extensive left lower lobe Klebsiella pneumonia, and an acute
right lower lobe pulmonary embolus.

Figure 1. CT chest show large pulmonary fungus ball in the left upper lobe, left lower lobe pneumonia,
and acute right lower lobe pulmonary embolus
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Clinical Images: Colorectal Foreign Body
Stephen Koczirka, MSIV, Anastasia Shnitser, MD, and Dina Halegoua-De Marzio, MD
Case Presentation

A 42 year-old male was admitted to the hospital
with a known retained foreign body. A can of
shaving cream was inserted into the patient’s
rectum several days prior to presentation. On
admission, an abdominal radiograph (Figure
1) was taken to confirm the position of the
foreign body and the absence of free air in
the abdomen. The patient was taken to the
operating room and under local anesthesia
underwent successful transanal removal of
the aerosol can using tenaculum forceps.
There was no evidence of bowel perforation.
The patient was transferred to the recovery
room in stable condition.

Discussion

Insertion of foreign objects into the anus
and rectum is a well described phenomenon.
Anorectal objects can be inserted for sexual,
medicinal or transportational purposes. They
are more common in men than in women.
Commonly found rectal foreign bodies may
include such objects as vibrators, bottles,
fruit, vegetables and toy balls. Some unusual
objects reported include a light bulb, a
magazine, a pair of spectacles and fish.1,2
The diagnosis of a retained foreign body
should be confirmed by a plain abdominal
radiograph. It will usually demonstrate a
radio-opaque object; however, vegetables and
rubber objects may not be visible. Low-lying
foreign bodies are distal to the rectosigmoid
junction while high-lying foreign bodies
are above it. Objects retained within the
sigmoid colon frequently require operative
intervention.3,4

Figure 1. Abdominal radiograph showing an aerosol can within the patient’s
colorectum.

Colorectal insertion of foreign bodies may be associated with
serious injuries. Delayed removal of rectal foreign bodies can
lead to severe complications, including perforation, peritonitis,
sepsis, mucosal ulcerations, obstruction and bleeding. Evaluation
must include a search for involvement of other structures and
an evaluation of the anal sphincter. In treating these patients
it is important to recognize previous attempts to remove the
object prior to their presentation to the emergency department.2
After successful extraction, all patients should be observed to
exclude rectal perforation. During that time, psychological
support should be provided as well as education to prevent
future occurrences.
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PAINLESS JAUNDICE
When dealing with jaundice that is painless,
Your thinking should not be aimless.
Last night we admitted this fellow,
Whose skin happens to be bright yellow.
Much to his dismay,
His poop looks like clay.
He found it important to remark,
That is pee-pee is very dark.
His AST/ALT and bilirubin are high,
But his alk phos is normal, and we want to know why.
There are many causes with potential,
So let’s begin with the differential.
When you begin your differential construction,
You might want to think about obstruction.
On the list is hemolysis,
Along with hepatic cirrhosis.
To avoid any complications,
First you should go over his medications.

Arising is another question,
Could it be ingestion?
If he drank a lot of booze,
That would be note-worthy news.
Another clue to solve the mystery,
Could be his family and travel history.
But none of this sheds any light
On why he is here tonight.
It didn’t hurt when we palpated his abs,
But let’s talk about some labs.
TSH, CBC, Hepatitis panel, AMA, UDS, CMP—
Let’s find out what’s darkening his pee.
HIV, EBV, Ceruloplasmin, Zoster, HSV—
I think we need abdominal CT.
We will wait to see the results of all the tests
And see what they might suggest.
There is a feeling of dread,
That this may be cancer of the pancreatic head.
But let’s not fly too close to the sun like Icarus,
Just because there is scleral icterus.

Nilay Kavathia, MD

Photograph courtesy of Sandarsh Kancherla, MD

67

Photograph courtesy of Sandarsh Kancherla, MD

68

Photograph courtesy of Ana Shnitser, MD

69

Friends of the Forum
Ronald Cantor, MD

Michael C. DiMarino, MD

David Richardson, MD

Thomas Chappell, MD

Amy Eschinger, MD

Himanshu Patel

Gregory Kane, MD

Eric Eschinger, MD

Nicole Weinberg

River Oaks Hospital

Kyle Helwig, MD

Jose Martinez, MD

Nancy Beggs, MD

Gregory Heyt, MD

Qingping Wang, MD

Mark Graham, MD

Joseph M. Higgins, MD

Ray Chen, MD

William Gaughan

Betty Muccino, MD (Lim)

Daniel Lin, MD

Jeffrey Abrams

David Muccino, MD

Alan H. Wang, MD

We offer our sincerest gratitude and appreciation for the support of our Jefferson Alumni. Without their
donations and continuing support, this Jefferson Forum would not have been possible.
Thank you.

JG 09-2536

Cover Art: “Chinese Lantern Flowers,” oil on canvas, Michelle Choi, MD

